<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.1.0//EN//XML?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName art510.dtd?>
  <?SourceDTD.Version 5.1.0?>
  <?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <?origin publisher?>
  <?FILEmeta_BIOCHI3381 xml ?>
  <?FILEmain xml ?>
  <?FILEgr1 jpg ?>
  <?FILEgr2 jpg ?>
  <?FILEgr3 jpg ?>
  <?FILEgr4 jpg ?>
  <?FILEgr5 jpg ?>
  <?FILEgr6 jpg ?>
  <?FILEgr7 jpg ?>
  <?FILEgr8 jpg ?>
  <?FILEfx1 jpg ?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Biochimie</journal-id>
      <journal-title-group>
        <journal-title>Biochimie</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0300-9084</issn>
      <issn pub-type="epub">1638-6183</issn>
      <publisher>
        <publisher-name>Editions Scientifiques Elsevier</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3014083</article-id>
      <article-id pub-id-type="pmid">20615447</article-id>
      <article-id pub-id-type="publisher-id">BIOCHI3381</article-id>
      <article-id pub-id-type="doi">10.1016/j.biochi.2010.06.022</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Goettig</surname>
            <given-names>Peter</given-names>
          </name>
          <email>peter.goettig@sbg.ac.at</email>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="cor1" ref-type="corresp">&#x2217;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Magdolen</surname>
            <given-names>Viktor</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brandstetter</surname>
            <given-names>Hans</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Division of Structural Biology, Department of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria</aff>
      <aff id="aff2"><label>b</label>Klinische Forschergruppe der Frauenklinik, Klinikum rechts der Isar der TU M&#xFC;nchen, Ismaninger Strasse 22, 81675 M&#xFC;nchen, Germany</aff>
      <author-notes>
        <corresp id="cor1"><label>&#x2217;</label>Corresponding author. Tel.: +43 662 8044 7283; fax: +43 662 8044 7209. <email>peter.goettig@sbg.ac.at</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <month>11</month>
        <year>2010</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2010</year>
      </pub-date>
      <volume>92</volume>
      <issue>11</issue>
      <fpage>1546</fpage>
      <lpage>1567</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>2</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>6</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xC2;&#xA9; 2010 Elsevier Masson SAS.</copyright-statement>
        <copyright-year>2010</copyright-year>
        <copyright-holder>Elsevier Masson SAS</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Including the true tissue kallikrein KLK1, kallikrein-related peptidases (KLKs) represent a family of fifteen mammalian serine proteases. While the physiological roles of several KLKs have been at least partially elucidated, their activation and regulation remain largely unclear. This obscurity may be related to the fact that a given KLK fulfills many different tasks in diverse fetal and adult tissues, and consequently, the timescale of some of their physiological actions varies significantly. To date, a variety of endogenous inhibitors that target distinct KLKs have been identified. Among them are the attenuating Zn<sup>2+</sup> ions, active&#xA0;site-directed proteinaceous inhibitors, such as serpins and the Kazal-type inhibitors, or the huge, unspecific compartment forming &#x3B1;<sub>2</sub>-macroglobulin. Failure of these inhibitory systems can lead to certain pathophysiological conditions. One of the most prominent examples is the Netherton syndrome, which is caused by dysfunctional domains of the Kazal-type inhibitor LEKTI-1 which fail to appropriately regulate KLKs in the skin. Small synthetic inhibitory compounds and natural polypeptidic exogenous inhibitors have been widely employed to characterize the activity and substrate specificity of KLKs and to further investigate their structures and biophysical properties. Overall, this knowledge leads not only to a better understanding of the physiological tasks of KLKs, but is also a strong fundament for the synthesis of small compound drugs and engineered biomolecules for pharmaceutical approaches. In several types of cancer, KLKs have been found to be overexpressed, which makes them clinically relevant biomarkers for prognosis and monitoring. Thus, down regulation of excessive KLK activity in cancer and in skin diseases by small inhibitor compounds may represent attractive therapeutical approaches.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Tissue kallikrein</kwd>
        <kwd>Specificity pockets</kwd>
        <kwd>Inhibitory compound</kwd>
        <kwd>Zinc</kwd>
        <kwd>Rule of five</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <label>1</label>
      <title>Introduction</title>
      <p>Regulation of protease activity in the living organism is a highly complex task that involves all levels of cellular organization. Control and timing of protease activity starts with gene expression, transcription and translation, and continues with protein targeting and&#xA0;zymogen activation. Once activated, the protease is often kept in check by endogenous inhibitors, while the last steps of protease regulation may be limited proteolysis and final degradation. The emerging research in the field of tissue kallikrein-related peptidases (KLKs) provides many diverse examples for nearly all aspects of protease regulation by inhibitors.</p>
      <p>Tissue kallikrein (Kallikrein 1, KLK1) and the kallikrein-related peptidases are (chymo)trypsin-like serine proteases, belonging to family S1A of clan PA(S) according to the MEROPS classification <xref rid="bib1" ref-type="bibr">[1]</xref>. Prior to the introduction of a new nomenclature in 2006, the KLKs were often referred to as hKs or rKs for human and rat proteins, respectively <xref rid="bib2" ref-type="bibr">[2]</xref>. Fully sequenced genomes of placental mammals, such as primates or rodents, and even of marsupials (e.g. the opossum), exhibit at least eleven <italic>KLK</italic> genes, but usually lack the counterparts of human <italic>KLK2</italic> and <italic>KLK3</italic> <xref rid="bib3 bib4" ref-type="bibr">[3,4]</xref>. However, the numbers of corresponding proteases vary from ten KLKs in cows, eleven in dogs, and 26 ones in mice. The latter possess a series of functional KLK1 paralogs <xref rid="bib2 bib5 bib6" ref-type="bibr">[2,5,6]</xref>. Kallikrein 1 and the kallikrein-related peptidase genes are organized in a single cluster on chromosome locus 19q13.4 <xref rid="bib7 bib8" ref-type="bibr">[7,8]</xref>. The 15 human KLK members are only distantly related to plasma kallikrein, which shares 38% identical residues with KLK1 in the catalytic domain, while KLK1 and trypsin share 46% identity <xref rid="bib9 bib10" ref-type="bibr">[9,10]</xref>.</p>
      <p>One or more <italic>KLK</italic> genes are expressed in nearly all tissues and&#xA0;fluids of the human body. They fulfill a diverse range of tasks throughout one&#x2019;s lifetime from embryonic development to processes in adulthood <xref rid="bib8 bib11 bib12 bib13" ref-type="bibr">[8,11&#x2013;13]</xref>. KLKs are intracellulary synthesized as precursors with a signal peptide (15&#x2013;34 amino acids) that is cleaved off upon secretion into the endoplasmatic reticulum. The proform or zymogen of the KLK protease is extracellularly activated by the removal of the propeptide (3&#x2013;37 amino acids), resulting in active proteases of 223&#x2013;238 residues (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>), and in some cases reaching molecular weights of up to 50&#xA0;kDa due to heavy glycosylation <xref rid="bib14" ref-type="bibr">[14]</xref>. The activation process of KLKs may involve autoactivation <xref rid="bib15 bib16 bib17" ref-type="bibr">[15&#x2013;17]</xref>, KLK activation cascades <xref rid="bib18 bib19 bib20" ref-type="bibr">[18&#x2013;20]</xref>, serine proteases from the thrombostasis axis, such as plasmin, plasma kallikrein, and factor Xa <xref rid="bib21" ref-type="bibr">[21]</xref>, or the proteolytic activity of other proteases, such as urokinase-type plasminogen activator (uPA), matrix metalloproteinases (MMPs), and dipeptidyl peptidase I <xref rid="bib22 bib23 bib24" ref-type="bibr">[22&#x2013;24]</xref>. However, the KLK activity is not restricted to regulation by steroid-dependent expression <xref rid="bib25 bib26 bib27" ref-type="bibr">[25&#x2013;27]</xref> or by fine-tuned zymogen activation. In the case of KLKs 6, 12, and 14, from example, regulation is likely, at least in part, achieved by autolysis <xref rid="bib17 bib28 bib29 bib30 bib31" ref-type="bibr">[17,28&#x2013;31]</xref>. Furthermore, in some cases an interplay of KLKs and their corresponding natural inhibitors has been established, even with pathophysiological significance <xref rid="bib32" ref-type="bibr">[32]</xref>. However, many potential inhibitors of KLKs have not yet been unambiguously assigned to a given KLK. Another unusual feature of certain KLKs is the timescale of their activity, which can reach months, if not years, as seen with KLK4 in tooth development, which was also observed in a comparison of <italic>Klk4/lacZ</italic> knockin mice and the wild type <xref rid="bib33 bib34" ref-type="bibr">[33,34]</xref>.</p>
      <p>Overall, the human KLKs can be subdivided into in several tissue-specific groups with distinct physiological substrates and&#xA0;functions. In the 1920s and 1930s, the first kallikrein (KLK1) was&#xA0;discovered and characterized as a proteolytic enzyme, mainly occurring in urine, kidney, and the pancreas, the latter being the inspiration for the protein&#x2019;s name which is derived from the Greek word for pancreas (&#x3BA;&#x3B1;&#x3BB;&#x3BB;&#x3B9;&#x3BA;&#x3C1;&#x25B;&#x3B1;&#x3C2;, Kallikreas) <xref rid="bib35 bib36 bib37" ref-type="bibr">[35&#x2013;37]</xref>. A major function of KLK1 is the reduction of blood pressure by releasing the peptide hormone Lys-bradykinin (kallidin) from low molecular weight kininogen, which effects muscle relaxation and inflammatory processes <xref rid="bib38" ref-type="bibr">[38]</xref>. Knockout of the <italic>Klk1</italic> gene in mice causes both cardiovascular abnormalities and a defect of efficient renal tubular calcium absorption <xref rid="bib39 bib40" ref-type="bibr">[39,40]</xref>. Intriguingly, administration of this protease can reduce cardiac and renal injuries, restenosis, and ischemic stroke and promotes angiogenesis and skin wound healing <xref rid="bib41" ref-type="bibr">[41]</xref>. Similar to the other &#x201C;classical&#x201D; KLKs, KLK 2 and 3, which were discovered in the late 1980s, KLK1 features an extended &#x201C;99-loop&#x201D; (also called kallikrein loop) of 11 inserted amino residues with respect to chymotrypsin. Among the &#x201C;new&#x201D; KLKs, KLK 4&#x2013;15 that were gradually characterized from the mid-1990s onwards, KLKs 8&#x2013;13 possess 99-loop insertions from two to eight residues (see alignment in <xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>).</p>
      <p>In the prostate, KLKs 2, 3, 4, 11, and to some extent KLKs 14 and 15, are produced for secretion into seminal plasma <xref rid="bib8 bib11" ref-type="bibr">[8,11]</xref>. There, they most likely activate each other in a cascade-like manner resulting in the degradation of semenogelins and fibronectin, mainly by KLK3 and KLK14, for semen liquefaction <xref rid="bib42 bib43" ref-type="bibr">[42,43]</xref>. Since KLK3 (PSA, &#x201C;prostate specific antigen&#x201D;) blood plasma levels correlate with prostate cancer progression, an immunoassay for PSA has become a widespread medical application, despite its moderate reliability as prognostic biomarker for malignant processes. Thus, there still remains the need for additional specific KLK tumor markers <xref rid="bib44 bib45 bib46" ref-type="bibr">[44&#x2013;46]</xref>. One of these promising markers is KLK4, which is distinctly expressed in the early stages of prostate cancer <xref rid="bib47" ref-type="bibr">[47]</xref>. Interestingly, KLK4 has the capacity to activate the proform of the urokinase-type plasminogen activator (pro-uPA) and to modulate the activity of its receptor uPAR, both of which play a significant role in prostate and ovarian cancer <xref rid="bib48 bib49" ref-type="bibr">[48,49]</xref>. In addition, KLKs 2, 4, 5, 6, and 14 seem to be potential players in signal transduction via activation of G-coupled protease receptors, such as&#xA0;PARs 1, 2, and 4, resulting, e.g. in inflammation or in tumor cell proliferation and migration <xref rid="bib50 bib51 bib52 bib53 bib54 bib55 bib56" ref-type="bibr">[50&#x2013;56]</xref>.</p>
      <p>In addition to its role in the prostate, which is not yet fully understood, KLK4 is imperative for tooth development, particularly in formation of enamel, which also depends on MMP-20 <xref rid="bib57" ref-type="bibr">[57]</xref>. Under normal circumstances, both proteases degrade the extracellular matrix required for the growth of dentin crystallites. Single mutations, however, result in either the malfunctioning of MMP-20 or KLK4, causing the hereditary disease <italic>amelogenesis imperfecta</italic>, which is characterized by very fragile teeth <xref rid="bib58 bib59" ref-type="bibr">[58,59]</xref>. More specifically, KLK4 seems to be crucial for the formation of large coherent enamel crystallites, as seen in <italic>Klk4</italic> knockout mice <xref rid="bib34" ref-type="bibr">[34]</xref>.</p>
      <p>A larger subset of kallikrein-related peptidases, namely KLKs 5, 7, 11, and 14, is highly expressed in human skin, mainly in the outermost layer, the <italic>stratum corneum</italic>, while KLKs 6, 8, 10, and 13 are found at medium expression levels <xref rid="bib11 bib13 bib60" ref-type="bibr">[11,13,60]</xref>. KLKs 5, 7, and 14 are capable of degrading proteins of the corneodesmosomes, leading to&#xA0;desquamation, the shedding of cornified skin cells <xref rid="bib61 bib62 bib63" ref-type="bibr">[61&#x2013;63]</xref>. In contrast, KLK8 is involved in cellular differentiation and healing of the skin <xref rid="bib64" ref-type="bibr">[64]</xref>, similar to KLK6, which induced rapid wound healing by promoting keratinocyte proliferation and migration in a mouse model based on the shedding of E-cadherin by Klk6 <xref rid="bib65" ref-type="bibr">[65]</xref>. Also, KLKs 4, 5, and 8 specifically activate the metalloproteinases meprin &#x3B1; and/or &#x3B2;, which are located in separate layers of the epidermis <xref rid="bib66" ref-type="bibr">[66]</xref>. Tight activity regulation of these KLKs by several types of inhibitors is necessary, otherwise diverse skin diseases will develop <xref rid="bib67" ref-type="bibr">[67]</xref>.</p>
      <p>Intriguingly, two KLKs, KLK6 and KLK8 (also termed neurosin and&#xA0;neuropsin, respectively), are expressed at higher levels in human brain <xref rid="bib8 bib68" ref-type="bibr">[8,68]</xref>. KLK6 accumulates at brain lesions of humans and investigations in mice suggest that excessive KLK6 activity causes inflammation of the central nervous system and promotes multiple sclerosis through demyelinating activity <xref rid="bib69 bib70" ref-type="bibr">[69,70]</xref>. The physiological role of KLK6 seems to be both de- and remyelination of&#xA0;glia cells, contributing to neurite and axon growth after injuries <xref rid="bib71" ref-type="bibr">[71]</xref>. In contrast, KLK8, which mostly occurs in the hippocampus, is involved in long term potentiation (LTP) and memory acquisition by restructuring synapses, as shown by mouse models <xref rid="bib72 bib73 bib74 bib75" ref-type="bibr">[72&#x2013;75]</xref>. Furthermore, in human brains with Alzheimer&#x2019;s disease a more than 10-fold expression of KLK8 was observed <xref rid="bib76" ref-type="bibr">[76]</xref>. On the other hand, <italic>Klk8</italic> knockout mice were shown to be susceptible to epileptic seizure <xref rid="bib77" ref-type="bibr">[77]</xref>. Furthermore, single nucleotide polymorphisms in the human <italic>KLK8</italic> gene are associated with manic-depressive disorder and cognitive impairment <xref rid="bib78" ref-type="bibr">[78]</xref>.</p>
      <p>Although the KLK9 protease is present in many tissues and dominates among all KLKs in fetal and adult heart <xref rid="bib11" ref-type="bibr">[11]</xref>, no physiological function has been defined so far, however, it may serve as an ovarian and breast cancer marker <xref rid="bib79" ref-type="bibr">[79]</xref>. Similarly, KLKs 10, 12, 13 and 15 are associated with distinct cancers without established (patho)physiological roles <xref rid="bib17 bib80 bib81" ref-type="bibr">[17,80,81]</xref>. Nevertheless, there are some indications of a tumor suppressor role for KLK10 in breast cancer <xref rid="bib82" ref-type="bibr">[82]</xref>, KLK12 may be involved in angiogenesis regulation <xref rid="bib83" ref-type="bibr">[83]</xref>, KLK13 in ovary tissue remodelling and interleukin processing <xref rid="bib84 bib85" ref-type="bibr">[84,85]</xref>, and KLK15 in KLK3/PSA activation <xref rid="bib86" ref-type="bibr">[86]</xref>. Intriguingly, expression of KLKs in the female reproductive system appears to be complementary to the expression pattern of KLKs in prostate, suggesting an activation cascade that probably involves all KLKs during impregnation <xref rid="bib87" ref-type="bibr">[87]</xref>.</p>
      <p>As we will see later for the KLKs, natural inhibitors of proteases often bind directly to the active site, exploiting some degree of complementarity at the interaction surface <xref rid="bib88 bib89 bib90" ref-type="bibr">[88&#x2013;90]</xref>. Expectedly, the more the components of the inhibitor bind to distinct specificity pockets of the protease, the more specificity and affinity can be gained for inhibition <xref rid="bib91" ref-type="bibr">[91]</xref>, which in some cases may be enhanced by additional binding of the inhibitor to so-called exosites <xref rid="bib92 bib93 bib94" ref-type="bibr">[92&#x2013;94]</xref>. Also, knowledge of the substrate specificity of the KLKs will be a guideline for the identification of endogenous (and perhaps exogenous) inhibitors, and for the design of synthetic substrates, as well as of highly specific inhibitors, which may eventually yield powerful pharmaceutical compounds. Numerous studies have investigated the specificity for all KLKs, using either individual chromogenic and fluorogenic substrates, such as in the case of KLKs 8, 12, 15 <xref rid="bib17 bib95 bib96 bib97" ref-type="bibr">[17,95&#x2013;97]</xref> or systematic positional scanning approaches for KLKs 3, 4, 5, 6, 7, 10, 11, 13, 14 <xref rid="bib98 bib99 bib100 bib101" ref-type="bibr">[98&#x2013;101]</xref>, phage display for KLKs 1, 2, 3, 4, 6, 14 <xref rid="bib102 bib103 bib104 bib105 bib106 bib107" ref-type="bibr">[102&#x2013;107]</xref>, or peptide libraries for KLKs 1, 2, and 3 <xref rid="bib108 bib109 bib110" ref-type="bibr">[108&#x2013;110]</xref>. In addition, KLK cleavage sites in natural substrates have also been analyzed to a large extent. Since these studies show many differences, sometimes stark discrepancies, for the single specificity subsites, a general overview is&#xA0;given in <xref rid="tbl1" ref-type="table">Table 1</xref> based on the statistical approach of the MEROPS specificity matrices (<ext-link ext-link-type="uri" xlink:href="http://merops.sanger.ac.uk/">http://merops.sanger.ac.uk/</ext-link>). The primary specificity of the kallikrein-related peptidases will allow a basic classification between inhibitors of the twelve tryptic KLKs (1, 2, 4&#x2013;6, 8, 10&#x2013;15) and of the three chymotryptic KLKs 3, 7, and presumably 9. The specificity of KLK9 remains still unclear, as it cleaved P1 Arg containing pro-KLKs at very slow rates <xref rid="bib20" ref-type="bibr">[20]</xref>, while enzymatic data are only available for the rat ortholog rKLK9 (<xref rid="tbl1" ref-type="table">Table 1</xref>) <xref rid="bib111 bib112" ref-type="bibr">[111,112]</xref>, which possesses as major determinant of P1 specificity an Asp189, in contrast to the unusual Gly189 of human KLK9 (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>). Furthermore, the preference of KLKs 1, 10, and 11 appears to be mixed tryptic and chymotryptic (<xref rid="tbl1" ref-type="table">Table 1</xref>) <xref rid="bib99" ref-type="bibr">[99]</xref>. It should be noted that the proteolytic activity of recombinant KLK10 is rather slow and only observed <italic>in vitro</italic> with Leu16 as N-terminal residue, followed by three inserted residues (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>) <xref rid="bib20" ref-type="bibr">[20]</xref>. In addition to a problematic KLK10 activation <italic>in vivo</italic> at Glu16C, if tryptic or chymotryptic proteases were the activators, KLK10 exhibits a Ser193 instead of the extremely conserved Gly193 (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>). A Ser193 might affect the oxyanion pocket function, similar to various factor XIa mutants of residue 193 with reduced activity and inhibitor binding capacity <xref rid="bib113" ref-type="bibr">[113]</xref>. Nevertheless, in addition to the proof of enzymatic activity of recombinantly expressed KLK10, it was demonstrated that native KLK10 from human ovarian ascites fluid is associated with two endogenous protease inhibitors and reacts with an activity-based probe <xref rid="bib114" ref-type="bibr">[114]</xref>.</p>
      <p>Fine tuning of any protease inhibitor interaction depends on characteristic structural features, including electrostatics, flexibility, and exosites on protein surfaces, which will be investigated in the following together with the most relevant biological, biochemical, and pharmaceutical aspects of KLK inhibition.</p>
    </sec>
    <sec id="sec2">
      <label>2</label>
      <title>Natural endogenous KLK inhibitors</title>
      <p>To date, a great variety of endogenous inhibitors with physiological significance in the activity regulation of mammalian kallikrein-related peptidases are known. They range from single metal ions to large protein complexes of more than 700&#xA0;kDa. In fact, natural exogenous inhibitors are widely used for scientific and pharmaceutical studies (see Sections <xref rid="sec3 sec4" ref-type="sec">3 and 4</xref>.). In general, nature employs the&#xA0;following basic principles of protease inhibition: attenuation by&#xA0;reversible binding of inhibitors, &#x201C;KO&#x201D; inhibition by irreversible binding to the inhibitory molecule, which often involves the formation of covalent bonds, and compartmentalization. The latter principle may be achieved by restricted tissue or organelle localization of&#xA0;the enzyme or inhibitor; by homo-oligomerization of the protease itself, which reduces the accessibility to the active site; or by compartment formation of large inhibitors that internalize proteases, for which some rare, but biologically significant examples exist.</p>
      <sec id="sec2.1">
        <label>2.1</label>
        <title>Inhibition of KLKs by metal ions</title>
        <p>The activity of several serine proteases is regulated by endogenous cations. Interestingly, alkali and earth alkali ions rather stimulate protease activity at distinct binding sites, as seen for the prominent examples of Na<sup>+</sup> with thrombin <xref rid="bib115 bib116 bib117" ref-type="bibr">[115&#x2013;117]</xref> or Ca<sup>2+</sup> with trypsin <xref rid="bib118 bib119" ref-type="bibr">[118,119]</xref>. Also, for KLKs 1, 3, 4, 6 and 8 activity stimulation by Ca<sup>2+</sup>, Mg<sup>2+</sup>, or Na<sup>+</sup> and K<sup>+</sup> ions has been observed <xref rid="bib107 bib120 bib121 bib122 bib123" ref-type="bibr">[107,120&#x2013;123]</xref>. Zn<sup>2+</sup> is a metal ion with manifold functions in living organisms and is present in about 300 human enzymes <xref rid="bib124 bib125" ref-type="bibr">[124,125]</xref>. It may play a dual role in activity regulation, as it can stimulate serine proteases, e.g. factor XII <xref rid="bib126" ref-type="bibr">[126]</xref>, and inhibit other ones, such as factor VIIa or uPA&#xA0;<xref rid="bib127 bib128" ref-type="bibr">[127,128]</xref>. To date, Zn<sup>2+</sup> inhibition as a significant regulatory mechanism for KLKs can only be excluded for the intensively studied KLK1 and KLK6, while KLKs 9&#x2013;11, 13, and 15 still require further inhibition studies. Strikingly, for KLKs 2, 3, 4, 5, 7, 8, 12 and 14, inhibition by Zn<sup>2+</sup> in the low &#x3BC;M range has been repeatedly reported (<xref rid="tbl2" ref-type="table">Table 2</xref>). Thus, Zn<sup>2+</sup> should be considered as &#x201C;attenuator&#x201D; of KLK activity, which binds in a reversible manner to the targets for fine tuning of their proteolytic action.</p>
        <sec id="sec2.1.1">
          <label>2.1.1</label>
          <title>Inhibition of prostatic KLKs 2, 3, and 4 by Zn<sup>2+</sup></title>
          <p>Human kallikrein-related peptidase 2, also known as glandular kallikrein 2 (KLK2), is a tryptic protease. While recombinant KLK2 was inhibited by various serpins in the picomolar range, Zn<sup>2+</sup> attenuated its activity against fluorogenic substrates, e.g. Pro-Phe-Arg-AMC, with a K<sub>i</sub> of 3&#xA0;&#x3BC;M <xref rid="bib129" ref-type="bibr">[129]</xref>. Lovgren and coworkers describe the inhibition mechanism as a mixture of competitive and non-competitive inhibition, hinting to the binding of more than one Zn<sup>2+</sup> per KLK2 molecule and interference with the substrate recognition region of KLK2. Based on the high sequence homology to KLK3 (79% identical residues <xref rid="bib130" ref-type="bibr">[130]</xref>) and in particular the presence of the conserved His91, His101, and His233, one can assume that the Zn<sup>2+</sup> inhibition mechanism of KLK2 may be, at least to some extent, similar to KLK3, which is described in the following.</p>
          <p>Zn<sup>2+</sup> inhibition of KLK3/PSA, which is mostly activated by KLK2 in seminal fluid, is clearly an important physiological regulatory process, especially because it is here that the highest Zn<sup>2+</sup> concentration in the human body is found, reaching up to 9&#xA0;mM <xref rid="bib131" ref-type="bibr">[131]</xref>. A first study on the activity of natural KLK3 against a chromogenic substrate, MeO-Suc-Arg-Pro-Tyr-pNA, demonstrated Zn<sup>2+</sup> inhibition with an IC<sub>50</sub> of 20&#xA0;&#x3BC;M (K<sub>i</sub> 6&#xA0;&#x3BC;M), whereby a competitive inhibition type was found, involving the binding of at least two Zn<sup>2+</sup> <xref rid="bib132" ref-type="bibr">[132]</xref>. Whereas one group using recombinant KLK3 reported a K<sub>iapp</sub> of 45&#xA0;&#x3BC;M for Zn<sup>2+</sup> with non-competitive inhibition, another group found for natural KLK3 an IC<sub>50</sub> of 24&#xA0;&#x3BC;M with competitive inhibition <xref rid="bib133 bib134" ref-type="bibr">[133,134]</xref>. From a modelled homology structure of human KLK3, a Zn<sup>2+</sup> binding site was proposed at His91, His101, and His233, and as a potential fourth ligand an Asp (95, 97, or 98). It was assumed that a Zn<sup>2+</sup> bound His101 could sufficiently distort the catalytic triad via a shift of Asp102, resulting in decreased proteolytic activity <xref rid="bib135" ref-type="bibr">[135]</xref>. Interestingly, in a horse kallikrein 3 (eKLK3) crystal structure an equivalent metal site was occupied by Zn<sup>2+</sup>: the coordinating atoms were Asp91 O&#x3B4;2, His101 N&#x3B4;1, and His234 N&#x25B;2 (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>A) <xref rid="bib136" ref-type="bibr">[136]</xref>. In human KLK3, that was crystallized with an antibody required for stabilization of the extended 99 loop but not containing Zn<sup>2+</sup>, the region around the 75-loop exhibited promising ligands for Zn<sup>2+</sup>: His25, His70, His75, Glu21, Glu77 and&#xA0;Asp78 <xref rid="bib134" ref-type="bibr">[134]</xref>. How Zn<sup>2+</sup> binding to these ligands could influence the protease activity will be elucidated by the example of KLK4.</p>
          <p>Recombinant KLK4 tested with the chromogenic substrate Z-Phe-Val-Arg-pNA was inhibited by Zn<sup>2+</sup> with an IC<sub>50</sub> value of 16&#xA0;&#x3BC;M, although a residual activity of about 25% was still observed at 1&#xA0;mM Zn<sup>2+</sup> concentration, hinting to a non-competitive or mixed inhibition type <xref rid="bib137" ref-type="bibr">[137]</xref>. Intriguingly, in enamel which can only form properly by KLK4 activity, the zinc content is equivalent to 15&#xA0;&#x3BC;M, which would correspond to the observed <italic>in vitro</italic> inhibition range <xref rid="bib138" ref-type="bibr">[138]</xref>. As seen in the crystal structure, KLK4 exhibits a unique metal binding site in the 75 loop with a short helical segment from Glu74-Gln76, which allows the Glu77 O&#x25B; to adopt an optimal conformation for Zn<sup>2+</sup> binding together with the His25 N&#x25B;2 (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>B) <xref rid="bib137" ref-type="bibr">[137]</xref>. In contrast, the 75 loop of trypsin binds an activity enhancing Ca<sup>2+</sup> through the Glu70 and Glu80 carboxylate groups <xref rid="bib118" ref-type="bibr">[118]</xref>, which are replaced by Leu70 and Ser80 in KLK4. Three external ligands from a second KLK4 molecule (Glu74 O&#x25B;, Asp75 O&#x3B4;, and Gln76 O&#x25B;) are&#xA0;additionally coordinating the Zn<sup>2+</sup> <xref rid="bib137" ref-type="bibr">[137]</xref>. Although these ligands could constitute a secondary Zn<sup>2+</sup> inhibition site, the single mutations His25Ala or Glu77Ala abolish the Zn<sup>2+</sup> inhibition of KLK4 completely. Thus, binding of Zn<sup>2+</sup> at the 75 loop has a long-range inhibitory effect on the active site that is probably transmitted through His25 to the N-terminus, causing disruption of the salt bridge between Ile16 and Asp194, which is required for a functional active site conformation (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>B). This mechanism was confirmed by a strong increase in the accessibility of the Ile16 &#x3B1;-amino of KLK4 for an acetylating agent in the presence of 70&#xA0;&#x3BC;M Zn<sup>2+</sup> <xref rid="bib137" ref-type="bibr">[137]</xref>. The same Zn<sup>2+</sup>-dependent phenomenon was previously observed for the low activity form of uncomplexed coagulation factor VIIa (FVIIa) <xref rid="bib139" ref-type="bibr">[139]</xref>. Interestingly, a Zn<sup>2+</sup> mediated cross-talk between the 75 loop and the active site has been proposed for FVIIa as an explanation for the attenuatory effect on its activity, in particular because its S1 subsite displays an intrinsic tendency to disorder <xref rid="bib127 bib140" ref-type="bibr">[127,140]</xref>.</p>
          <p>The physiological significance of Zn<sup>2+</sup> inhibition of KLKs 2, 3, and 4 is most likely the finely balanced regulation of activation and protease activity <xref rid="bib81 bib130 bib141" ref-type="bibr">[81,130,141]</xref>. Prostatic fluid contains Zn<sup>2+</sup> concentrations up to 9&#xA0;mM, which keeps the prostatic KLKs in an inactive state <xref rid="bib131" ref-type="bibr">[131]</xref>. Upon ejaculation, the prostatic fluid mixes with epididymal fluid containing the spermatozoa and with seminal vesicles, which are rich in the structural proteins semenogelin I and II (SgI and II) being responsible for initial sperm immobilization in the seminal coagulum <xref rid="bib142" ref-type="bibr">[142]</xref>. However, as both SgI and SgII harbor at least ten binding sites for Zn<sup>2+</sup>, most of the seminal plasma Zn<sup>2+</sup> will eventually be chelated leading to the activation the prostatic KLKs. Especially KLK3/PSA, as the major SgI and II degrading enzyme, will then rapidly process these proteins which results in semen liquefaction and allows the initiation of sperm movement <xref rid="bib81 bib130 bib141 bib142" ref-type="bibr">[81,130,141,142]</xref>.</p>
        </sec>
        <sec id="sec2.1.2">
          <label>2.1.2</label>
          <title>Inhibition of epidermal KLKs 5, 7 and 14 by Zn<sup>2+</sup></title>
          <p>It has been reported that the tryptic KLK5 activity against tripeptidyl-AMC substrates is inhibited around 12&#xA0;nM Zn<sup>2+</sup> with 25% residual activity <xref rid="bib143" ref-type="bibr">[143]</xref>, whereas comparable studies found an IC<sub>50</sub> value of 4&#xA0;&#x3BC;M and apparent inhibition constants K<sub>i</sub>&#xA0;=&#xA0;8&#xA0;&#x3BC;M at pH 7.0 and K<sub>i</sub>&#xA0;=&#xA0;2.0&#xA0;&#x3BC;M at pH 8.0 <xref rid="bib15 bib144" ref-type="bibr">[15,144]</xref>. Considering the extracellular Zn<sup>2+</sup> concentration of roughly 15&#xA0;&#x3BC;M in skin, a low nanomolar inhibition constant would render its target protease virtually inactive. In contrast, a micromolar inhibitor or attenuator would allow the modulation of proteolytic activity in addition to stronger polypeptidic KLK inhibitors that are also present in the outer layers of the skin (see Section <xref rid="sec2.2.2" ref-type="sec">2.2.2</xref>). The studies by Brattsand et&#xA0;al. and Debela et&#xA0;al. confirmed the reversibility of the Zn<sup>2+</sup> inhibition by addition of either EDTA or Zn<sup>2+</sup>-binding substrates, respectively. A comparison of a Zn<sup>2+</sup>-free KLK5 crystal structure (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>C, left panel) with the Zn<sup>2+</sup>-bound KLK5 and rat kallikrein 2 (rKLK2, tonin) structure can explain the inhibition mechanism to a large extent (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>C) <xref rid="bib144 bib145" ref-type="bibr">[144,145]</xref>. In KLK5, Zn<sup>2+</sup> is coordinated by the His96 N&#x3B4;1 and the His99 N&#x25B;2 and two water molecules. The&#xA0;His96 side chain has to rotate by more than 90&#xB0; from the Zn<sup>2+</sup>-free conformation to its position in the Zn<sup>2+</sup> coordination sphere, while the&#xA0;rotation of His99 is less than 20&#xB0;. In the KLK5 Zn<sup>2+</sup> structure, the presence of the inhibitor leupeptin (not shown in <xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>C, middle panel) bound to the catalytic Ser195 and occupying the S2 pocket with a Leu side chain prevented most likely the formation of a coordination sphere for Zn<sup>2+</sup> with a third ligand, namely His57. This conformation, representing the fully inhibited KLK, can be seen in the rKLK2 (tonin) structure, which exhibits the Zn<sup>2+</sup> ligands His99, His97 (similarly positioned as the His96 of KLK5), and most significantly, His57, which is relocated from its position in the catalytic triad (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>C, right panel). The consequence of a disrupted catalytic triad must be inactivation of the enzyme. However, substrate binding should be possible in this inhibited state, due to the largely free S2 subsite, which only has to be unoccupied for the His57 side chain rotation. Also, the observed non-competitive Zn<sup>2+</sup> inhibition of KLK5 is in good agreement with this mechanistic model, since Zn<sup>2+</sup> does not compete with substrates for active site binding <xref rid="bib144" ref-type="bibr">[144]</xref>. Interestingly, the substrate H-Gly-His-Arg-AMC yielded a K<sub>i</sub> value of about 20&#xA0;&#x3BC;M for Zn<sup>2+</sup>, with a residual activity of 25% even at 100&#xA0;&#x3BC;M <xref rid="bib144" ref-type="bibr">[144]</xref> which can be explained by a replacement of His57 in the Zn<sup>2+</sup> coordination sphere with the P2-His N&#x25B;2 or by a &#x201C;substrate-assisted catalysis&#x201D; mechanism. In the first case, the His57 of KLK5 would be pushed back into the catalytic triad, in the second case, the P2-His substrate would transiently reconstitute a functional catalytic triad and catalyze its own cleavage, as in the classic example of a subtilisin His64Ala mutant <xref rid="bib146" ref-type="bibr">[146]</xref>. In any case, the employed Phe or Pro-P2 side chains of other fluorogenic or chromogenic substrates could not play the mechanistic role of His which has the capacity either to coordinate Zn<sup>2+</sup> or to activate the Ser O&#x3B3; nucleophile.</p>
          <p>Also, the chymotryptic counterpart of KLK5, KLK7, is inhibited by&#xA0;Zn<sup>2+</sup> (K<sub>i</sub><sub>(app)</sub>&#xA0;=&#xA0;10&#xA0;&#x3BC;M) when measured with tetrapeptidyl-AMC substrates, and reveals an even stronger inhibition with Cu<sup>2+</sup> (K<sub>i</sub><sub>(app)</sub>&#xA0;=&#xA0;0.6&#xA0;&#x3BC;M) <xref rid="bib147" ref-type="bibr">[147]</xref>. Crystal structures of KLK7 without bound ions (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>D, left panel) and in complex with Cu<sup>2+</sup> revealed direct metal binding by the His99&#xA0;N&#x25B;2 and by the Thr96 carbonyl O via hydrogen bonds to a water molecule (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>D, middle panel). Since the mutation His99Ala abolished Zn<sup>2+</sup> inhibition of KLK7 activity completely, this metal binding site must be the structural basis of the attenuating or inhibitory effect of Zn<sup>2+</sup> and Cu<sup>2+</sup> <xref rid="bib147" ref-type="bibr">[147]</xref>. Similar to the coordination of Zn<sup>2+</sup> in rKLK2 the catalytic His57 could constitute a more stable coordination sphere for the cation <xref rid="bib145" ref-type="bibr">[145]</xref>. A striking parallel to the situation in KLK7 is found in a Cu<sup>2+</sup> complex structure of the Arg96His mutant of rat trypsin which can also be inhibited by Cu<sup>2+</sup> (21&#xA0;&#x3BC;M) and Zn<sup>2+</sup> (128&#xA0;&#x3BC;M) <xref rid="bib148" ref-type="bibr">[148]</xref>. In this structure, the metal ion is liganded by His96 and His57 that has rotated out of the catalytic triad, which explains the inactivation of the enzyme <xref rid="bib149" ref-type="bibr">[149]</xref>. Most likely, the disrupted catalytic triad with His57 bound to Zn<sup>2+</sup> (or Cu<sup>2+</sup>) represents the equivalent inhibited state for KLK7 (<xref rid="fig2" ref-type="fig">Fig.&#xA0;2</xref>D, right panel). Again, the non-competitive Zn<sup>2+</sup> inhibition of KLK7 agrees well with this structure based mechanistic model, in which substrate binding is still possible, as long as P2 side chains are not too large <xref rid="bib147" ref-type="bibr">[147]</xref>.</p>
          <p>Recently, the group of Diamandis reported that a Zn<sup>2+</sup> concentration in the low nanomolar range is sufficient for inhibition of KLK14 (IC<sub>50</sub>&#xA0;=&#xA0;12&#xA0;nM) <xref rid="bib31" ref-type="bibr">[31]</xref>, similar to their findings on Zn<sup>2+</sup> inhibition of KLK5 (IC<sub>50</sub>&#xA0;&lt;&#xA0;12&#xA0;nM) <xref rid="bib143" ref-type="bibr">[143]</xref>. However, these values seem to be problematic in that both proteases would basically never be active in the tissues or fluids, e.g. the epidermis, where they are predominantly expressed. Moreover, an earlier study measured an IC<sub>50</sub> of 2&#xA0;&#x3BC;M for KLK14 <xref rid="bib15" ref-type="bibr">[15]</xref>.</p>
          <p>Zn<sup>2+</sup> modulated activity of epidermal KLKs may be highly relevant under physiological conditions. Because Zn<sup>2+</sup> levels in mammalian epidermis are in the higher micromolar range (50&#x2013;70&#xA0;&#x3BC;g/g dry weight) with the Zn<sup>2+</sup>/Ca<sup>2+</sup> ratio playing a role in skin maturation <xref rid="bib150 bib151" ref-type="bibr">[150,151]</xref>, this metal ion could be important in the activity regulation of the KLKs 5, 7 and 14, in addition to their natural polypeptide inhibitors, the lympho-epithelial Kazal-type inhibitor (LEKTI) (see Section 2.2.2.). Notably, topical ZnO as contained in the widely used zinc ointments for skin improves wound healing and re-epithelialization <xref rid="bib151" ref-type="bibr">[151]</xref>, which may be based on reduction of an otherwise excessive KLK activity. Although copper regulation of proteases is not established, one should consider this alternative to Zn<sup>2+</sup>, in particular for tissues that contain relatively high Cu<sup>2+</sup> ion levels, such as the brain (0.5&#xA0;&#x3BC;M), where KLK7 is also expressed <xref rid="bib130 bib152" ref-type="bibr">[130,152]</xref>.</p>
        </sec>
        <sec id="sec2.1.3">
          <label>2.1.3</label>
          <title>Inhibition of KLKs 8, 10, and 12 by Zn<sup>2+</sup></title>
          <p>The tissue distribution of the KLKs 8, 10, and 12 is more diverse than the aforementioned prostatic and epidermal KLK groups. Nevertheless, it has been demonstrated that KLKs 8 and 12 are inhibited by Zn<sup>2+</sup> as well. For example KLK8, which is thought to have an important function in the hippocampus of the mammalian brain, is stimulated by 10&#xA0;&#x3BC;M Ca<sup>2+</sup>, but inhibited by 3&#xA0;&#x3BC;M Zn<sup>2+</sup> <xref rid="bib123" ref-type="bibr">[123]</xref>. According to the sequence alignment (<xref rid="fig1" ref-type="fig">Fig.&#xA0;1</xref>) it possesses a His99, which could coordinate the inhibiting metal ion together with His57 and a backbone carbonyl, as in KLK7. In the case of KLK10 little is known about activation, natural substrates and regulation, except for the non-prime specificity and its relatively slow cleavage of some pro-KLK peptides <xref rid="bib20 bib99" ref-type="bibr">[20,99]</xref>. Since KLK10 possesses a Zn<sup>2+</sup> binding site involving the catalytic triad with His57 and Asp102, as well as Asp99 in the S2 pocket, it is likely that bound Zn<sup>2+</sup> would interfere with substrate binding and catalysis <xref rid="bib107" ref-type="bibr">[107]</xref>. Similarly, knowledge of the physiological functions of KLK12 is scarce, although a systematic study on its inhibitors showed that its activity against fluorogenic substrates is attenuated by Zn<sup>2+</sup> with an IC<sub>50</sub> of 10&#xA0;&#x3BC;M <xref rid="bib17" ref-type="bibr">[17]</xref>.</p>
        </sec>
      </sec>
      <sec id="sec2.2">
        <label>2.2</label>
        <title>Proteinaceous endogenous KLK inhibitors</title>
        <p>To date, the most important proteinaceous endogenous KLK inhibitors belong to the serpins (MEROPS class I.04), Kazal-type inhibitors (I.01) and the macroglobulins (I.39) <xref rid="bib1" ref-type="bibr">[1]</xref>. Only two endogenous Kunitz-type inhibitors (I.02) acting on KLKs are known. The&#xA0;first one, bikunin, binds KLK1 in the picomolar range, which may also play an important role in lung function and diseases <xref rid="bib153 bib154" ref-type="bibr">[153,154]</xref>, while&#xA0;bikunin is also associated with KLKs 6 and 10 in ovarian cancer ascites fluid <xref rid="bib114" ref-type="bibr">[114]</xref>. The second one is an inhibitor of hepatocyte growth factor activator (HGFA), which is involved in tumor progression and is itself activated by KLKs 4 and 5, which in turn are inhibited by the domains of HGFA inhibitory type 1 (HAI-1) <xref rid="bib155" ref-type="bibr">[155]</xref>. One member of the whey acidic protein (WAP) type inhibitor family (I.17), the secretory leukocyte peptidase inhibitor (SLPI, also anti-leukoprotease, ALP) was shown to inhibit KLK7, which appears to be significant in protease regulation during desquamation <xref rid="bib156" ref-type="bibr">[156]</xref>.</p>
        <sec id="sec2.2.1">
          <label>2.2.1</label>
          <title>Serpins &#x2013; KLK inhibition in blood and prostate</title>
          <p>Serpins (derived from <italic>SER</italic>ine <italic>P</italic>rotease <italic>IN</italic>hibitor) are proteins of 33&#x2013;46&#xA0;kDa that account for about 10% of human blood plasma <xref rid="bib157 bib158 bib159" ref-type="bibr">[157&#x2013;159]</xref>. They occur in all kingdoms of life, inhibit (chymo)trypsin-like and subtilisin-like serine proteases, as well as cysteine proteases, and play physiological roles even beyond protease inhibition <xref rid="bib160 bib161 bib162" ref-type="bibr">[160&#x2013;162]</xref>. In contrast to the substrate-like binding of canonical protease inhibitors, serpins act via a unique &#x201C;springe suicide&#x201D; mechanism on their target protease. After cleaving the P1&#x2013;P1&#x2032;-bond in the reactive center loop by formation of a covalent bond from the P1 residue to the catalytic Ser195, it is then rapidly translocated by about 70&#xA0;&#xC5; to the opposite part of the inhibitor <xref rid="bib163 bib164" ref-type="bibr">[163,164]</xref>. Eventually, this reaction causes a massive structural disorder in the protease (up to 40%), mainly because all stabilizing interactions that were formed during enzyme activation are lost now, thus preparing the protease itself for final degradation by other proteases (<xref rid="fig3" ref-type="fig">Fig.&#xA0;3</xref>) <xref rid="bib165" ref-type="bibr">[165]</xref>. A wealth of mechanistic and structural studies, including several complex structures, have revealed fine details of various steps in serpin protease interaction (<xref rid="fig4" ref-type="fig">Fig.&#xA0;4</xref>) <xref rid="bib166 bib167 bib168 bib169" ref-type="bibr">[166&#x2013;169]</xref>. Although no serpin-KLK complex structure is known to date and the physiological connection of KLK serpin interaction is often unclear, serpins are the best studied KLK inhibitors <xref rid="bib12 bib25" ref-type="bibr">[12,25]</xref>.</p>
          <p>At first glance it seems surprising, that the serpin &#x3B1;<sub>1</sub>-antitrypsin (AAT) fails to inhibit the definite tryptic KLKs 1, 2, 5, 6, 8, 11, and 13 <italic>in vitro</italic>, whereas strong inhibition is observed for the chymotryptic KLK7 with an association constant k<sub>ass</sub> of 3.9&#xA0;&#xD7;&#xA0;10<sup>6</sup>&#xA0;M<sup>&#x2212;1</sup>&#xA0;s<sup>&#x2212;1</sup> (<xref rid="tbl2" ref-type="table">Table&#xA0;2</xref>) <xref rid="bib170 bib171 bib172 bib173 bib174 bib175" ref-type="bibr">[170&#x2013;175]</xref>. However, this inhibition pattern can be explained by the substrate-like reactive loop of AAT with the scissile bond between P1 Met and P1&#x2032; Ser that should be preferred by chymotryptic proteases, albeit with a low reaction rate of KLK3 <xref rid="bib175" ref-type="bibr">[175]</xref>. The KLK3-AAT complex is found increased in benign forms of&#xA0;prostate hyperplasia from about 2% to 4% of total KLK3 in serum <xref rid="bib176 bib177" ref-type="bibr">[176,177]</xref>. Recently, immunological analyses of ovarian cancer ascites fluid indicated that fractions of KLKs 5, 6, 8, and 10 form complexes with ATT <xref rid="bib114" ref-type="bibr">[114]</xref>. Also, AAT strongly inhibits the tryptic KLKs 4 and 14 and to a lesser degree KLK12 <xref rid="bib17 bib31 bib170 bib178" ref-type="bibr">[17,31,170,178]</xref>.</p>
          <p>Contrary to AAT, &#x3B1;<sub>1</sub>-chymotrypsin (ACT) has been detected in complex with up to 85% of total KLK3 in blood plasma by immunoassays, whereby an increased ratio of free to ACT-complexed KLK3 is correlated with progression of prostate cancer <xref rid="bib176 bib179" ref-type="bibr">[176,179]</xref>. Despite a significant concentration of ACT in seminal plasma, it is not bound&#xA0;to KLK3, which was explained by an interference of Zn<sup>2+</sup> with complex formation <xref rid="bib180" ref-type="bibr">[180]</xref>. The association constants k<sub>ass</sub> for ACT with the chymotryptic KLK3, which seems to obey a slow inhibition kinetic, and KLK7 were 3.1&#xA0;&#xD7;&#xA0;10<sup>3</sup> and 3.9&#xA0;&#xD7;&#xA0;10<sup>6</sup>&#xA0;M<sup>&#x2212;1</sup>&#xA0;s<sup>&#x2212;1</sup>, respectively <xref rid="bib133 bib170" ref-type="bibr">[133,170]</xref>. In line with the presence of a P1 Leu-P1&#x2032; Ser scissile bond, ACT does not or only moderately inhibit the tryptic KLKs 1, 2, 4, 5, 8, and 11&#x2013;14 <italic>in vitro</italic> (<xref rid="tbl2" ref-type="table">Table 2</xref>) <xref rid="bib31 bib170 bib172 bib173 bib178 bib181 bib182" ref-type="bibr">[31,170,172,173,178,181,182]</xref>. Interestingly, analyses of human milk and ascites showed that about 5% of the tryptic KLK6 are bound to ACT in an ACT-KLK6 complex, which remains stable after HPLC purification <xref rid="bib182" ref-type="bibr">[182]</xref>.</p>
          <p>Antithrombin III (AT) is the major inhibitor of fibrin clot generating thrombin and other coagulation factors in blood plasma, which is further enhanced by a ternary complex with heparin that links positively charged exosites of AT and its target protease for optimal binding <xref rid="bib183 bib184" ref-type="bibr">[183,184]</xref>. The relatively slow AT inhibition seen for&#xA0;thrombin (<italic>k</italic><sub>ass</sub>&#xA0;=&#xA0;10<sup>4</sup>&#xA0;M<sup>&#x2212;1</sup>&#xA0;s<sup>&#x2212;1</sup>) is accelerated up to 1000-fold by&#xA0;heparin <xref rid="bib185 bib186" ref-type="bibr">[185,186]</xref>. A comparable effect of heparin has been observed for the inhibition of KLK2 by AT, which shows elevated expression and colocalization with KLK2 in tumor cells <xref rid="bib187" ref-type="bibr">[187]</xref>. In&#xA0;accordance with a reactive center containing a P1 Arg-P1&#x2032; Ser, the chymotryptic KLK3 and KLK7 are not inhibited by AT <xref rid="bib170 bib187" ref-type="bibr">[170,187]</xref>. Among the tryptic KLKs, only KLK6 and KLK14 are moderately inhibited by AT, although no heparin was added <xref rid="bib31 bib174" ref-type="bibr">[31,174]</xref>.</p>
          <p>&#x3B1;<sub>2</sub>-Antiplasmin (AP), the major inhibitor of the fibrinolytic plasmin, is unique in that it binds to the zymogen and the mature protease <xref rid="bib188 bib189" ref-type="bibr">[188,189]</xref>. Whether AP is significant for the regulation of KLKs is an unsolved question. In agreement with the reactive bond P1-Arg-P1&#x2032;-Met that seems to be designed for tryptic proteases, AP strongly inhibits KLKs 2, 4, 5, and 12 (<italic>k</italic><sub>ass</sub>&#xA0;=&#xA0;2.2&#xA0;&#xD7;&#xA0;10<sup>5</sup>&#xA0;M<sup>&#x2212;1</sup>&#xA0;s<sup>&#x2212;1</sup>) and moderately inhibits KLKs 7, 8, and 13 <xref rid="bib17 bib31 bib170 bib172" ref-type="bibr">[17,31,170,172]</xref>.</p>
          <p>The relatively unspecific heparin-dependent proteinase C inhibitor (PCI) inhibits various coagulation factors, and can probably switch between the P2 Phe-P1 Arg-P1&#x2032; Ser residues in the reactive center, so that either Phe or Arg inserts into the S1 pocket of the protease <xref rid="bib190 bib191" ref-type="bibr">[190,191]</xref>. PCI is a fast binding inhibitor of KLKs 1, 2, 5, 7, 8, 13, 14, and a slow binding inhibitor for KLKs 3, and 12 <xref rid="bib17 bib170 bib192" ref-type="bibr">[17,170,192]</xref>. Besides a fourfold increased association constant for PCI with KLK2 in the presence of heparin (<italic>k</italic><sub>ass</sub>&#xA0;=&#xA0;8.7&#xA0;&#xD7;&#xA0;10<sup>5</sup>&#xA0;M<sup>&#x2212;1</sup>&#xA0;s<sup>&#x2212;1</sup>), an inhibition constant below 25 pM has been described <xref rid="bib129" ref-type="bibr">[129]</xref>. Since PCI is present at high molar excess in seminal plasma, roughly 30% of total KLK2 and to a lower extent KLK3 are complexed with PCI, which are both implicated in the fertilization process <xref rid="bib193 bib194 bib195" ref-type="bibr">[193&#x2013;195]</xref>.</p>
          <p>Seemingly, one of the serpins, kallistatin, displays high specificity for KLKs, being a strong inhibitor of KLK1 and KLK7, while KLK14 is slowly inhibited <xref rid="bib170 bib196" ref-type="bibr">[170,196]</xref>. In spite of the apparent dual preference for tryptic and chymotryptic KLKs, it cannot inhibit KLKs 5 and 11&#x2013;13 <xref rid="bib170" ref-type="bibr">[170]</xref>. The expression of kallistatin in pancreas and kidney matches that of KLK1 <xref rid="bib197" ref-type="bibr">[197]</xref>. Interestingly, the specificity of kallistatin for KLK1 is derived from the reactive bond P1 Phe-P1&#x2032; Ser, since an exchange to P1-Arg results in a twofold higher inhibition of KLK, but also in similar inhibition of various other serine proteases that are not inhibited by wild type kallistatin <xref rid="bib198 bib199" ref-type="bibr">[198,199]</xref>. Most likely, kallistatin regulates the KLK1 activity, influencing blood pressure and angiogenesis, which may also depend on the heparin binding capacity of kallistatin <xref rid="bib200 bib201 bib202" ref-type="bibr">[200&#x2013;202]</xref>.</p>
          <p>Inhibition of KLKs 5, 7, 8, 12&#x2013;14 by the C1 inhibitor was only moderate <italic>in vitro</italic>, and may also not be significant <italic>in vivo</italic>, as well as the KLK3 inhibition by the monocyte/neutrophil elastase inhibitor (MNEI), which can switch at the reactive center P2 Phe-P1 Cys-P1&#x2032; Met to Phe as P1 residue for chymotrypsin-like proteases <xref rid="bib170 bib203" ref-type="bibr">[170,203]</xref>. The complex of KLK2 with serpin PI-6 that is associated with tissue damage, necrosis or neoplasia and the complex with PAI-1 that&#xA0;seems to promote cancer by inactivation of the primary uPA inhibitor <xref rid="bib204 bib205" ref-type="bibr">[204,205]</xref> are likely to be of physiological relevance in the prostate. However, serpins may interact with KLKs in other tissues, as exemplified by the human KLK8 (neuropsin) colocalization in keratinocytes with its strong inhibitor PI-6 <xref rid="bib206" ref-type="bibr">[206]</xref> and by the inhibition of murine KLK8 by the tight binding serine proteinase inhibitor 3, which colocalize in mouse brain <xref rid="bib207" ref-type="bibr">[207]</xref>.</p>
        </sec>
        <sec id="sec2.2.2">
          <label>2.2.2</label>
          <title>LEKTI-1 and 2 &#x2013; multi-domain Kazal-type KLK inhibitors in skin</title>
          <p>Soon after the discovery of the 15 domain, 120&#xA0;kDa Kazal-type inhibitor, which was called lympho-epithelial Kazal-type inhibitor (LEKTI), it was found that mutations in its gene (<italic>SPINK5</italic>) cause Netherton syndrome. The syndrome is characterized by a severe autosomal recessive genodermatosis with altered desquamation, impaired keratinization, hair malformation and a skin barrier defect <xref rid="bib208 bib209" ref-type="bibr">[208,209]</xref>. <italic>SPINK5</italic> knockout mice feature a Netherton syndrome-like condition, which is based on the hyperactivity of KLKs 5 and 7 that are not sufficiently controlled by their natural inhibitor, LEKTI-1 <xref rid="bib210" ref-type="bibr">[210]</xref>. Human mutations in <italic>SPINK5</italic> generate LEKTI-variants that have lost different C-terminal domains, such as d1-4 or d1-8, which is accompanied by higher concentrations and activity levels of most epidermal KLKs <xref rid="bib211" ref-type="bibr">[211]</xref>. Mutations in the <italic>SPINK5</italic> gene are also responsible for the widespread atopic dermatitis, which enhances the susceptibility of patients to food allergies and asthma <xref rid="bib212 bib213 bib214" ref-type="bibr">[212&#x2013;214]</xref>. In addition to the elevated degradation of corneodesmosomes in the stratum corneum, KLK5 causes atopic dermatitis-like lesions via PAR2-mediated thymic stromal lymphopoietin expression <xref rid="bib215" ref-type="bibr">[215]</xref>. An NMR analysis of LEKTI-1 domains 1 and 6 demonstrated that their structures differ from the classical Kazal-type architecture, especially in the reactive center loops. This may be due to the lack of a third disulfide bond, which is present in the classical canonical serine protease inhibitor scheme. Only two of the 15 LEKTI-1 domains contain three disulfide bonds <xref rid="bib216" ref-type="bibr">[216]</xref>. Nevertheless, several domains of LEKTI-1 are potent serine protease inhibitors and function according to the substrate-like canonical binding. Canonical Kazal-type inhibitors present the scissile bond between P1&#x2013;P1&#x2032; to the protease, however, its cleavage is very slow compared with substrate turnover, as the hydrolysis constant K<sub>hydr</sub> is in the range of unity (<italic>K</italic><sub>hydr</sub>&#xA0;=&#xA0;[Inhibitor<sub>cleaved]</sub>/[Inhibitor<sub>uncleaved</sub>]&#xA0;=&#xA0;1) and the cleaved bond may be reconstituted again (<xref rid="fig5" ref-type="fig">Fig.&#xA0;5</xref>) <xref rid="bib89 bib217" ref-type="bibr">[89,217]</xref>. Full length LEKTI-1 contains mostly potential P1 Arg residues, but also a P1 Gln-P1&#x2032; Asp in the reactive center loop of the first domain that might target chymotryptic proteases, in particular KLK7. This suggestion is supported by a study on natural truncated versions of LEKTI-1 that usually comprise the first domain and did not fail to inhibit the chymotryptic activity in the outer layers of skin <xref rid="bib211" ref-type="bibr">[211]</xref>. Further investigations revealed that domain 6 alone can inhibit both KLK5 and KLK7 <xref rid="bib218" ref-type="bibr">[218]</xref>. Recombinant LEKTI-1 fragments of domains 6&#x2013;8 and 9&#x2013;12 inhibited KLK5 with K<sub>i</sub> values between 1.2 and 5.5&#xA0;nM, while fragment d6-9&#x2032; (a truncated domain 9) inhibited KLK7 with a K<sub>i</sub> of 11&#xA0;nM <xref rid="bib219" ref-type="bibr">[219]</xref>. Additionally, LEKTI-1 d1-6, d6-9&#x2032;, and d9-12 inhibited KLK5, KLK6, KLK13, and KLK14 with K<sub>i</sub> values in the range of 2&#x2013;416&#xA0;nM, while only KLK5 was inhibited by d12-d15 (<italic>K</italic><sub>i</sub>&#xA0;=&#xA0;22&#xA0;nM) <xref rid="bib63" ref-type="bibr">[63]</xref>.</p>
          <p>In cultured keratinocytes and in the epidermis it was demonstrated that the LEKTI-1 precursor is secreted as several fragments, of which d5, d6, d8-11, and d9-15 specifically inhibit KLK 5, 7, and 14, whereby the strongest inhibition was seen for KLK5 with d8-11, although a shift to acidic pH dissociated the otherwise nearly irreversible, tight binding complex <xref rid="bib32" ref-type="bibr">[32]</xref>.</p>
          <p>Recently, a polypeptide of 85 amino acids, expressed in skin and encoded by the <italic>SPINK9</italic> gene with high homology to LEKTI-1 was discovered and termed LEKTI-2 <xref rid="bib220" ref-type="bibr">[220]</xref>. This polypeptide was found colocalized with KLK5 in the epidermis, which possesses the unusual reactive bond P1-His-P1-Met and inhibits recombinant KLK5 (<italic>K</italic><sub>i</sub>&#xA0;=&#xA0;65&#xA0;nM), KLK8, but not KLK7 or 14 <xref rid="bib221" ref-type="bibr">[221]</xref>.</p>
        </sec>
        <sec id="sec2.2.3">
          <label>2.2.3</label>
          <title>Macroglobulins &#x2013; large compartments for unspecific protease removal</title>
          <p>In a classical paper, Barret and Starkey elaborated a mechanism for &#x3B1;<sub>2</sub>-macroglobulin (&#x3B1;<sub>2</sub>M) inhibition, a huge protein of 720&#xA0;kDa that was able to block the proteolytic activity of nearly all proteases. At that time it was also known that an &#x3B1;<sub>2</sub>M inhibited protease was still active against small substrates, but no longer cleaved proteins. Thus, it was proposed that &#x3B1;<sub>2</sub>M is proteolytically attacked by its target protease in a so-called bait region, which causes a conformational change in &#x3B1;<sub>2</sub>M, resulting in an irreversibly trapped protease <xref rid="bib222" ref-type="bibr">[222]</xref>. This mechanistic description has remained valid and has been supported and elaborated on by&#xA0;structural information from electron microscopy and X-ray crystallography. The structural arrangement of the protease free &#x3B1;<sub>2</sub>M comprises two dimers with a large central cavity <xref rid="bib223" ref-type="bibr">[223]</xref>. Upon protease cleavage in the bait sequence P<sup>692</sup>QLQQYEMHGPEGLRVGFYESDV-MGRGHARLVHVEEPHT<sup>730</sup> and subsequent thiol ester cleavage near the central region, two &#x3B2;-strands of &#x3B1;<sub>2</sub>M untwist to expose the central cavity to proteases, e.g. to chymotrypsin, of which two molecules were covalently linked inside the central cavity <xref rid="bib224 bib225" ref-type="bibr">[224,225]</xref>. Since the reactive internal &#x3B2;-cysteinyl-&#x3B3;-glutamyl-ester of &#x3B1;<sub>2</sub>M can react with any exposed Lys side chain on a protein surface, any protease can be trapped, and thus &#x3B1;<sub>2</sub>M has been termed a &#x201C;panproteinase inhibitor&#x201D;, which clears the blood from proteases destined for degradation <xref rid="bib226 bib227" ref-type="bibr">[226,227]</xref>. Typically, the protease is not fixed to a large extent and retains a considerable flexibility inside the &#x3B1;<sub>2</sub>M cavity after trapping <xref rid="bib228" ref-type="bibr">[228]</xref>.</p>
          <p>The ability of &#x3B1;<sub>2</sub>M to effectively internalize and trap KLK1 has been demonstrated <italic>in vitro</italic> and it was even used as a tool to remove it from samples, where the KLK1 activity was unwanted <xref rid="bib222 bib229" ref-type="bibr">[222,229]</xref>. However, &#x3B1;<sub>2</sub>M complex formation with KLKs is of physiological significance, too, as observed for KLK2 in serum of prostate cancer patients <xref rid="bib230 bib231" ref-type="bibr">[230,231]</xref>. Also, KLK3 forms readily stable complexes with &#x3B1;<sub>2</sub>M in blood serum, as well as with the &#x3B1;<sub>2</sub>M homologue pregnancy zone protein (PZP), which exhibits some interesting mechanistic differences to &#x3B1;<sub>2</sub>M <xref rid="bib232 bib233" ref-type="bibr">[232,233]</xref>. Interestingly, KLKs 4, 5, 6, 12, and 13&#xA0;were not significantly inhibited by &#x3B1;<sub>2</sub>M <xref rid="bib17 bib101 bib173 bib174 bib178" ref-type="bibr">[17,101,173,174,178]</xref>, although in mouse brain KLK8 (neuropsin) was inhibited by the &#x3B1;<sub>2</sub>M homologue murinoglobulin 1 and a novel inhibitor, phosphatidyl ethanolamine binding protein (PEBP) <xref rid="bib207 bib234" ref-type="bibr">[207,234]</xref>.</p>
        </sec>
        <sec id="sec2.2.4">
          <label>2.2.4</label>
          <title>Autoinhibition in KLK4 oligomers &#x2013; an exceptional case?</title>
          <p>Compartmentalization within proteinaceous inhibitors as in the macroglobulins is quite rarely realized, whereas proteases provide more examples of that kind. In the proteasome, bleomycin hydrolase, tricorn protease, or &#x3B1;- and &#x3B2;-tryptases the oligomerization leads to the formation of an internal cavity or blocking of the active sites that are not accessible for most potential protein substrates <xref rid="bib235 bib236 bib237 bib238 bib239 bib240" ref-type="bibr">[235&#x2013;240]</xref>. This compartmentalization represents some kind of self-inhibition, and can be overcome by activators, which induce a conformational change or transfer substrates to the active site as in the 26S proteasome <xref rid="bib241" ref-type="bibr">[241]</xref>.</p>
          <p>In this context, recombinant, refolded KLK4 exhibited 700&#xA0;kDa oligomers in solution, corresponding, to 24-mers, which were hardly active against chromogenic and fluorogenic substrates <xref rid="bib137" ref-type="bibr">[137]</xref>. On the contrary, KLK4 that was refolded in the presence of 2&#xA0;mM Ca<sup>2+</sup> was&#xA0;only monomeric (ca. 25&#xA0;kDa) and highly active, resulting even in&#xA0;autodegradation within a few hours <xref rid="bib107" ref-type="bibr">[107]</xref>. Also, these studies revealed that in three known crystal forms KLK4 assembled to oligomers, consisting of stacked cyclic tetramers or octamers, respectively, in which the active sites are partially blocked (<xref rid="fig6" ref-type="fig">Fig.&#xA0;6</xref>). Since binding and turnover of even small tripeptidyl-pNA substrates is sterically not possible, in particular due to a partially blocked S2 subsite, the tetramers and octamers appear to be self-inhibiting protease forms with regulatory potential <xref rid="bib137" ref-type="bibr">[137]</xref>.</p>
        </sec>
      </sec>
    </sec>
    <sec id="sec3">
      <label>3</label>
      <title>Exogenous and synthetic inhibitors in KLK research</title>
      <p>In biochemical and biophysical studies both exogenous natural inhibitors and synthetic small molecules have been used, mostly to analyze the primary specificity of the respective kallikrein-related peptidase and then for refined studies of extended substrate specificity. This approach can be exemplified by a study on mouse KLK1b27, in which the enzyme was characterized as chymotryptic serine protease, according to its inhibition by diisopropylfluorophosphate (DIFP), phenylmethylsulfonyl fluoride (PMSF), and tosyl-phenyl-chloromethyl ketone (TPCK) and chymostatin, in contrast to the weaker inhibition by the tryptic enzyme inhibitors tosyllysylchloromethyl ketone (TLCK), leupeptin, antipain, soybean trypsin inhibitor (SBTI), and aprotinin (bovine pancreatic trypsin inhibitor, BPTI) <xref rid="bib242" ref-type="bibr">[242]</xref>. Such knowledge often helps to improve the purification of a KLK by preventing autodegradation. Although the above mentioned inhibitor molecules are rather unspecific and bind to a great variety of&#xA0;proteases, they may serve as starting point for highly specific compounds, as in the recent example of an activity-based compound that was employed for immunofluorimetric measurements of active KLK6: the compound biotin-(PEG)<sub>4</sub>-Pro-Lys-diphenylphosphonate formed a covalent bond to the nucleophilic Ser195 O&#x3B3; <xref rid="bib243" ref-type="bibr">[243]</xref>.</p>
      <sec id="sec3.1">
        <label>3.1</label>
        <title>Small molecules</title>
        <sec id="sec3.1.1">
          <label>3.1.1</label>
          <title>Sulfonyfluorides and diisopropylfluorophosphate as catalytic serine inhibitors</title>
          <p>The unspecific irreversible, but toxic serine protease and esterase inhibitors PMSF (Pubchem CID 4784, <ext-link ext-link-type="uri" xlink:href="http://pubchem.ncbi.nlm.nih.gov/">http://pubchem.ncbi.nlm.nih.gov/</ext-link>) or DIFP (Pubchem CID 5936) and their derivatives react with nucleophilic serine and cysteine residues, as does the non-toxic trypsin-specific aminoethyl benzenesulfonyl fluoride (AEBSF, Pubchem CID 1701) <xref rid="bib244" ref-type="bibr">[244]</xref>. For KLK1, inhibition by PMSF and for KLK3, reaction with PMSF and AEBSF has been reported <xref rid="bib42 bib245" ref-type="bibr">[42,245]</xref>. Due to the high toxicity, the volatile DIFP is not used for purification purposes.</p>
        </sec>
        <sec id="sec3.1.2">
          <label>3.1.2</label>
          <title>Benzamidines as tryptic S1 inhibitors</title>
          <p>Both benzamidine (BEN) and its derivative para-aminobenzamidine (p-ABA) are specific for tryptic proteases, since they fill the S1 pocket and usually form a salt bridge between their positively charged amidino group and the negatively charged Asp189. Due to a lack of additional interaction with the protease, such as binding to the oxyanion pocket or to the S2&#x2013;S4 subsites, inhibition constants of benzamidine range from high &#x3BC;M to mM. In case of KLK6 63&#xA0;&#x3BC;M BEN was required for 20% inhibition, while the inhibitor was applied at&#xA0;20&#xA0;mM for crystallization and was well defined in the S1 site of the KLK6 structure <xref rid="bib174 bib246" ref-type="bibr">[174,246]</xref>. Definitely, BEN and p-ABA are useful tools in protein purification and crystallization of tryptic KLKs, since they inhibit the proteolytic activity and rigidify the active site, as corroborated by more than 100 corresponding crystal structures (Pubchem CIDs 2332 and 1725, <ext-link ext-link-type="uri" xlink:href="http://pubchem.ncbi.nlm.nih.gov/">http://pubchem.ncbi.nlm.nih.gov/</ext-link>). Thus, crystal structures of pKLK1, KLKs 4 and 6 in complex with benzamidine or para-aminobenzamidine were solved, respectively, explaining subtle differences of the S1 specificity determinants (<xref rid="tbl3 tbl4" ref-type="table">Tables 3, 4</xref>) (<xref rid="fig7" ref-type="fig">Fig.&#xA0;7</xref>A, B, C) <xref rid="bib137 bib246 bib247" ref-type="bibr">[137,246,247]</xref>.</p>
        </sec>
        <sec id="sec3.1.3">
          <label>3.1.3</label>
          <title>The aldehydes leupeptin, antipain, chymostatin interact with the S1 to S4 pockets</title>
          <p>Remarkably, higher organisms utilize exclusively ions or polypeptides as protease activity attenuators or inhibitors, whereas microorganisms produce various small molecule inhibitors, which target host proteases <xref rid="bib89" ref-type="bibr">[89]</xref>. For example, leupeptin (acetyl-Leu-Leu-Arginal) and antipain (carboxyphenylethyl-carbamoyl-Arg-Val-Argininal) are suitable competitive KLK inhibitors that are produced by Actinobacteria, such as <italic>Streptomyces</italic> <xref rid="bib248" ref-type="bibr">[248]</xref>. The aldehyde function of leupeptin and antipain reacts with Ser and Cys nucleophiles to a transition state-like inhibited protease complex, which is reversible. Their P1 Arg is suited to inhibit tryptic KLKs, e.g. KLK2 around 100&#xA0;&#x3BC;M, while antipain was a much stronger inhibitor of KLK8 (IC<sub>50</sub>&#xA0;=&#xA0;460&#xA0;nM) than leupeptin (IC<sub>50</sub>&#xA0;=&#xA0;66&#xA0;&#x3BC;M) <xref rid="bib123 bib129" ref-type="bibr">[123,129]</xref>. Also, Leupeptin inhibited KLK5 at 1.7 to 10&#xA0;&#x3BC;M and cocrystallized with this&#xA0;protease, whereby the N-terminal extension occupied the subsites S2&#x2013;S4 <xref rid="bib15 bib144" ref-type="bibr">[15,144]</xref> (<xref rid="fig7" ref-type="fig">Fig.&#xA0;7</xref>D). The widely used chymostatin is the counterpart of leupeptin and antipain and is directed against chymotryptic proteases. It corresponds largely to a tetrapeptide with a leucyl-phenylalaninal moiety and reacts with proteases as the above described aldehydes. Chymostatin inhibition was described for the chymotryptic KLK3, but also for the tryptic KLKs 8 and 14 (IC<sub>50</sub>&#xA0;=&#xA0;8&#xA0;&#x3BC;M and 30&#xA0;&#x3BC;M) <xref rid="bib15 bib123 bib249" ref-type="bibr">[15,123,249]</xref>.</p>
        </sec>
        <sec id="sec3.1.4">
          <label>3.1.4</label>
          <title>Chloromethyl ketones</title>
          <p>Contrary to reversible binding inhibitors, chloromethyl ketones (CKs, CMKs) are widely used irreversible cysteine- and serine protease inhibitors, which, similar to aldehydes, allow the design of specific inhibitors for an individual target. For example, such covalent inhibitors are suitable for co-crystallization with proteases, but often require an iterative process of optimization. For the analysis of the primary KLK specificity some standard compounds have been applied. In case of the tryptic KLKs 1, 4, 8 of tosyl-lysyl chloromethyl ketone (TLCK) was an efficient inhibitor, as well as <sc>d</sc>-phenylalanyl-<sc>l</sc>-prolyl-<sc>l</sc>-arginyl chloromethyl ketone (PPACK), which inhibited KLK2 at 5&#xA0;&#x3BC;M <xref rid="bib48 bib123 bib129 bib245" ref-type="bibr">[48,123,129,245]</xref>. Surprisingly, the chymotryptic counterpart tosyl-phenylalanyl chloromethyl ketone (TPCK) does not seem suitable to inhibit KLK3, whereas KLK7 was successfully crystallized with Ala-Ala-Phe-CMK and succinyl-Ala-Ala-Pro-Phe-CMK, resulting in structures with a resolution up to 1.0&#xA0;&#xC5; (<xref rid="fig7" ref-type="fig">Fig.&#xA0;7</xref>E, F) <xref rid="bib147" ref-type="bibr">[147]</xref>.</p>
        </sec>
      </sec>
      <sec id="sec3.2">
        <label>3.2</label>
        <title>Polypeptidic inhibitors</title>
        <sec id="sec3.2.1">
          <label>3.2.1</label>
          <title>Kunitz- type trypsin inhibitors</title>
          <p>Several canonical substrate-like binding Kunitz-type inhibitors have been employed in research for the analysis of KLK enzymatic activity (<xref rid="tbl3" ref-type="table">Table 3</xref>) <xref rid="bib89" ref-type="bibr">[89]</xref>. The most common ones are the soybean trypsin inhibitor (SBTI, I03.001 according to MEROPS), the lima bean trypsin/Bowman-Birk inhibitor (LBTI, I12.001, which occurs as compound inhibitor LI12-001 consisting of I12.001 and I12.008) and aprotinin, the bovine pancreatic trypsin inhibitor (BPTI, I02.001), which is only found in the genus <italic>Bos</italic>. Interactions of proteases and&#xA0;the 181 amino acid SBTI are well understood on functional and structural level, not least because its reactive P1 Arg-P1&#x2032; Ile bond was an early target of bioengineering <xref rid="bib250 bib251" ref-type="bibr">[250,251]</xref>. The much shorter LBTI comprises 71 residues with a P1 Lys-P1&#x2032; Ser reactive bond for trypsin-like and a P1 Leu-P1&#x2032; Ser for chymotrypsin-like proteases, but some related Bowman-Birk inhibitors possess a second reactive bond with P1 Arg <xref rid="bib252 bib253" ref-type="bibr">[252,253]</xref>. Due to its anticarcinogenic effects this inhibitor type from plant nutrients gained much interest in medical sciences <xref rid="bib254" ref-type="bibr">[254]</xref>. SBTI efficiently inhibited the tryptic KLKs 5 and 14 at an IC<sub>50</sub> of 100&#xA0;nM, while KLK6 required only 16&#xA0;nM for 82% inhibition and KLK4 about 50&#xA0;&#x3BC;M for 99% inhibition <xref rid="bib15 bib48 bib174" ref-type="bibr">[15,48,174]</xref>. It was also demonstrated that SBTI is a good inhibitor of rKlk2 or tonin (<italic>K</italic><sub>i</sub>&#xA0;=&#xA0;160&#xA0;nM) and rKlk1-c9 (<italic>K</italic><sub>i</sub>&#xA0;=&#xA0;70&#xA0;nM) <xref rid="bib111" ref-type="bibr">[111]</xref>.</p>
          <p>Mature BPTI is 58 residues long and presents a reactive loop with a scissile P1 Lys-P1&#x2032; Ala bond to tryptic proteases. The BPTI/bovine trypsin complex was one of the first refined crystal structures and revealed, in addition to details of canonical binding, that the Ser195 O&#x3B3; is covalently bound to the tetrahedral C atom of Lys15, representing the transition state of the cleavage reaction <xref rid="bib255 bib256" ref-type="bibr">[255,256]</xref>. These findings were consistent with kinetic studies that found for BPTI with trypsin <italic>K</italic><sub>Hydrolysis</sub>&#xA0;=&#xA0;[BPTI<sub>cleaved</sub>]/[BPTI<sub>uncleaved</sub>]&#xA0;=&#xA0;0.33, whereby equilibrium is reached in about one year <xref rid="bib257" ref-type="bibr">[257]</xref>. Applications of BPTI are manifold in laboratories, such as the engineering of its specificity, or its use in cardiopulmonary surgery and organ transplantation <xref rid="bib258 bib259" ref-type="bibr">[258,259]</xref>.</p>
          <p>Astonishingly, the pioneers of kallikrein protease research, Kraut, Werle, and Frey discovered as early as 1930 that certain extracts of bovine glands (containing BPTI) inhibited the enzymatic activity of kallikrein (KLK1) <xref rid="bib260" ref-type="bibr">[260]</xref>. These seminal studies were later confirmed and evidence was found that other tryptic KLKs are well inhibited by BPTI, such as KLK 2 (IC<sub>50</sub>&#xA0;=&#xA0;30&#xA0;&#x3BC;M), rKlk2 (<italic>K</italic><sub>i</sub>&#xA0;=&#xA0;76&#xA0;&#x3BC;M), KLK4 (100% inhibition with 4&#xA0;&#x3BC;M BPTI), KLK5 (IC<sub>50</sub>&#xA0;=&#xA0;3&#xA0;&#x3BC;M), KLK12 (IC<sub>50</sub>&#xA0;=&#xA0;2&#xA0;&#x3BC;M), and KLK14 (IC<sub>50</sub>&#xA0;=&#xA0;3&#xA0;&#x3BC;M) <xref rid="bib15 bib17 bib48 bib129 bib245" ref-type="bibr">[15,17,48,129,245]</xref>. Despite its considerable specificity for tryptic KLKs, to date, only one kallikrein structure in complex with BPTI has been solved, demonstrating canonical inhibitor binding in a transition state-like manner for porcine pKLK1 (<xref rid="fig8" ref-type="fig">Fig.&#xA0;8</xref>A, B) <xref rid="bib247" ref-type="bibr">[247]</xref>.</p>
        </sec>
        <sec id="sec3.2.2">
          <label>3.2.2</label>
          <title>Hirustasin</title>
          <p>Although produced by the leech <italic>Hirudo medicinalis</italic>, the canonical 55 residue inhibitor hirustasin with a reactive P1 Arg-P1&#x2032; Ile bond apparently inhibits not blood coagulation, as the thrombin inhibitor hirudin or other protease inhibitors from leech <xref rid="bib261 bib262" ref-type="bibr">[261,262]</xref>. Moreover, hirustasin discriminates strongly between KLK1 (<italic>K</italic><sub>i</sub>&#xA0;=&#xA0;13&#xA0;nM) and plasma kallikrein, which is not inhibited at all <xref rid="bib261" ref-type="bibr">[261]</xref>. A P2 Cys forming a disulfide characterizes this unusual inhibitor type (I15.001) from the antistasin family, of which a crystal structure was solved in complex with KLK1, exhibiting the typical transition state geometry at the reactive P1-Arg and tight interactions from P4 to P2 with the corresponding specificity pockets of the protease (<xref rid="fig8" ref-type="fig">Fig.&#xA0;8</xref>C, D) <xref rid="bib263" ref-type="bibr">[263]</xref>.</p>
        </sec>
      </sec>
    </sec>
    <sec id="sec4">
      <label>4</label>
      <title>Pharmaceutical approaches</title>
      <p>Most of the small molecule inhibitors that have been employed in biochemical studies of KLKs are often of insufficient specificity, or&#xA0;cannot be administered to patients. Thus, the synthesis of biotolerable drugs or the engineering of large biomolecules from natural sources is required. The function of distinct KLKs in certain diseases is not always well defined, as shown in an overview disease matrix (<xref rid="tbl5" ref-type="table">Table 5</xref>). However, KLKs are attractive diagnostic and therapeutic targets, particularly the members of the family that are involved in prostate cancer and skin diseases <xref rid="bib264" ref-type="bibr">[264]</xref>.</p>
      <sec id="sec4.1">
        <label>4.1</label>
        <title>Synthetic small compounds directed against KLK3 and KLK7</title>
        <p>In order to maximize bioavailability and efficiency some basic principles should hold true for the compound to be designed. A famous and successful guideline for small molecule drugs is to obey Lipinski&#x2019;s &#x201C;rule of five&#x201D; and its recent modifications <xref rid="bib265 bib266 bib267" ref-type="bibr">[265&#x2013;267]</xref>; nonetheless, a significant part of pharmaceuticals is derived from natural compounds which tend to exceed the initial rule&#x2019;s suggested molecular weight of 500&#xA0;Da <xref rid="bib268" ref-type="bibr">[268]</xref>. It is also of high importance to consider the exact time and tissue localization in an organism for the administration of a given drug, in order to avoid undesirable side effects <xref rid="bib269" ref-type="bibr">[269]</xref>. Strategies to obtain optimal drugs usually employ combinations of 1) massive screening campaigns; 2) &#x201C;directed evolution&#x201D;; 3) &#x201C;rational design&#x201D;, often supported by structural data of biomolecules as well as a more sophisticated multiparameter design, yielding extremely tight binding serine protease inhibitors <xref rid="bib270 bib271 bib272 bib273" ref-type="bibr">[270&#x2013;273]</xref>. Common features of small molecule serine protease inhibitors are peptidomimetic groups that bind some of the specificity pockets and an altered &#x201C;scissile&#x201D; bond, which may react with the catalytic serine, such as those present in phosphonyl, boronic acid, inverse substrate esters, &#x3B1;-keto heterocycles, isocoumarins, and succinimide derivatives <xref rid="bib274" ref-type="bibr">[274]</xref>.</p>
        <p>The major target among the KLKs for medical and pharmaceutical research is definitely KLK3/PSA. Thus, small molecules have been designed by pharmaceutical researchers and companies, stimulated by the recent advancements of structural data on several KLKs (<xref rid="tbl4" ref-type="table">Table 4</xref>). Due to the required mimicking of a natural active site binding molecule, such inhibitory compounds often contain amino acid derived groups, as the &#x3B2;-lactam derived 2-azetidinone with a Tyr side chain that inhibited KLK3 with an IC<sub>50</sub> of 226&#xA0;nM and was apparently designed obeying the &#x201C;rule of five&#x201D; <xref rid="bib275" ref-type="bibr">[275]</xref>. In particular, for KLK3 heterocyclic compounds in a structure&#x2013;activity relationship approach reached an IC<sub>50</sub> of 300&#xA0;nM <xref rid="bib276" ref-type="bibr">[276]</xref>.</p>
        <p>The pharmaceutical relevance of KLK7 inhibitors is evidenced by&#xA0;patents for a small molecule KLK7 inhibitor <xref rid="bib277" ref-type="bibr">[277]</xref> (&#x201C;Use of cyclic&#xA0;depsipeptides to inhibit Kallikrein 7&#x201D;, WO2009024528 (A1). Novartis) that was analyzed by X-ray crystallography with the purpose of applying such compounds in treatments for human skin diseases, in particular atopic dermatitis, psoriasis or Netherton&#x2019;s syndrome <xref rid="bib278" ref-type="bibr">[278]</xref>.</p>
      </sec>
      <sec id="sec4.2">
        <label>4.2</label>
        <title>Peptide-based inhibitors of KLKs</title>
        <p>Already in 1981, a very efficient inhibitor of KLK1 was generated, which contained a P3-<sc>d</sc>-Phe residue and reached an IC<sub>50</sub> of 800&#xA0;nM <xref rid="bib279" ref-type="bibr">[279]</xref>. Potent analgesic and anti-inflammatory peptidic compounds that contain the non-natural amino acid <sc>l</sc>-4-aminomethyl-phenylalanine inhibited KLK1 with a K<sub>i</sub> of 1.2&#xA0;&#x3BC;M <xref rid="bib280" ref-type="bibr">[280]</xref>. Another synthetic peptide-based inhibitor specific for KLK1 (<ext-link ext-link-type="uri" xlink:href="ncbi-n:FE999024">FE999024</ext-link>) was capable to attenuate breast cancer cell invasion in a Matrigel assay <xref rid="bib281" ref-type="bibr">[281]</xref>. Pure peptide based-inhibitors of KLK2 for targeting prostate cancer were found by screening phage display peptide libraries, resulting in 10&#x2013;11 amino acid long linear peptides with IC<sub>50</sub> values reaching 1.4&#xA0;&#x3BC;M <xref rid="bib282" ref-type="bibr">[282]</xref>. This basic approach was extended and improved by introducing cyclic peptides as efficient KLK2 inhibitors <xref rid="bib283 bib284" ref-type="bibr">[283,284]</xref>. Also, so-called azapeptides that contain one N-atom instead of a C&#x3B1;, e.g. tBOC-Ser-Phe-aza-Tyr-phenoxy, resulted in KLK3 inhibition with a K<sub>i</sub> of 500&#xA0;nM <xref rid="bib285" ref-type="bibr">[285]</xref>. Non-hydrolyzable boronic acid inhibitors, such as carbobenzyloxy-Ser-Ser-Lys-P1-Leu-(boro)-P1&#x2032;-Leu, turned out to be much more specific for the chymotryptic KLK3 with a K<sub>i</sub> of 65&#xA0;nM than for chymotrypsin itself&#xA0;(K<sub>i</sub>&#xA0;=&#xA0;3.9&#xA0;&#x3BC;M) <xref rid="bib286" ref-type="bibr">[286]</xref>. This inhibitor type was improved by introducing the non-natural amino acid nor-leucine (Nle) into CBZ-Ser-Ser-Gln-Nle-(boro)-Leu to result for KLK3 in a K<sub>i</sub> of 25&#xA0;nM, which could be employed as imaging agent for prostate cancer by attachment of a metal chelating group to the compound <xref rid="bib287" ref-type="bibr">[287]</xref>. A&#xA0;detailed overview of peptide based and other small molecule inhibitors of KLK3 by LeBeau and coworkers is focussed on their usage in selective imaging and in targetted treatment of prostate cancer <xref rid="bib288" ref-type="bibr">[288]</xref>. Recently, the naturally occurring 14 residue long cyclic sunflower trypsin inhibitor (SFTI of the Bowman-Birk family) was re-engineered by a combination of molecular modeling and sparse matrix substrate screening, to block the proteolytic activity of KLK4 (<italic>K</italic><sub>i</sub>&#xA0;=&#xA0;3.6&#xA0;nM) and potentially block stimulation of PAR activity <xref rid="bib289" ref-type="bibr">[289]</xref>. Fully synthetic domain 6 of LEKTI, which was generated by fragment condensation of residues 1&#x2013;22 and 23&#x2013;68, inhibited KLK5 with an IC<sub>50</sub> of 120&#xA0;nM, which is slightly lower than measured for the recombinantly produced peptide (IC<sub>50</sub>&#xA0;=&#xA0;135&#xA0;nM) <xref rid="bib290" ref-type="bibr">[290]</xref>.</p>
      </sec>
      <sec id="sec4.3">
        <label>4.3</label>
        <title>Endogenous human inhibitors serve as scaffold for therapeutic agents</title>
        <p>After determination of the substrate specificity of KLK2 <xref rid="bib106" ref-type="bibr">[106]</xref>, selected substrates sequences were transplanted into the reactive site loop of &#x3B1;1-antichymotrypsin (ACT), yielding a highly specific KLK2 inhibitor with high reactivity, which could be a useful tool to detect and target prostate cancer progression <xref rid="bib291" ref-type="bibr">[291]</xref>. In a related approach, based on determination of the KLK14 specificity by phage display <xref rid="bib104" ref-type="bibr">[104]</xref>, selected substrates were incorporated as modified reactive site loop into the scaffold of serpins &#x3B1;1-antitrypsin (AAT) or ACT, which formed covalent complexes with KLK14, especially the engineered ACT inhibitors <xref rid="bib292" ref-type="bibr">[292]</xref>.</p>
      </sec>
      <sec id="sec4.4">
        <label>4.4</label>
        <title>Engineered antibodies inhibit the proteolytic activity of KLKs</title>
        <p>The antibody scaffold for the design of novel protease inhibitors offers some advantages over common inhibitors that bind in a substrate-like manner, since antibodies can in addition to binding of the often conserved protease active sites exploit binding to more variable individual exosites on the protease surface, which may enhance the selectivity of inhibition extraordinarily <xref rid="bib293" ref-type="bibr">[293]</xref>. In case of KLK1 an engineered antibody bound specifically to the active site of the tryptic protease, resulting in inhibition of the peptidase activity with an inhibition constant around 130 pM, paving the way for a novel cure of asthma <xref rid="bib294" ref-type="bibr">[294]</xref>. Also, a monoclonal antibody against KLK4 was capable of reducing its activity <italic>in vitro</italic>, although this engineered molecule needs further optimization <xref rid="bib178" ref-type="bibr">[178]</xref>. Similarly, for KLK13, which is overexpressed in ovarian cancer patients, a monoclonal antibody inhibited its activity, leading possibly to a therapeutic application <xref rid="bib14" ref-type="bibr">[14]</xref>.</p>
      </sec>
    </sec>
    <sec id="sec5">
      <label>5</label>
      <title>Conclusions and outlook</title>
      <p>Kallikrein-related peptidases are a family of serine proteases that has diversified through evolution for physiological tasks that have arisen with the special developments of mammals compared with their ancestors. These novel functions comprise proteolytic processes in fertilization, desquamation, or a sophisticated neuronal plasticity. However, the activity of KLK proteases requires tight regulation by modulators, as activating or attenuating ions or reversible and irreversible proteinaceous inhibitors. In some cases, the failure of endogenous inhibitory systems in humans leads to excessive activity of KLKs with pathophysiological consequences.</p>
      <p>Apart from the current scientific and pharmacological key interest, KLK functions may go far beyond the normal protease activity, as seen in some impressive examples depicting the regulatory potential of KLKs. First, in mouse nerve growth factor 7S, the two active mouse KLK b3 proteases or &#x3B3; subunits are inhibited by Zn<sup>2+</sup> mediated complex formation with an inactive &#x3B2; subunit and two inactive &#x3B1; subunits (KLK homologs), whereby the &#x3B3; active sites are shielded from potential substrates <xref rid="bib295 bib296 bib297" ref-type="bibr">[295&#x2013;297]</xref>. Secondly, the mysterious localization of KLK4 in the cytoplasm as full length protein and&#xA0;in the nucleus of transfected prostate cancer cells (PC-3) as N-terminally truncated KLK4-205 awaits new functional models for KLKs, in particular due to a likely involvement in cancer <xref rid="bib298 bib299" ref-type="bibr">[298,299]</xref>. Built according to the rather simple scaffold of (chymo)trypsin-like serine proteases, the kallikrein-related peptidases represent exciting biomolecules with astonishing variations in their structure, function, and physiological regulation. Eventually, our increasing knowledge of&#xA0;the underlying mechanisms of KLK activity control, will help to design very specific compounds directed to individual KLKs in order to cure diseases in which they play an important role.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barrett</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Tolle</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Rawlings</surname>
              <given-names>N.D.</given-names>
            </name>
          </person-group>
          <article-title>Managing peptidases in the genomic era</article-title>
          <source>Biol. Chem.</source>
          <volume>384</volume>
          <year>2003</year>
          <fpage>873</fpage>
          <lpage>882</lpage>
          <pub-id pub-id-type="pmid">12887054</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lundwall</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Band</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Courty</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Fritz</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Malm</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Maltais</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Olsson</surname>
              <given-names>A.Y.</given-names>
            </name>
            <name>
              <surname>Petraki</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Scorilas</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Stenman</surname>
              <given-names>U.H.</given-names>
            </name>
            <name>
              <surname>Stephan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Talieri</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yousef</surname>
              <given-names>G.M.</given-names>
            </name>
          </person-group>
          <article-title>A comprehensive nomenclature for serine proteases with homology to tissue kallikreins</article-title>
          <source>Biol. Chem.</source>
          <volume>387</volume>
          <year>2006</year>
          <fpage>637</fpage>
          <lpage>641</lpage>
          <pub-id pub-id-type="pmid">16800724</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Distribution of tissue kallikrein in the integumental blood vessel system of wild mammals</article-title>
          <source>Cell. Mol. Biol. (Noisy-le-grand)</source>
          <volume>47</volume>
          <year>2001</year>
          <fpage>OL125</fpage>
          <lpage>130</lpage>
          <pub-id pub-id-type="pmid">11936857</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Irwin</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families</article-title>
          <source>Genomics</source>
          <volume>88</volume>
          <year>2006</year>
          <fpage>591</fpage>
          <lpage>599</lpage>
          <pub-id pub-id-type="pmid">16829021</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rawlings</surname>
              <given-names>N.D.</given-names>
            </name>
            <name>
              <surname>Morton</surname>
              <given-names>F.R.</given-names>
            </name>
            <name>
              <surname>Kok</surname>
              <given-names>C.Y.</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>MEROPS: the peptidase database</article-title>
          <source>Nucleic Acids Res.</source>
          <volume>36</volume>
          <year>2008</year>
          <fpage>D320</fpage>
          <lpage>D325</lpage>
          <pub-id pub-id-type="pmid">17991683</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olsson</surname>
              <given-names>A.Y.</given-names>
            </name>
            <name>
              <surname>Lundwall</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Organization and evolution of the glandular kallikrein locus in Mus musculus</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>299</volume>
          <year>2002</year>
          <fpage>305</fpage>
          <lpage>311</lpage>
          <pub-id pub-id-type="pmid">12437987</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yousef</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Scorilas</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>276</volume>
          <year>2000</year>
          <fpage>125</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="pmid">11006094</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harvey</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Hooper</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Stephenson</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Ashworth</surname>
              <given-names>L.K.</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4</article-title>
          <source>J. Biol. Chem.</source>
          <volume>275</volume>
          <year>2000</year>
          <fpage>37397</fpage>
          <lpage>37406</lpage>
          <pub-id pub-id-type="pmid">10969073</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmaier</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Mccrae</surname>
              <given-names>K.R.</given-names>
            </name>
          </person-group>
          <article-title>The plasma kallikrein-kinin system: its evolution from contact activation</article-title>
          <source>J. Thromb. Haemost.</source>
          <volume>5</volume>
          <year>2007</year>
          <fpage>2323</fpage>
          <lpage>2329</lpage>
          <pub-id pub-id-type="pmid">17883591</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Colman</surname>
              <given-names>R.W.</given-names>
            </name>
          </person-group>
          <article-title>Plasma prekallikrein and kallikrein</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Barrett</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Rawlings</surname>
              <given-names>N.D.</given-names>
            </name>
            <name>
              <surname>Woessner</surname>
              <given-names>J.F.</given-names>
            </name>
          </person-group>
          <source>Handbook of Proteolytic Enzymes</source>
          <year>2004</year>
          <publisher-name>Elsevier Academic Press</publisher-name>
          <publisher-loc>London</publisher-loc>
          <fpage>1644</fpage>
          <lpage>1651</lpage>
        </element-citation>
      </ref>
      <ref id="bib11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>J.L.V.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Distribution of 15 human kallikreins in tissues and biological fluids</article-title>
          <source>Clin. Chem.</source>
          <volume>53</volume>
          <year>2007</year>
          <fpage>1423</fpage>
          <lpage>1432</lpage>
          <pub-id pub-id-type="pmid">17573418</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emami</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family</article-title>
          <source>Mol. Oncol.</source>
          <volume>1</volume>
          <year>2007</year>
          <fpage>269</fpage>
          <lpage>287</lpage>
          <pub-id pub-id-type="pmid">19383303</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clements</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hooper</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Harvey</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions</article-title>
          <source>Biol. Chem.</source>
          <volume>382</volume>
          <year>2001</year>
          <fpage>5</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="pmid">11258672</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kapadia</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Yousef</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Grass</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Soosaipillai</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Howarth</surname>
              <given-names>D.H.C.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay</article-title>
          <source>Clin. Chem.</source>
          <volume>49</volume>
          <year>2003</year>
          <fpage>77</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="pmid">12507963</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brattsand</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Stefansson</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Lundh</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Haasum</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Egelrud</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>A proteolytic cascade of kallikreins in the stratum corneum</article-title>
          <source>J. Invest. Dermatol.</source>
          <volume>124</volume>
          <year>2005</year>
          <fpage>198</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="pmid">15654974</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Denmeade</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>L&#xF6;vgren</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>J.T.</given-names>
            </name>
          </person-group>
          <article-title>Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing</article-title>
          <source>Prostate</source>
          <volume>48</volume>
          <year>2001</year>
          <fpage>122</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="pmid">11433422</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Memari</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>L.-Y.</given-names>
            </name>
          </person-group>
          <article-title>Enzymatic properties of human kallikrein-related peptidase 12 (KLK12)</article-title>
          <source>Biol. Chem.</source>
          <volume>388</volume>
          <year>2007</year>
          <fpage>427</fpage>
          <lpage>435</lpage>
          <pub-id pub-id-type="pmid">17391064</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yousef</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Human tissue kallikreins: a new enzymatic cascade pathway?</article-title>
          <source>Biol. Chem.</source>
          <volume>383</volume>
          <year>2002</year>
          <fpage>1045</fpage>
          <lpage>1057</lpage>
          <pub-id pub-id-type="pmid">12437087</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoon</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Laxmikanthan</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kogot</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Activation profiles and regulatory cascades of the human kallikrein-related peptidases</article-title>
          <source>J. Biol. Chem.</source>
          <volume>282</volume>
          <year>2007</year>
          <fpage>31852</fpage>
          <lpage>31864</lpage>
          <pub-id pub-id-type="pmid">17823117</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoon</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Debela</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Goettig</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15</article-title>
          <source>Biol. Chem.</source>
          <volume>390</volume>
          <year>2009</year>
          <fpage>373</fpage>
          <lpage>377</lpage>
          <pub-id pub-id-type="pmid">19090718</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Juliano</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
          </person-group>
          <article-title>Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>311</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="pmid">20128685</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ryu</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Yamakoshi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Villemain</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bartlett</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Simmer</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>Porcine kallikrein-4 activation, glycosylation, activity, and expression in prokaryotic and eukaryotic hosts</article-title>
          <source>Eur. J. Oral Sci.</source>
          <volume>110</volume>
          <year>2002</year>
          <fpage>358</fpage>
          <lpage>365</lpage>
          <pub-id pub-id-type="pmid">12664466</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tye</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Pham</surname>
              <given-names>C.T.</given-names>
            </name>
            <name>
              <surname>Simmer</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Bartlett</surname>
              <given-names>J.D.</given-names>
            </name>
          </person-group>
          <article-title>DPPI may activate KLK4 during enamel formation</article-title>
          <source>J. Dent. Res.</source>
          <volume>88</volume>
          <year>2009</year>
          <fpage>323</fpage>
          <lpage>327</lpage>
          <pub-id pub-id-type="pmid">19407151</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beaufort</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Plaza</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Utzschneider</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Burkhart</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Creutzburg</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Debela</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ries</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Magdolen</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Interdependence of kallikrein-related peptidases in proteolytic networks</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>581</fpage>
          <lpage>587</lpage>
          <pub-id pub-id-type="pmid">20302517</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borgo&#xF1;o</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Michael</surname>
              <given-names>I.P.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Human tissue kallikreins: physiologic roles and applications in cancer</article-title>
          <source>Mol. Cancer Res.</source>
          <volume>2</volume>
          <year>2004</year>
          <fpage>257</fpage>
          <lpage>280</lpage>
          <pub-id pub-id-type="pmid">15192120</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines</article-title>
          <source>Biol. Chem.</source>
          <volume>389</volume>
          <year>2008</year>
          <fpage>1409</fpage>
          <lpage>1419</lpage>
          <pub-id pub-id-type="pmid">19031603</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawrence</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus</article-title>
          <source>Endocr. Rev.</source>
          <year>2010</year>
          <comment>er.2009-0034</comment>
        </element-citation>
      </ref>
      <ref id="bib28">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Bernett</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Dhanarajan</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Seavy</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Enzymatic properties of rat myelencephalon-specific protease</article-title>
          <source>Biochemistry</source>
          <volume>41</volume>
          <year>2002</year>
          <fpage>1165</fpage>
          <lpage>1173</lpage>
          <pub-id pub-id-type="pmid">11802715</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Juliano</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The autolytic regulation of human kallikrein-related peptidase 6</article-title>
          <source>Biochemistry</source>
          <volume>46</volume>
          <year>2007</year>
          <fpage>5209</fpage>
          <lpage>5217</lpage>
          <pub-id pub-id-type="pmid">17417874</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bay&#xE9;s</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tsetsenis</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ventura</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Vendrell</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Aviles</surname>
              <given-names>F.X.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation</article-title>
          <source>Biol. Chem.</source>
          <volume>385</volume>
          <year>2004</year>
          <fpage>517</fpage>
          <lpage>524</lpage>
          <pub-id pub-id-type="pmid">15255184</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borgo&#xF1;o</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Michael</surname>
              <given-names>I.P.</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>J.L.V.</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>L.-Y.</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Soosaipillai</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Grass</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Katsaros</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14</article-title>
          <source>J.&#xA0;Biol. Chem.</source>
          <volume>282</volume>
          <year>2007</year>
          <fpage>2405</fpage>
          <lpage>2422</lpage>
          <pub-id pub-id-type="pmid">17110383</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deraison</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bonnart</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lopez</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Besson</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Jayakumar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wagberg</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Brattsand</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hachem</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Leonardsson</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hovnanian</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction</article-title>
          <source>Mol. Biol. Cell</source>
          <year>2007</year>
          <comment>E07-02-0124</comment>
        </element-citation>
      </ref>
      <ref id="bib33">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Papagerakis</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Yamakoshi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>J.C.C.</given-names>
            </name>
            <name>
              <surname>Bartlett</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Simmer</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>Functions of KLK4 and MMP-20 in dental enamel formation</article-title>
          <source>Biol. Chem.</source>
          <volume>389</volume>
          <year>2008</year>
          <fpage>695</fpage>
          <lpage>700</lpage>
          <pub-id pub-id-type="pmid">18627287</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simmer</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Lertlam</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Yamakoshi</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>J.C.C.</given-names>
            </name>
          </person-group>
          <article-title>Hypomaturation enamel defects in Klk4 knockout/LacZ knockin mice</article-title>
          <source>J. Biol. Chem.</source>
          <volume>284</volume>
          <year>2009</year>
          <fpage>19110</fpage>
          <lpage>19121</lpage>
          <pub-id pub-id-type="pmid">19578120</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frey</surname>
              <given-names>E.K.</given-names>
            </name>
          </person-group>
          <article-title>Zusammenh&#xE4;nge zwischen Herzarbeit und Nierent&#xE4;tigkeit</article-title>
          <source>Arch. Klin. Chir.</source>
          <volume>142</volume>
          <year>1926</year>
          <fpage>663</fpage>
        </element-citation>
      </ref>
      <ref id="bib36">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kraut</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>E.K.</given-names>
            </name>
            <name>
              <surname>Werle</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Der Nachweis eines Kreislaufhormones in der Pankreasdr&#xFC;se Z</article-title>
          <source>Physiol. Chem.</source>
          <volume>189</volume>
          <year>1930</year>
          <fpage>97</fpage>
        </element-citation>
      </ref>
      <ref id="bib37">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Werle</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>G&#xF6;tze</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Kappler</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>&#xDC;ber die Wirkung des Kallikreins auf den isolierten Darm und &#xFC;ber eine neue darmkontrahierende Substanz</article-title>
          <source>Biochem. Z.</source>
          <volume>289</volume>
          <year>1937</year>
          <fpage>217</fpage>
          <lpage>233</lpage>
        </element-citation>
      </ref>
      <ref id="bib38">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Chao</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Human kallikrein 1, tissue kallikrein</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Barrett</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Rawlings</surname>
              <given-names>N.D.</given-names>
            </name>
            <name>
              <surname>Woessner</surname>
              <given-names>J.F.</given-names>
            </name>
          </person-group>
          <source>Handbook of Proteolytic Enzymes</source>
          <year>2004</year>
          <publisher-name>Elsevier Academic Press</publisher-name>
          <publisher-loc>London</publisher-loc>
          <fpage>1577</fpage>
          <lpage>1580</lpage>
        </element-citation>
      </ref>
      <ref id="bib39">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meneton</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bloch-Faure</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hagege</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Ruetten</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Bergaya</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ceiler</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Gehring</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Salmon</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Boulanger</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Nussberger</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Crozatier</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Gasc</surname>
              <given-names>J.-M.</given-names>
            </name>
            <name>
              <surname>Heudes</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bruneval</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Doetschman</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>M&#xE9;nard</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Alhenc-Gelas</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice</article-title>
          <source>Proc. Natl. Acad. Sci. U S A</source>
          <volume>98</volume>
          <year>2001</year>
          <fpage>2634</fpage>
          <lpage>2639</lpage>
          <pub-id pub-id-type="pmid">11226291</pub-id>
        </element-citation>
      </ref>
      <ref id="bib40">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Picard</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Van Abel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Campone</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Seiler</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bloch-Faure</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hoenderop</surname>
              <given-names>J.G.J.</given-names>
            </name>
            <name>
              <surname>Loffing</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Meneton</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bindels</surname>
              <given-names>R.J.M.</given-names>
            </name>
            <name>
              <surname>Paillard</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Alhenc-Gelas</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Houillier</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Tissue kallikrein-deficient mice display a defect in renal tubular calcium absorption</article-title>
          <source>J. Am. Soc. Nephrol.</source>
          <volume>16</volume>
          <year>2005</year>
          <fpage>3602</fpage>
          <lpage>3610</lpage>
          <pub-id pub-id-type="pmid">16251243</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chao</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>C.-F.</given-names>
            </name>
            <name>
              <surname>Bledsoe</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>345</fpage>
          <lpage>355</lpage>
          <pub-id pub-id-type="pmid">20180644</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robert</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gibbs</surname>
              <given-names>B.F.</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Gagnon</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I</article-title>
          <source>Biochemistry</source>
          <volume>36</volume>
          <year>1997</year>
          <fpage>3811</fpage>
          <lpage>3819</lpage>
          <pub-id pub-id-type="pmid">9092810</pub-id>
        </element-citation>
      </ref>
      <ref id="bib43">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emami</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Deperthes</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Malm</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Major role of human KLK14 in seminal clot liquefaction</article-title>
          <source>J. Biol. Chem.</source>
          <volume>283</volume>
          <year>2008</year>
          <fpage>19561</fpage>
          <lpage>19569</lpage>
          <pub-id pub-id-type="pmid">18482984</pub-id>
        </element-citation>
      </ref>
      <ref id="bib44">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borgo&#xF1;o</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>The emerging roles of human tissue kallikreins in cancer</article-title>
          <source>Nat. Rev. Cancer</source>
          <volume>4</volume>
          <year>2004</year>
          <fpage>876</fpage>
          <lpage>890</lpage>
          <pub-id pub-id-type="pmid">15516960</pub-id>
        </element-citation>
      </ref>
      <ref id="bib45">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stephan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Lein</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>PSA and other tissue kallikreins for prostate cancer detection</article-title>
          <source>Eur. J. Cancer</source>
          <volume>43</volume>
          <year>2007</year>
          <fpage>1918</fpage>
          <lpage>1926</lpage>
          <pub-id pub-id-type="pmid">17689069</pub-id>
        </element-citation>
      </ref>
      <ref id="bib46">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schroder</surname>
              <given-names>F.H.</given-names>
            </name>
            <name>
              <surname>Hugosson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Roobol</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Tammela</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Ciatto</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nelen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kwiatkowski</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lujan</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Zappa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Denis</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Recker</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Berenguer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Maattanen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Bangma</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Aus</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Villers</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rebillard</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>van der Kwast</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Blijenberg</surname>
              <given-names>B.G.</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>de Koning</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Auvinen</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Screening and prostate-cancer mortality in a randomized European study</article-title>
          <source>N. Engl. J. Med.</source>
          <volume>360</volume>
          <year>2009</year>
          <fpage>1320</fpage>
          <lpage>1328</lpage>
          <pub-id pub-id-type="pmid">19297566</pub-id>
        </element-citation>
      </ref>
      <ref id="bib47">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seiz</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Kotzsch</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Grebenchtchikov</surname>
              <given-names>N.I.</given-names>
            </name>
            <name>
              <surname>Geurts-Moespot</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Fuessel</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Goettig</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gkazepis</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wirth</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lossnitzer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sweep</surname>
              <given-names>F.C.G.J.</given-names>
            </name>
            <name>
              <surname>Magdolen</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>391</fpage>
          <lpage>401</lpage>
          <pub-id pub-id-type="pmid">20180634</pub-id>
        </element-citation>
      </ref>
      <ref id="bib48">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takayama</surname>
              <given-names>T.K.</given-names>
            </name>
            <name>
              <surname>McMullen</surname>
              <given-names>B.A.</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Matsumura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Fujikawa</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase</article-title>
          <source>Biochemistry</source>
          <volume>40</volume>
          <year>2001</year>
          <fpage>15341</fpage>
          <lpage>15348</lpage>
          <pub-id pub-id-type="pmid">11735417</pub-id>
        </element-citation>
      </ref>
      <ref id="bib49">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beaufort</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Debela</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Creutzburg</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kellermann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pidard</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Magdolen</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR)</article-title>
          <source>Biol. Chem.</source>
          <volume>387</volume>
          <year>2006</year>
          <fpage>217</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="pmid">16497155</pub-id>
        </element-citation>
      </ref>
      <ref id="bib50">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mize</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Takayama</surname>
              <given-names>T.K.</given-names>
            </name>
          </person-group>
          <article-title>Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2</article-title>
          <source>Mol. Cancer Res.</source>
          <volume>6</volume>
          <year>2008</year>
          <fpage>1043</fpage>
          <lpage>1051</lpage>
          <pub-id pub-id-type="pmid">18567807</pub-id>
        </element-citation>
      </ref>
      <ref id="bib51">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramsay</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Linn</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Samaratunga</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Hooper</surname>
              <given-names>J.D.</given-names>
            </name>
          </person-group>
          <article-title>Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs)</article-title>
          <source>J. Biol. Chem.</source>
          <volume>283</volume>
          <year>2008</year>
          <fpage>12293</fpage>
          <lpage>12304</lpage>
          <pub-id pub-id-type="pmid">18308730</pub-id>
        </element-citation>
      </ref>
      <ref id="bib52">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oikonomopoulou</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>K.K.</given-names>
            </name>
            <name>
              <surname>Saifeddine</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vergnolle</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Tea</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Hollenberg</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs)</article-title>
          <source>Biol. Chem.</source>
          <volume>387</volume>
          <year>2006</year>
          <fpage>817</fpage>
          <lpage>824</lpage>
          <pub-id pub-id-type="pmid">16800746</pub-id>
        </element-citation>
      </ref>
      <ref id="bib53">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oikonomopoulou</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>K.K.</given-names>
            </name>
            <name>
              <surname>Saifeddine</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tea</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Andrade-Gordon</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cottrell</surname>
              <given-names>G.S.</given-names>
            </name>
            <name>
              <surname>Bunnett</surname>
              <given-names>N.W.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Hollenberg</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>Proteinase-activated receptors, targets for kallikrein signaling</article-title>
          <source>J. Biol. Chem.</source>
          <volume>281</volume>
          <year>2006</year>
          <fpage>32095</fpage>
          <lpage>32112</lpage>
          <pub-id pub-id-type="pmid">16885167</pub-id>
        </element-citation>
      </ref>
      <ref id="bib54">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stefansson</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Brattsand</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Roosterman</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kempkes</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bocheva</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Steinhoff</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Egelrud</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases</article-title>
          <source>J. Invest. Dermatol.</source>
          <volume>128</volume>
          <year>2008</year>
          <fpage>18</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">17625593</pub-id>
        </element-citation>
      </ref>
      <ref id="bib55">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gratio</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Beaufort</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Seiz</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Maier</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Virca</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Debela</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Grebenchtchikov</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Magdolen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Darmoul</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Kallikrein-related peptidase 4 (KLK4): a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells</article-title>
          <source>Am. J. Pathol</source>
          <volume>176</volume>
          <year>2010</year>
          <fpage>1452</fpage>
          <lpage>1461</lpage>
          <pub-id pub-id-type="pmid">20056842</pub-id>
        </element-citation>
      </ref>
      <ref id="bib56">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oikonomopoulou</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Hollenberg</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>299</fpage>
          <lpage>310</lpage>
          <pub-id pub-id-type="pmid">20180639</pub-id>
        </element-citation>
      </ref>
      <ref id="bib57">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simmer</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Expression, structure, and function of enamel proteinases</article-title>
          <source>Connect. Tissue Res.</source>
          <volume>43</volume>
          <year>2002</year>
          <fpage>441</fpage>
          <lpage>449</lpage>
          <pub-id pub-id-type="pmid">12489196</pub-id>
        </element-citation>
      </ref>
      <ref id="bib58">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hart</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Michalec</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Ryu</surname>
              <given-names>O.H.</given-names>
            </name>
            <name>
              <surname>Simmons</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>J.T.</given-names>
            </name>
          </person-group>
          <article-title>Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta</article-title>
          <source>J. Med. Genet.</source>
          <volume>41</volume>
          <year>2004</year>
          <fpage>545</fpage>
          <lpage>549</lpage>
          <pub-id pub-id-type="pmid">15235027</pub-id>
        </element-citation>
      </ref>
      <ref id="bib59">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wright</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Simmons</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Suggs</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Daley</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Simmer</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bartlett</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>Z.A.</given-names>
            </name>
            <name>
              <surname>Seow</surname>
              <given-names>W.K.</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>C.W.</given-names>
            </name>
          </person-group>
          <article-title>Human and mouse enamel phenotypes resulting from mutation or altered expression of AMEL, ENAM, MMP20 and KLK4</article-title>
          <source>Cells Tissues Organs</source>
          <volume>189</volume>
          <year>2009</year>
          <fpage>224</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="pmid">18714142</pub-id>
        </element-citation>
      </ref>
      <ref id="bib60">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Komatsu</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Saijoh</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kuk</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shirasaki</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Takehara</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients</article-title>
          <source>Exp. Dermatol.</source>
          <volume>16</volume>
          <year>2007</year>
          <fpage>513</fpage>
          <lpage>519</lpage>
          <pub-id pub-id-type="pmid">17518992</pub-id>
        </element-citation>
      </ref>
      <ref id="bib61">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stefansson</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Brattsand</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ny</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Glas</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Egelrud</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum</article-title>
          <source>Biol. Chem.</source>
          <volume>387</volume>
          <year>2006</year>
          <fpage>761</fpage>
          <lpage>768</lpage>
          <pub-id pub-id-type="pmid">16800737</pub-id>
        </element-citation>
      </ref>
      <ref id="bib62">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caubet</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jonca</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Brattsand</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Guerrin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bernard</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Egelrud</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Serre</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7</article-title>
          <source>J. Invest. Dermatol.</source>
          <volume>122</volume>
          <year>2004</year>
          <fpage>1235</fpage>
          <lpage>1244</lpage>
          <pub-id pub-id-type="pmid">15140227</pub-id>
        </element-citation>
      </ref>
      <ref id="bib63">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borgo&#xF1;o</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Michael</surname>
              <given-names>I.P.</given-names>
            </name>
            <name>
              <surname>Komatsu</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Jayakumar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kapadia</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Clayman</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation</article-title>
          <source>J. Biol. Chem.</source>
          <volume>282</volume>
          <year>2007</year>
          <fpage>3640</fpage>
          <lpage>3652</lpage>
          <pub-id pub-id-type="pmid">17158887</pub-id>
        </element-citation>
      </ref>
      <ref id="bib64">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirihara</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Matsumoto-Miyai</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sadayama</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Prolonged recovery of ultraviolet B-irradiated skin in neuropsin (KLK8)-deficient mice</article-title>
          <source>Br. J. Dermatol.</source>
          <volume>149</volume>
          <year>2003</year>
          <fpage>700</fpage>
          <lpage>706</lpage>
          <pub-id pub-id-type="pmid">14616360</pub-id>
        </element-citation>
      </ref>
      <ref id="bib65">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klucky</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Mueller</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Vogt</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Teurich</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hartenstein</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Breuhahn</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Flechtenmacher</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Angel</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion</article-title>
          <source>Cancer Res.</source>
          <volume>67</volume>
          <year>2007</year>
          <fpage>8198</fpage>
          <lpage>8206</lpage>
          <pub-id pub-id-type="pmid">17804733</pub-id>
        </element-citation>
      </ref>
      <ref id="bib66">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohler</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Debela</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Magdolen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Becker-Pauly</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Analyzing the protease web in skin: meprin metalloproteases are activated specifically by KLK4, 5 and 8 vice versa leading to processing of proKLK7 thereby triggering its activation</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>455</fpage>
          <lpage>460</lpage>
          <pub-id pub-id-type="pmid">20128684</pub-id>
        </element-citation>
      </ref>
      <ref id="bib67">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ovaere</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lippens</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Vandenabeele</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Declercq</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>The emerging roles of serine protease cascades in the epidermis</article-title>
          <source>Trends Biochem. Sci.</source>
          <volume>34</volume>
          <year>2009</year>
          <fpage>453</fpage>
          <lpage>463</lpage>
          <pub-id pub-id-type="pmid">19726197</pub-id>
        </element-citation>
      </ref>
      <ref id="bib68">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Taniguchi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hirata</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Sequence analysis and expression of human neuropsin cDNA and gene</article-title>
          <source>Gene</source>
          <volume>213</volume>
          <year>1998</year>
          <fpage>9</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="pmid">9714609</pub-id>
        </element-citation>
      </ref>
      <ref id="bib69">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Lucchinetti</surname>
              <given-names>C.F.</given-names>
            </name>
            <name>
              <surname>Genain</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Activity of a newly identified serine protease in CNS demyelination</article-title>
          <source>Brain</source>
          <volume>125</volume>
          <year>2002</year>
          <fpage>1283</fpage>
          <lpage>1296</lpage>
          <pub-id pub-id-type="pmid">12023317</pub-id>
        </element-citation>
      </ref>
      <ref id="bib70">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Ciric</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Christophi</surname>
              <given-names>G.P.</given-names>
            </name>
            <name>
              <surname>Bernett</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
          </person-group>
          <article-title>Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease</article-title>
          <source>FASEB J.</source>
          <volume>18</volume>
          <year>2004</year>
          <fpage>920</fpage>
          <lpage>922</lpage>
          <pub-id pub-id-type="pmid">15033932</pub-id>
        </element-citation>
      </ref>
      <ref id="bib71">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Sabharwal</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Vandell</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Ameenuddin</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Papke</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Fehlings</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Reeves</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Windebank</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Dynamic role of kallikrein 6 in traumatic spinal cord injury</article-title>
          <source>Eur. J. Neurosci.</source>
          <volume>24</volume>
          <year>2006</year>
          <fpage>1457</fpage>
          <lpage>1469</lpage>
          <pub-id pub-id-type="pmid">16987227</pub-id>
        </element-citation>
      </ref>
      <ref id="bib72">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakamura</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Tamura</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Horinouchi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Role of neuropsin in formation and maturation of Schaffer-collateral L1cam-immunoreactive synaptic boutons</article-title>
          <source>J. Cell Sci.</source>
          <volume>119</volume>
          <year>2006</year>
          <fpage>1341</fpage>
          <lpage>1349</lpage>
          <pub-id pub-id-type="pmid">16537644</pub-id>
        </element-citation>
      </ref>
      <ref id="bib73">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Komai</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Matsuyama</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Imamura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ugawa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Neuropsin regulates an early phase of Schaffer-collateral long-term potentiation in the murine hippocampus</article-title>
          <source>Eur. J.&#xA0;Neurosci.</source>
          <volume>12</volume>
          <year>2000</year>
          <fpage>1479</fpage>
          <lpage>1486</lpage>
          <pub-id pub-id-type="pmid">10762375</pub-id>
        </element-citation>
      </ref>
      <ref id="bib74">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tamura</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hino</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kaku</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Neuropsin is essential for early processes of memory acquisition and Schaffer collateral long-term potentiation in adult mouse hippocampus in vivo</article-title>
          <source>J.&#xA0;Physiol.</source>
          <volume>570</volume>
          <year>2006</year>
          <fpage>541</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="pmid">16308352</pub-id>
        </element-citation>
      </ref>
      <ref id="bib75">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoshida</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Klk8, a multifunctional protease in the brain and skin: analysis of knockout mice</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>375</fpage>
          <lpage>380</lpage>
          <pub-id pub-id-type="pmid">20180635</pub-id>
        </element-citation>
      </ref>
      <ref id="bib76">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimizu-Okabe</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Yousef</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fahnestock</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Expression of the kallikrein gene family in normal and Alzheimer&#x2019;s disease brain</article-title>
          <source>Neuroreport</source>
          <volume>12</volume>
          <year>2001</year>
          <fpage>2747</fpage>
          <lpage>2751</lpage>
          <pub-id pub-id-type="pmid">11522960</pub-id>
        </element-citation>
      </ref>
      <ref id="bib77">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Kearns</surname>
              <given-names>I.R.</given-names>
            </name>
            <name>
              <surname>Ure</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Lathe</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Loss of hippocampal serine protease BSP1/neuropsin predisposes to global seizure activity</article-title>
          <source>J. Neurosci.</source>
          <volume>21</volume>
          <year>2001</year>
          <fpage>6993</fpage>
          <lpage>7000</lpage>
          <pub-id pub-id-type="pmid">11549709</pub-id>
        </element-citation>
      </ref>
      <ref id="bib78">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Izumi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Iijima</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Noguchi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Numakawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Okada</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hori</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Tatsumi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kosuga</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kamijima</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Asada</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Arima</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Saitoh</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kunugi</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Genetic Variations of human neuropsin gene and psychiatric disorders: polymorphism screening and possible association with bipolar disorder and cognitive functions</article-title>
          <source>Neuropsychopharmacology</source>
          <volume>33</volume>
          <year>2008</year>
          <fpage>3237</fpage>
          <lpage>3245</lpage>
          <pub-id pub-id-type="pmid">18354391</pub-id>
        </element-citation>
      </ref>
      <ref id="bib79">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Memari</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Grass</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Karakucuk</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Human tissue kallikrein 9: production of recombinant proteins and specific antibodies</article-title>
          <source>Biol. Chem.</source>
          <volume>387</volume>
          <year>2006</year>
          <fpage>733</fpage>
          <lpage>740</lpage>
          <pub-id pub-id-type="pmid">16800734</pub-id>
        </element-citation>
      </ref>
      <ref id="bib80">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Darling</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Jackson-Boeters</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Daley</surname>
              <given-names>T.D.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Human kallikrein 13 expression in salivary gland tumors</article-title>
          <source>Int. J. Biol. Markers</source>
          <volume>21</volume>
          <year>2006</year>
          <fpage>106</fpage>
          <lpage>110</lpage>
          <pub-id pub-id-type="pmid">16847813</pub-id>
        </element-citation>
      </ref>
      <ref id="bib81">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pampalakis</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Functional roles of human kallikrein-related peptidases</article-title>
          <source>J. Biol. Chem.</source>
          <volume>284</volume>
          <year>2009</year>
          <fpage>32989</fpage>
          <lpage>32994</lpage>
          <pub-id pub-id-type="pmid">19819870</pub-id>
        </element-citation>
      </ref>
      <ref id="bib82">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>L.Y.</given-names>
            </name>
            <name>
              <surname>Meyts</surname>
              <given-names>E.R.-D.</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue</article-title>
          <source>Br. J. Cancer</source>
          <volume>85</volume>
          <year>2001</year>
          <fpage>220</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="pmid">11461080</pub-id>
        </element-citation>
      </ref>
      <ref id="bib83">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giusti</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Serrat&#xEC;</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Margheri</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Papucci</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Poggi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Magi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rosso</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Cinelli</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Guiducci</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kahaleh</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Matucci-Cerinic</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Abbate</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Fibbi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Rosso</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis</article-title>
          <source>Arthritis Rheum.</source>
          <volume>52</volume>
          <year>2005</year>
          <fpage>3618</fpage>
          <lpage>3628</lpage>
          <pub-id pub-id-type="pmid">16255054</pub-id>
        </element-citation>
      </ref>
      <ref id="bib84">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kapadia</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Grass</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Human kallikrein 13 involvement in extracellular matrix degradation</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>323</volume>
          <year>2004</year>
          <fpage>1084</fpage>
          <lpage>1090</lpage>
          <pub-id pub-id-type="pmid">15381110</pub-id>
        </element-citation>
      </ref>
      <ref id="bib85">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pampalakis</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>321</fpage>
          <lpage>331</lpage>
          <pub-id pub-id-type="pmid">20180637</pub-id>
        </element-citation>
      </ref>
      <ref id="bib86">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>J.L.V.</given-names>
            </name>
            <name>
              <surname>Grass</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids</article-title>
          <source>Clin. Biochem.</source>
          <volume>40</volume>
          <year>2007</year>
          <fpage>104</fpage>
          <lpage>110</lpage>
          <pub-id pub-id-type="pmid">17045982</pub-id>
        </element-citation>
      </ref>
      <ref id="bib87">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>J.L.V.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology</article-title>
          <source>Biol. Chem.</source>
          <volume>389</volume>
          <year>2008</year>
          <fpage>681</fpage>
          <lpage>688</lpage>
          <pub-id pub-id-type="pmid">18627298</pub-id>
        </element-citation>
      </ref>
      <ref id="bib88">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Groll</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bochtler</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Brandstetter</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Clausen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Molecular machines for protein degradation</article-title>
          <source>Chembiochem</source>
          <volume>6</volume>
          <year>2005</year>
          <fpage>222</fpage>
          <lpage>256</lpage>
          <pub-id pub-id-type="pmid">15678420</pub-id>
        </element-citation>
      </ref>
      <ref id="bib89">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Natural protein proteinase inhibitors and their interaction with proteinases</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>204</volume>
          <year>1992</year>
          <fpage>433</fpage>
          <lpage>451</lpage>
          <pub-id pub-id-type="pmid">1541261</pub-id>
        </element-citation>
      </ref>
      <ref id="bib90">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maskos</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases</article-title>
          <source>Mol. Biotechnol.</source>
          <volume>25</volume>
          <year>2003</year>
          <fpage>241</fpage>
          <lpage>266</lpage>
          <pub-id pub-id-type="pmid">14668538</pub-id>
        </element-citation>
      </ref>
      <ref id="bib91">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buczek</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Koscielska-Kasprzak</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Krowarsch</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Dadlez</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Otlewski</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Analysis of serine proteinase&#x2013;inhibitor interaction by alanine shaving</article-title>
          <source>Protein Sci.</source>
          <volume>11</volume>
          <year>2002</year>
          <fpage>806</fpage>
          <lpage>819</lpage>
          <pub-id pub-id-type="pmid">11910024</pub-id>
        </element-citation>
      </ref>
      <ref id="bib92">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maraganore</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Bourdon</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Jablonski</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ramachandran</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Fenton</surname>
              <given-names>J.W.</given-names>
              <suffix>II</suffix>
            </name>
          </person-group>
          <article-title>Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin</article-title>
          <source>Biochemistry</source>
          <volume>29</volume>
          <year>1990</year>
          <fpage>7095</fpage>
          <lpage>7101</lpage>
          <pub-id pub-id-type="pmid">2223763</pub-id>
        </element-citation>
      </ref>
      <ref id="bib93">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naski</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Fenton</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Maraganore</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>S.T.</given-names>
            </name>
            <name>
              <surname>Shafer</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen</article-title>
          <source>J. Biol. Chem.</source>
          <volume>265</volume>
          <year>1990</year>
          <fpage>13484</fpage>
          <lpage>13489</lpage>
          <pub-id pub-id-type="pmid">2380171</pub-id>
        </element-citation>
      </ref>
      <ref id="bib94">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rydel</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Tulinsky</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Refined structure of the hirudin-thrombin complex</article-title>
          <source>J. Mol. Biol.</source>
          <volume>221</volume>
          <year>1991</year>
          <fpage>583</fpage>
          <lpage>601</lpage>
          <pub-id pub-id-type="pmid">1920434</pub-id>
        </element-citation>
      </ref>
      <ref id="bib95">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimizu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Momota</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Midorikawa</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kamachi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kawabe</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of recombinant and brain neuropsin, a plasticity-related serine protease</article-title>
          <source>J. Biol. Chem.</source>
          <volume>273</volume>
          <year>1998</year>
          <fpage>11189</fpage>
          <lpage>11196</lpage>
          <pub-id pub-id-type="pmid">9556608</pub-id>
        </element-citation>
      </ref>
      <ref id="bib96">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shinmura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kataoka</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sanjar</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Yoshimura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Sugimura</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Splice-site genetic polymorphism of the human kallikrein 12 (<italic>KLK12</italic>) gene correlates with no substantial expression of KLK12 protein having serine protease activity</article-title>
          <source>Hum. Mutat.</source>
          <volume>24</volume>
          <year>2004</year>
          <fpage>273</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="pmid">15300858</pub-id>
        </element-citation>
      </ref>
      <ref id="bib97">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takayama</surname>
              <given-names>T.K.</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR</article-title>
          <source>Biochemistry</source>
          <volume>40</volume>
          <year>2001</year>
          <fpage>1679</fpage>
          <lpage>1687</lpage>
          <pub-id pub-id-type="pmid">11327827</pub-id>
        </element-citation>
      </ref>
      <ref id="bib98">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsumura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bhatt</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Andress</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Clegg</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Takayama</surname>
              <given-names>T.K.</given-names>
            </name>
            <name>
              <surname>Craik</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>P.S.</given-names>
            </name>
          </person-group>
          <article-title>Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries</article-title>
          <source>Prostate</source>
          <volume>62</volume>
          <year>2005</year>
          <fpage>1</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">15389820</pub-id>
        </element-citation>
      </ref>
      <ref id="bib99">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Debela</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Magdolen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Schechter</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Valachova</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lottspeich</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Craik</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Choe</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Goettig</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences</article-title>
          <source>J. Biol. Chem.</source>
          <volume>281</volume>
          <year>2006</year>
          <fpage>25678</fpage>
          <lpage>25688</lpage>
          <pub-id pub-id-type="pmid">16740631</pub-id>
        </element-citation>
      </ref>
      <ref id="bib100">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borgo&#xF1;o</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Gavigan</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bowles</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Defining the extended substrate specificity of kallikrein 1-related peptidases</article-title>
          <source>Biol. Chem.</source>
          <volume>388</volume>
          <year>2007</year>
          <fpage>1215</fpage>
          <lpage>1225</lpage>
          <pub-id pub-id-type="pmid">17976015</pub-id>
        </element-citation>
      </ref>
      <ref id="bib101">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Rogakos</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Tsetsenis</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Pampalakis</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Zafiropoulos</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Simillides</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Yiotakis</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Emerging interest in the kallikrein gene family for understanding and diagnosing cancer</article-title>
          <source>Oncol. Res.</source>
          <volume>13</volume>
          <year>2003</year>
          <fpage>381</fpage>
          <lpage>391</lpage>
          <pub-id pub-id-type="pmid">12725528</pub-id>
        </element-citation>
      </ref>
      <ref id="bib102">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coombs</surname>
              <given-names>G.S.</given-names>
            </name>
            <name>
              <surname>Bergstrom</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Pellequer</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Navre</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Tainer</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Madison</surname>
              <given-names>E.L.</given-names>
            </name>
            <name>
              <surname>Corey</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Substrate specificity of prostate-specific antigen (PSA)</article-title>
          <source>Chem. Biol.</source>
          <volume>5</volume>
          <year>1998</year>
          <fpage>475</fpage>
          <lpage>488</lpage>
          <pub-id pub-id-type="pmid">9751643</pub-id>
        </element-citation>
      </ref>
      <ref id="bib103">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>H.X.</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>B.Y.</given-names>
            </name>
            <name>
              <surname>Laxmikanthan</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Golubkov</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Ren</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Iverson</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Georgiou</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Substrate specificity of human kallikreins 1 and 6 determined by phage display</article-title>
          <source>Protein Sci.</source>
          <volume>17</volume>
          <year>2008</year>
          <fpage>664</fpage>
          <lpage>672</lpage>
          <pub-id pub-id-type="pmid">18359858</pub-id>
        </element-citation>
      </ref>
      <ref id="bib104">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Felber</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Borgono</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Cloutier</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Kundig</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Kishi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ribeiro Chagas</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Jichlinski</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gygi</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Leisinger</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Deperthes</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Enzymatic profiling of human kallikrein 14 using phage-display substrate technology</article-title>
          <source>Biol. Chem.</source>
          <volume>386</volume>
          <year>2005</year>
          <fpage>291</fpage>
          <lpage>298</lpage>
          <pub-id pub-id-type="pmid">15843175</pub-id>
        </element-citation>
      </ref>
      <ref id="bib105">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Oikonomopoulou</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Renaux</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Hollenberg</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Rancourt</surname>
              <given-names>D.E.</given-names>
            </name>
          </person-group>
          <article-title>Substrate specificity determination of mouse implantation serine proteinase and human kallikrein-related peptidase 6 by phage display</article-title>
          <source>Biol. Chem.</source>
          <volume>389</volume>
          <year>2008</year>
          <fpage>1097</fpage>
          <lpage>1105</lpage>
          <pub-id pub-id-type="pmid">18979633</pub-id>
        </element-citation>
      </ref>
      <ref id="bib106">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cloutier</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Chagas</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Mach</surname>
              <given-names>J.-P.</given-names>
            </name>
            <name>
              <surname>Gygi</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Leisinger</surname>
              <given-names>H.-J.</given-names>
            </name>
            <name>
              <surname>Deperthes</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>269</volume>
          <year>2002</year>
          <fpage>2747</fpage>
          <lpage>2754</lpage>
          <pub-id pub-id-type="pmid">12047384</pub-id>
        </element-citation>
      </ref>
      <ref id="bib107">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Debela</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Crystal Structures of the Human Tissue Kallikreins 4, 5, 7, 10, Characterisation of Their Substrate Specificity and Analysis of Their Various Zinc Inhibition Mechanisms</article-title>
          <year>2007</year>
          <publisher-name>Max-Planck-Institute of Biochemistry, TU Munich</publisher-name>
          <publisher-loc>Munich</publisher-loc>
          <comment>p. 191</comment>
        </element-citation>
      </ref>
      <ref id="bib108">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bourgeois</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Brillard-Bourdet</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Deperthes</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Juliano</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Juliano</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Tremblay</surname>
              <given-names>R.R.</given-names>
            </name>
            <name>
              <surname>Dub&#xE9;</surname>
              <given-names>J.Y.</given-names>
            </name>
            <name>
              <surname>Gauthier</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2</article-title>
          <source>J. Biol. Chem.</source>
          <volume>272</volume>
          <year>1997</year>
          <fpage>29590</fpage>
          <lpage>29595</lpage>
          <pub-id pub-id-type="pmid">9368023</pub-id>
        </element-citation>
      </ref>
      <ref id="bib109">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janssen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Jakobsen</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Rosen</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Ricklis</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Reineke</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>S.B.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Denmeade</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer</article-title>
          <source>Mol. Cancer Ther.</source>
          <volume>3</volume>
          <year>2004</year>
          <fpage>1439</fpage>
          <lpage>1450</lpage>
          <pub-id pub-id-type="pmid">15542783</pub-id>
        </element-citation>
      </ref>
      <ref id="bib110">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>C.F.</given-names>
            </name>
            <name>
              <surname>Porter</surname>
              <given-names>E.S.</given-names>
            </name>
            <name>
              <surname>Boths</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kanyi</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hsieh</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Cooperman</surname>
              <given-names>B.S.</given-names>
            </name>
          </person-group>
          <article-title>Design of synthetic hexapeptide substrates for prostate-specific antigen using single-position minilibraries</article-title>
          <source>J. Pept. Res.</source>
          <volume>54</volume>
          <year>1999</year>
          <fpage>444</fpage>
          <lpage>448</lpage>
          <pub-id pub-id-type="pmid">10563510</pub-id>
        </element-citation>
      </ref>
      <ref id="bib111">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreau</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Brillard-Bourdet</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bouhnik</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gauthier</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Protein products of the rat kallikrein gene family. Substrate specificities of kallikrein rK2 (tonin) and kallikrein rK9</article-title>
          <source>J. Biol. Chem.</source>
          <volume>267</volume>
          <year>1992</year>
          <fpage>10045</fpage>
          <lpage>10051</lpage>
          <pub-id pub-id-type="pmid">1315752</pub-id>
        </element-citation>
      </ref>
      <ref id="bib112">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sugita</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Shirosaki</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ohkuri</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Katsukawa</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nonaka</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Imoto</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ninomiya</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Induction of salivary kallikreins by the diet containing a sweet-suppressive peptide, gurmarin, in the rat</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>346</volume>
          <year>2006</year>
          <fpage>386</fpage>
          <lpage>392</lpage>
          <pub-id pub-id-type="pmid">16765321</pub-id>
        </element-citation>
      </ref>
      <ref id="bib113">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmidt</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>M.-f.</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Bajaj</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Gailani</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Functional role of residue 193 (chymotrypsin numbering) in serine proteases: influence of side chain length and b-branching on the catalytic activity of blood coagulation factor XIa</article-title>
          <source>Biochemistry</source>
          <volume>47</volume>
          <year>2008</year>
          <fpage>1326</fpage>
          <lpage>1335</lpage>
          <pub-id pub-id-type="pmid">18186617</pub-id>
        </element-citation>
      </ref>
      <ref id="bib114">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oikonomopoulou</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Batruch</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Soosaipillai</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Hollenberg</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <article-title>Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>381</fpage>
          <lpage>390</lpage>
          <pub-id pub-id-type="pmid">20180649</pub-id>
        </element-citation>
      </ref>
      <ref id="bib115">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orthner</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Kosow</surname>
              <given-names>D.P.</given-names>
            </name>
          </person-group>
          <article-title>Evidence that human [alpha]-thrombin is a monovalent cation-activated enzyme</article-title>
          <source>Arch. Biochem. Biophys.</source>
          <volume>202</volume>
          <year>1980</year>
          <fpage>63</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="pmid">7396537</pub-id>
        </element-citation>
      </ref>
      <ref id="bib116">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wells</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Di Cera</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Thrombin is a sodium ion activated enzyme</article-title>
          <source>Biochemistry</source>
          <volume>31</volume>
          <year>1992</year>
          <fpage>11721</fpage>
          <lpage>11730</lpage>
          <pub-id pub-id-type="pmid">1445907</pub-id>
        </element-citation>
      </ref>
      <ref id="bib117">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Cera</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Guinto</surname>
              <given-names>E.R.</given-names>
            </name>
            <name>
              <surname>Vindigni</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Dang</surname>
              <given-names>Q.D.</given-names>
            </name>
            <name>
              <surname>Ayala</surname>
              <given-names>Y.M.</given-names>
            </name>
            <name>
              <surname>Wuyi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tulinsky</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The Na+ binding site of thrombin</article-title>
          <source>J. Biol. Chem.</source>
          <volume>270</volume>
          <year>1995</year>
          <fpage>22089</fpage>
          <lpage>22092</lpage>
          <pub-id pub-id-type="pmid">7673182</pub-id>
        </element-citation>
      </ref>
      <ref id="bib118">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Schwager</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>The single calcium-binding site of crystallin bovin beta-trypsin</article-title>
          <source>FEBS Lett.</source>
          <volume>56</volume>
          <year>1975</year>
          <fpage>139</fpage>
          <lpage>143</lpage>
          <pub-id pub-id-type="pmid">1157929</pub-id>
        </element-citation>
      </ref>
      <ref id="bib119">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delaage</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lazdunski</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The binding of Ca2+ to trypsinogen and its relation to the mechanism of activation</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>28</volume>
          <year>1967</year>
          <fpage>390</fpage>
          <lpage>394</lpage>
          <pub-id pub-id-type="pmid">6055166</pub-id>
        </element-citation>
      </ref>
      <ref id="bib120">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lieberthal</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Oza</surname>
              <given-names>N.B.</given-names>
            </name>
            <name>
              <surname>Bernard</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Levinsky</surname>
              <given-names>N.G.</given-names>
            </name>
          </person-group>
          <article-title>The effect of cations on the activity of human urinary kallikrein</article-title>
          <source>J. Biol. Chem.</source>
          <volume>257</volume>
          <year>1982</year>
          <fpage>10827</fpage>
          <lpage>10830</lpage>
          <pub-id pub-id-type="pmid">6921202</pub-id>
        </element-citation>
      </ref>
      <ref id="bib121">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Angelo</surname>
              <given-names>P.F.</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>F.M.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Juliano</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Juliano</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects</article-title>
          <source>J. Biol. Chem.</source>
          <volume>281</volume>
          <year>2006</year>
          <fpage>3116</fpage>
          <lpage>3126</lpage>
          <pub-id pub-id-type="pmid">16321973</pub-id>
        </element-citation>
      </ref>
      <ref id="bib122">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hsieh</surname>
              <given-names>M.-C.</given-names>
            </name>
            <name>
              <surname>Cooperman</surname>
              <given-names>B.S.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of prostate-specific antigen (PSA) by alpha1-antichymotrypsin: salt-dependent activation mediated by a conformational change</article-title>
          <source>Biochemistry</source>
          <volume>41</volume>
          <year>2002</year>
          <fpage>2990</fpage>
          <lpage>2997</lpage>
          <pub-id pub-id-type="pmid">11863437</pub-id>
        </element-citation>
      </ref>
      <ref id="bib123">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kishi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Cloutier</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>K&#xFC;ndig</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Deperthes</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Activation and enzymatic characterization of recombinant human kallikrein 8</article-title>
          <source>Biol. Chem.</source>
          <volume>387</volume>
          <year>2006</year>
          <fpage>723</fpage>
          <lpage>731</lpage>
          <pub-id pub-id-type="pmid">16800733</pub-id>
        </element-citation>
      </ref>
      <ref id="bib124">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coleman</surname>
              <given-names>J.E.</given-names>
            </name>
          </person-group>
          <article-title>Zinc proteins: enzymes, storage proteins, transcription factors, and replication proteins</article-title>
          <source>Annu. Rev. Biochem.</source>
          <volume>61</volume>
          <year>1992</year>
          <fpage>897</fpage>
          <lpage>946</lpage>
          <pub-id pub-id-type="pmid">1497326</pub-id>
        </element-citation>
      </ref>
      <ref id="bib125">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tapiero</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Tew</surname>
              <given-names>K.D.</given-names>
            </name>
          </person-group>
          <article-title>Trace elements in human physiology and pathology: zinc and metallothioneins</article-title>
          <source>Biomed. Pharmacother.</source>
          <volume>57</volume>
          <year>2003</year>
          <fpage>399</fpage>
          <lpage>411</lpage>
          <pub-id pub-id-type="pmid">14652165</pub-id>
        </element-citation>
      </ref>
      <ref id="bib126">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernardo</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Day</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>S.T.</given-names>
            </name>
            <name>
              <surname>Shore</surname>
              <given-names>J.D.</given-names>
            </name>
          </person-group>
          <article-title>Surface-independent acceleration of factor XII activation by zinc ions. I. Kinetic characterization of the metal ion rate enhancement</article-title>
          <source>J. Biol. Chem.</source>
          <volume>268</volume>
          <year>1993</year>
          <fpage>12468</fpage>
          <lpage>12476</lpage>
          <pub-id pub-id-type="pmid">8509386</pub-id>
        </element-citation>
      </ref>
      <ref id="bib127">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petersen</surname>
              <given-names>L.C.</given-names>
            </name>
            <name>
              <surname>Olsen</surname>
              <given-names>O.H.</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Freskgard</surname>
              <given-names>P.O.</given-names>
            </name>
            <name>
              <surname>Persson</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Binding of Zn2+ to a Ca2+ loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor</article-title>
          <source>Protein Sci.</source>
          <volume>9</volume>
          <year>2000</year>
          <fpage>859</fpage>
          <lpage>866</lpage>
          <pub-id pub-id-type="pmid">10850795</pub-id>
        </element-citation>
      </ref>
      <ref id="bib128">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ishii</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Usui</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Sugimura</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yoshikawa</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of Aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells</article-title>
          <source>Biol. Pharm. Bull.</source>
          <volume>24</volume>
          <year>2001</year>
          <fpage>226</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="pmid">11256475</pub-id>
        </element-citation>
      </ref>
      <ref id="bib129">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lovgren</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Airas</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>262</volume>
          <year>1999</year>
          <fpage>781</fpage>
          <lpage>789</lpage>
          <pub-id pub-id-type="pmid">10411640</pub-id>
        </element-citation>
      </ref>
      <ref id="bib130">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lundwall</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Brattsand</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Kallikrein-related peptidases</article-title>
          <source>Cell. Mol. Life Sci.</source>
          <volume>65</volume>
          <year>2008</year>
          <fpage>2019</fpage>
          <lpage>2038</lpage>
          <pub-id pub-id-type="pmid">18344018</pub-id>
        </element-citation>
      </ref>
      <ref id="bib131">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kavanagh</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>Sodium, potassium, calcium, magnesium, zinc, citrate and chloride content of human prostatic and seminal fluid</article-title>
          <source>J. Reprod. Fertil.</source>
          <volume>75</volume>
          <year>1985</year>
          <fpage>35</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">4032375</pub-id>
        </element-citation>
      </ref>
      <ref id="bib132">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malm</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hellman</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hogg</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor</article-title>
          <source>Prostate</source>
          <volume>45</volume>
          <year>2000</year>
          <fpage>132</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="pmid">11027412</pub-id>
        </element-citation>
      </ref>
      <ref id="bib133">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hsieh</surname>
              <given-names>M.-C.</given-names>
            </name>
            <name>
              <surname>Cooperman</surname>
              <given-names>B.S.</given-names>
            </name>
          </person-group>
          <article-title>The preparation and catalytic properties of recombinant human prostate-specific antigen (rPSA)</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1481</volume>
          <year>2000</year>
          <fpage>75</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">10962094</pub-id>
        </element-citation>
      </ref>
      <ref id="bib134">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menez</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Michel</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>B.H.</given-names>
            </name>
            <name>
              <surname>Bossus</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ducancel</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Jolivet-Reynaud</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Stura</surname>
              <given-names>E.A.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody</article-title>
          <source>J.&#xA0;Mol. Biol.</source>
          <volume>376</volume>
          <year>2008</year>
          <fpage>1021</fpage>
          <lpage>1033</lpage>
          <pub-id pub-id-type="pmid">18187150</pub-id>
        </element-citation>
      </ref>
      <ref id="bib135">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Villoutreix</surname>
              <given-names>B.O.</given-names>
            </name>
            <name>
              <surname>Getzoff</surname>
              <given-names>E.D.</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>J.H.</given-names>
            </name>
          </person-group>
          <article-title>A structural model for the prostate disease marker, human prostate-specific antigen</article-title>
          <source>Protein Sci.</source>
          <volume>3</volume>
          <year>1994</year>
          <fpage>2033</fpage>
          <lpage>2044</lpage>
          <pub-id pub-id-type="pmid">7535613</pub-id>
        </element-citation>
      </ref>
      <ref id="bib136">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Sanz</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Barettino</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Calvete</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Romao</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA</article-title>
          <source>J. Mol. Biol.</source>
          <volume>322</volume>
          <year>2002</year>
          <fpage>325</fpage>
          <lpage>337</lpage>
          <pub-id pub-id-type="pmid">12217694</pub-id>
        </element-citation>
      </ref>
      <ref id="bib137">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Debela</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Magdolen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Grimminger</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Sommerhoff</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Messerschmidt</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Goettig</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site</article-title>
          <source>J. Mol. Biol.</source>
          <volume>362</volume>
          <year>2006</year>
          <fpage>1094</fpage>
          <lpage>1107</lpage>
          <pub-id pub-id-type="pmid">16950394</pub-id>
        </element-citation>
      </ref>
      <ref id="bib138">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerlach</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>A.P.d.</given-names>
            </name>
            <name>
              <surname>Cury</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Line</surname>
              <given-names>S.R.P.</given-names>
            </name>
          </person-group>
          <article-title>Effect of lead, cadmium and zinc on the activity of enamel matrix proteinases <italic>in vitro</italic></article-title>
          <source>Eur. J. Oral Sci.</source>
          <volume>108</volume>
          <year>2000</year>
          <fpage>327</fpage>
          <lpage>334</lpage>
          <pub-id pub-id-type="pmid">10946768</pub-id>
        </element-citation>
      </ref>
      <ref id="bib139">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higashi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Iwanaga</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity</article-title>
          <source>J. Biol. Chem.</source>
          <volume>271</volume>
          <year>1996</year>
          <fpage>26569</fpage>
          <lpage>26574</lpage>
          <pub-id pub-id-type="pmid">8900128</pub-id>
        </element-citation>
      </ref>
      <ref id="bib140">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sichler</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Banner</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>D&#x2019;Arcy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hopfner</surname>
              <given-names>K.P.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Kresse</surname>
              <given-names>G.B.</given-names>
            </name>
            <name>
              <surname>Kopetzki</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Brandstetter</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structures of uninhibited factor VIIa link its cofactor and substrate-assisted activation to specific interactions</article-title>
          <source>J. Mol. Biol.</source>
          <volume>322</volume>
          <year>2002</year>
          <fpage>591</fpage>
          <lpage>603</lpage>
          <pub-id pub-id-type="pmid">12225752</pub-id>
        </element-citation>
      </ref>
      <ref id="bib141">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pampalakis</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1776</volume>
          <year>2007</year>
          <fpage>22</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">17629406</pub-id>
        </element-citation>
      </ref>
      <ref id="bib142">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Lamirande</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Semenogelin, the main protein of the human semen coagulum, regulates sperm function</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <volume>33</volume>
          <year>2007</year>
          <fpage>60</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">17253191</pub-id>
        </element-citation>
      </ref>
      <ref id="bib143">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Michael</surname>
              <given-names>I.P.</given-names>
            </name>
            <name>
              <surname>Pampalakis</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Mikolajczyk</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Malm</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression</article-title>
          <source>J. Biol. Chem.</source>
          <volume>281</volume>
          <year>2006</year>
          <fpage>12743</fpage>
          <lpage>12750</lpage>
          <comment>Epub 12006 Mar 12743</comment>
          <pub-id pub-id-type="pmid">16517595</pub-id>
        </element-citation>
      </ref>
      <ref id="bib144">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Debela</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Goettig</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Magdolen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Schechter</surname>
              <given-names>N.M.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Structural basis of the zinc inhibition of human tissue kallikrein 5</article-title>
          <source>J. Mol. Biol.</source>
          <volume>373</volume>
          <year>2007</year>
          <fpage>1017</fpage>
          <lpage>1031</lpage>
          <pub-id pub-id-type="pmid">17881000</pub-id>
        </element-citation>
      </ref>
      <ref id="bib145">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujinaga</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>James</surname>
              <given-names>M.N.</given-names>
            </name>
          </person-group>
          <article-title>Rat submaxillary gland serine protease, tonin. Structure solution and refinement at 1.8 A resolution</article-title>
          <source>J. Mol. Biol.</source>
          <volume>195</volume>
          <year>1987</year>
          <fpage>373</fpage>
          <lpage>396</lpage>
          <pub-id pub-id-type="pmid">2821276</pub-id>
        </element-citation>
      </ref>
      <ref id="bib146">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carter</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Engineering enzyme specificity by &#x201C;substrate-assisted catalysis&#x201D;</article-title>
          <source>Science</source>
          <volume>237</volume>
          <year>1987</year>
          <fpage>394</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="pmid">3299704</pub-id>
        </element-citation>
      </ref>
      <ref id="bib147">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Debela</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Magdolen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Schechter</surname>
              <given-names>N.M.</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Goettig</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Chymotryptic specificity determinants in the 1.0 &#xC5; structure of the zinc-inhibited human tissue kallikrein 7</article-title>
          <source>Proc. Natl. Acad. Sci. U S A</source>
          <volume>104</volume>
          <year>2007</year>
          <fpage>16086</fpage>
          <lpage>16091</lpage>
          <pub-id pub-id-type="pmid">17909180</pub-id>
        </element-citation>
      </ref>
      <ref id="bib148">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higaki</surname>
              <given-names>J.N.</given-names>
            </name>
            <name>
              <surname>Haymore</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fletterick</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Craik</surname>
              <given-names>C.S.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of serine protease activity by an engineered metal switch</article-title>
          <source>Biochemistry</source>
          <volume>29</volume>
          <year>1990</year>
          <fpage>8582</fpage>
          <lpage>8586</lpage>
          <pub-id pub-id-type="pmid">2125468</pub-id>
        </element-citation>
      </ref>
      <ref id="bib149">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McGrath</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Haymore</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Summers</surname>
              <given-names>N.L.</given-names>
            </name>
            <name>
              <surname>Craik</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Fletterick</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>Structure of an engineered, metal-actuated switch in trypsin</article-title>
          <source>Biochemistry</source>
          <volume>32</volume>
          <year>1993</year>
          <fpage>1914</fpage>
          <lpage>1919</lpage>
          <pub-id pub-id-type="pmid">8448149</pub-id>
        </element-citation>
      </ref>
      <ref id="bib150">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nitzan</surname>
              <given-names>Y.B.</given-names>
            </name>
            <name>
              <surname>Sekler</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Silverman</surname>
              <given-names>W.F.</given-names>
            </name>
          </person-group>
          <article-title>Histochemical and histofluorescence tracing of chelatable zinc in the developing mouse</article-title>
          <source>J. Histochem. Cytochem.</source>
          <volume>52</volume>
          <year>2004</year>
          <fpage>529</fpage>
          <lpage>539</lpage>
          <pub-id pub-id-type="pmid">15034004</pub-id>
        </element-citation>
      </ref>
      <ref id="bib151">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lansdown</surname>
              <given-names>A.B.G.</given-names>
            </name>
            <name>
              <surname>Mirastschijski</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Stubbs</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Scanlon</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>&#xC5;gren</surname>
              <given-names>M.S.</given-names>
            </name>
          </person-group>
          <article-title>Zinc in wound healing: theoretical, experimental, and clinical aspects</article-title>
          <source>Wound Repair Regen.</source>
          <volume>15</volume>
          <year>2007</year>
          <fpage>2</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="pmid">17244314</pub-id>
        </element-citation>
      </ref>
      <ref id="bib152">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lech</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sadlik</surname>
              <given-names>J.K.</given-names>
            </name>
          </person-group>
          <article-title>Copper concentration in body tissues and fluids in normal subjects of southern Poland</article-title>
          <source>Biol. Trace Elem. Res.</source>
          <volume>118</volume>
          <year>2007</year>
          <fpage>10</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">17848725</pub-id>
        </element-citation>
      </ref>
      <ref id="bib153">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forteza</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Casalino-Matsuda</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Monzon</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Fries</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Rugg</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Milner</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Day</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>TSG-6 potentiates the antitissue kallikrein activity of inter-alpha-inhibitor through bikunin release</article-title>
          <source>Am. J. Respir. Cell Mol. Biol.</source>
          <volume>36</volume>
          <year>2007</year>
          <fpage>20</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">16873769</pub-id>
        </element-citation>
      </ref>
      <ref id="bib154">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delaria</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>D.K.</given-names>
            </name>
            <name>
              <surname>Marlor</surname>
              <given-names>C.W.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Roczniak</surname>
              <given-names>S.O.</given-names>
            </name>
            <name>
              <surname>Tamburini</surname>
              <given-names>P.P.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of placental bikunin, a novel human serine protease inhibitor</article-title>
          <source>J. Biol. Chem.</source>
          <volume>272</volume>
          <year>1997</year>
          <fpage>12209</fpage>
          <lpage>12214</lpage>
          <pub-id pub-id-type="pmid">9115295</pub-id>
        </element-citation>
      </ref>
      <ref id="bib155">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mukai</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fukushima</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Naka</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Osada</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kataoka</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases</article-title>
          <source>FEBS J.</source>
          <volume>275</volume>
          <year>2008</year>
          <fpage>1003</fpage>
          <lpage>1017</lpage>
          <pub-id pub-id-type="pmid">18221492</pub-id>
        </element-citation>
      </ref>
      <ref id="bib156">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franzke</surname>
              <given-names>C.-W.</given-names>
            </name>
            <name>
              <surname>Baici</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bartels</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Christophers</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Wiedow</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Antileukoprotease inhibits stratum corneum chymotryptic enzyme</article-title>
          <source>J. Biol. Chem.</source>
          <volume>271</volume>
          <year>1996</year>
          <fpage>21886</fpage>
          <lpage>21890</lpage>
          <pub-id pub-id-type="pmid">8702990</pub-id>
        </element-citation>
      </ref>
      <ref id="bib157">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carrell</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Travis</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>alpha1-Antitrypsin and the serpins: variation and countervariation</article-title>
          <source>Trends Biochem. Sci.</source>
          <volume>10</volume>
          <year>1980</year>
          <fpage>20</fpage>
          <lpage>24</lpage>
        </element-citation>
      </ref>
      <ref id="bib158">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>L.T.</given-names>
            </name>
            <name>
              <surname>Dayhoff</surname>
              <given-names>M.O.</given-names>
            </name>
          </person-group>
          <article-title>A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha1-proteinase inhibitor</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>95</volume>
          <year>1980</year>
          <fpage>864</fpage>
          <lpage>871</lpage>
          <pub-id pub-id-type="pmid">6968211</pub-id>
        </element-citation>
      </ref>
      <ref id="bib159">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Potempa</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Korzus</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Travis</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>The serpin superfamily of proteinase inhibitors: structure, function, and regulation</article-title>
          <source>J. Biol. Chem.</source>
          <volume>269</volume>
          <year>1994</year>
          <fpage>15957</fpage>
          <lpage>15960</lpage>
          <pub-id pub-id-type="pmid">8206889</pub-id>
        </element-citation>
      </ref>
      <ref id="bib160">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Irving</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Steenbakkers</surname>
              <given-names>P.J.M.</given-names>
            </name>
            <name>
              <surname>Lesk</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Op den Camp</surname>
              <given-names>H.J.M.</given-names>
            </name>
            <name>
              <surname>Pike</surname>
              <given-names>R.N.</given-names>
            </name>
            <name>
              <surname>Whisstock</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Serpins in prokaryotes</article-title>
          <source>Mol. Biol. Evol.</source>
          <volume>19</volume>
          <year>2002</year>
          <fpage>1881</fpage>
          <lpage>1890</lpage>
          <pub-id pub-id-type="pmid">12411597</pub-id>
        </element-citation>
      </ref>
      <ref id="bib161">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Silverman</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Bird</surname>
              <given-names>P.I.</given-names>
            </name>
            <name>
              <surname>Carrell</surname>
              <given-names>R.W.</given-names>
            </name>
            <name>
              <surname>Church</surname>
              <given-names>F.C.</given-names>
            </name>
            <name>
              <surname>Coughlin</surname>
              <given-names>P.B.</given-names>
            </name>
            <name>
              <surname>Gettins</surname>
              <given-names>P.G.W.</given-names>
            </name>
            <name>
              <surname>Irving</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Lomas</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Luke</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Moyer</surname>
              <given-names>R.W.</given-names>
            </name>
            <name>
              <surname>Pemberton</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Remold-O&#x2019;Donnell</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Salvesen</surname>
              <given-names>G.S.</given-names>
            </name>
            <name>
              <surname>Travis</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Whisstock</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>The serpins are an expanding superfamily of structurally similar but functionally diverse proteins</article-title>
          <source>J. Biol. Chem.</source>
          <volume>276</volume>
          <year>2001</year>
          <fpage>33293</fpage>
          <lpage>33296</lpage>
          <pub-id pub-id-type="pmid">11435447</pub-id>
        </element-citation>
      </ref>
      <ref id="bib162">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roberts</surname>
              <given-names>T.H.</given-names>
            </name>
            <name>
              <surname>Hejgaard</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Saunders</surname>
              <given-names>N.F.W.</given-names>
            </name>
            <name>
              <surname>Cavicchioli</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Curmi</surname>
              <given-names>P.M.G.</given-names>
            </name>
          </person-group>
          <article-title>Serpins in unicellular eukarya, archaea, and bacteria: sequence analysis and evolution</article-title>
          <source>J. Mol. Evol.</source>
          <volume>59</volume>
          <year>2004</year>
          <fpage>437</fpage>
          <lpage>447</lpage>
          <pub-id pub-id-type="pmid">15638455</pub-id>
        </element-citation>
      </ref>
      <ref id="bib163">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Engh</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Schulze</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Divining the serpin inhibition mechanism: a suicide substrate &#x2019;springe&#x2019;?</article-title>
          <source>Trends Biotechnol.</source>
          <volume>13</volume>
          <year>1995</year>
          <fpage>503</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="pmid">8595135</pub-id>
        </element-citation>
      </ref>
      <ref id="bib164">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krowarsch</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Cierpicki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Jelen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Otlewski</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Canonical protein inhibitors of serine proteases</article-title>
          <source>Cell. Mol. Life Sci.</source>
          <volume>60</volume>
          <year>2003</year>
          <fpage>2427</fpage>
          <lpage>2444</lpage>
          <pub-id pub-id-type="pmid">14625687</pub-id>
        </element-citation>
      </ref>
      <ref id="bib165">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huntington</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Read</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Carrell</surname>
              <given-names>R.W.</given-names>
            </name>
          </person-group>
          <article-title>Structure of a serpin-protease complex shows inhibition by deformation</article-title>
          <source>Nature</source>
          <volume>407</volume>
          <year>2000</year>
          <fpage>923</fpage>
          <lpage>926</lpage>
          <pub-id pub-id-type="pmid">11057674</pub-id>
        </element-citation>
      </ref>
      <ref id="bib166">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dementiev</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Simonovic</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Volz</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Gettins</surname>
              <given-names>P.G.W.</given-names>
            </name>
          </person-group>
          <article-title>Canonical inhibitor-like interactions explain reactivity of a1-proteinase inhibitor Pittsburgh and antithrombin with proteinases</article-title>
          <source>J. Biol. Chem.</source>
          <volume>278</volume>
          <year>2003</year>
          <fpage>37881</fpage>
          <lpage>37887</lpage>
          <pub-id pub-id-type="pmid">12860985</pub-id>
        </element-citation>
      </ref>
      <ref id="bib167">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ye</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cech</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Belmares</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bergstrom</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Tong</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Corey</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Kanost</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Goldsmith</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>The structure of a Michaelis serpin&#x2013;protease complex</article-title>
          <source>Nat. Struct. Biol.</source>
          <volume>8</volume>
          <year>2001</year>
          <fpage>979</fpage>
          <lpage>983</lpage>
          <pub-id pub-id-type="pmid">11685246</pub-id>
        </element-citation>
      </ref>
      <ref id="bib168">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marszal</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Shrake</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Serpin crystal structure and serpin polymer structure</article-title>
          <source>Arch. Biochem. Biophys.</source>
          <volume>453</volume>
          <year>2006</year>
          <fpage>123</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="pmid">16631102</pub-id>
        </element-citation>
      </ref>
      <ref id="bib169">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huntington</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Shape-shifting serpins &#x2013; advantages of a mobile mechanism</article-title>
          <source>Trends Biochem. Sci.</source>
          <volume>31</volume>
          <year>2006</year>
          <fpage>427</fpage>
          <lpage>435</lpage>
          <pub-id pub-id-type="pmid">16820297</pub-id>
        </element-citation>
      </ref>
      <ref id="bib170">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>L.-Y.</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition profiles of human tissue kallikreins by serine protease inhibitors</article-title>
          <source>Biol. Chem.</source>
          <volume>387</volume>
          <year>2006</year>
          <fpage>813</fpage>
          <lpage>816</lpage>
          <pub-id pub-id-type="pmid">16800745</pub-id>
        </element-citation>
      </ref>
      <ref id="bib171">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Geiger</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Stuckstedte</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Clausnitzer</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Fritz</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Progressive inhibition of human glandular (urinary) kallikrein by human serum and identification of the progressive antikallikrein as alpha 1-antitrypsin (alpha 1-protease inhibitor)</article-title>
          <source>Hoppe Seylers Z. Physiol. Chem.</source>
          <volume>362</volume>
          <year>1981</year>
          <fpage>317</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="pmid">6971794</pub-id>
        </element-citation>
      </ref>
      <ref id="bib172">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mikolajczyk</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Millar</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Saedi</surname>
              <given-names>M.S.</given-names>
            </name>
          </person-group>
          <article-title>Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors</article-title>
          <source>Prostate</source>
          <volume>34</volume>
          <year>1998</year>
          <fpage>44</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">9428387</pub-id>
        </element-citation>
      </ref>
      <ref id="bib173">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Michael</surname>
              <given-names>I.P.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pampalakis</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Magklara</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wasney</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression</article-title>
          <source>J. Biol. Chem.</source>
          <volume>280</volume>
          <year>2005</year>
          <fpage>14628</fpage>
          <lpage>14635</lpage>
          <comment>Epub 12005 Feb 14615</comment>
          <pub-id pub-id-type="pmid">15713679</pub-id>
        </element-citation>
      </ref>
      <ref id="bib174">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Magklara</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mellati</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Wasney</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Little</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>G.W.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>307</volume>
          <year>2003</year>
          <fpage>948</fpage>
          <lpage>955</lpage>
          <pub-id pub-id-type="pmid">12878203</pub-id>
        </element-citation>
      </ref>
      <ref id="bib175">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>W.-M.</given-names>
            </name>
            <name>
              <surname>Leinonen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kalkkinen</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Stenman</surname>
              <given-names>U.-H.</given-names>
            </name>
          </person-group>
          <article-title>Prostate-specific antigen forms a complex with and cleaves alpha1-protease inhibitor in vitro</article-title>
          <source>Prostate</source>
          <volume>33</volume>
          <year>1997</year>
          <fpage>87</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="pmid">9316649</pub-id>
        </element-citation>
      </ref>
      <ref id="bib176">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stenman</surname>
              <given-names>U.-H.</given-names>
            </name>
            <name>
              <surname>Leinonen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Alfthan</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Rannikko</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tuhkanen</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Alfthan</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>A complex between prostate-specific antigen and {alpha}1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer</article-title>
          <source>Cancer Res.</source>
          <volume>51</volume>
          <year>1991</year>
          <fpage>222</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="pmid">1703033</pub-id>
        </element-citation>
      </ref>
      <ref id="bib177">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>W.-M.</given-names>
            </name>
            <name>
              <surname>Finne</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Leinonen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Vesalainen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nordling</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Stenman</surname>
              <given-names>U.-H.</given-names>
            </name>
          </person-group>
          <article-title>Measurement of the complex between prostate-specific antigen and {alpha}1-protease inhibitor in serum</article-title>
          <source>Clin. Chem.</source>
          <volume>45</volume>
          <year>1999</year>
          <fpage>814</fpage>
          <lpage>821</lpage>
          <pub-id pub-id-type="pmid">10351990</pub-id>
        </element-citation>
      </ref>
      <ref id="bib178">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Obiezu</surname>
              <given-names>C.V.</given-names>
            </name>
            <name>
              <surname>Michael</surname>
              <given-names>I.P.</given-names>
            </name>
            <name>
              <surname>Levesque</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins</article-title>
          <source>Biol. Chem.</source>
          <volume>387</volume>
          <year>2006</year>
          <fpage>749</fpage>
          <lpage>759</lpage>
          <pub-id pub-id-type="pmid">16800736</pub-id>
        </element-citation>
      </ref>
      <ref id="bib179">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Becker</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Individual prostate-specific antigen (PSA) forms as prostate tumor markers</article-title>
          <source>Clin. Chim. Acta</source>
          <volume>257</volume>
          <year>1997</year>
          <fpage>117</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="pmid">9028629</pub-id>
        </element-citation>
      </ref>
      <ref id="bib180">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qian</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sensibar</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Zelner</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Schaeffer</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Finlay</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Rittenhouse</surname>
              <given-names>H.G.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Two-dimensional gel electrophoresis detects prostate-specific antigen-a1-antichymotrypsin complex in serum but not in prostatic fluid</article-title>
          <source>Clin. Chem.</source>
          <volume>43</volume>
          <year>1997</year>
          <fpage>352</fpage>
          <lpage>359</lpage>
          <pub-id pub-id-type="pmid">9023139</pub-id>
        </element-citation>
      </ref>
      <ref id="bib181">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mikolajczyk</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Catalona</surname>
              <given-names>W.J.</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Linton</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Millar</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Marker</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Katir</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Amirkhan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rittenhouse</surname>
              <given-names>H.G.</given-names>
            </name>
          </person-group>
          <article-title>Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer</article-title>
          <source>Clin. Chem.</source>
          <volume>50</volume>
          <year>2004</year>
          <fpage>1017</fpage>
          <lpage>1025</lpage>
          <pub-id pub-id-type="pmid">15054080</pub-id>
        </element-citation>
      </ref>
      <ref id="bib182">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hutchinson</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>L.-Y.</given-names>
            </name>
            <name>
              <surname>Yousef</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Soosaipillai</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Purification of human kallikrein 6 from biological fluids and identification of its complex with {alpha}1-antichymotrypsin</article-title>
          <source>Clin. Chem.</source>
          <volume>49</volume>
          <year>2003</year>
          <fpage>746</fpage>
          <lpage>751</lpage>
          <pub-id pub-id-type="pmid">12709365</pub-id>
        </element-citation>
      </ref>
      <ref id="bib183">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Cera</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Thrombin</article-title>
          <source>Mol. Aspects Med.</source>
          <volume>29</volume>
          <year>2008</year>
          <fpage>203</fpage>
          <lpage>254</lpage>
          <pub-id pub-id-type="pmid">18329094</pub-id>
        </element-citation>
      </ref>
      <ref id="bib184">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dementiev</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Petitou</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Herbert</surname>
              <given-names>J.-M.</given-names>
            </name>
            <name>
              <surname>Gettins</surname>
              <given-names>P.G.W.</given-names>
            </name>
          </person-group>
          <article-title>The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity</article-title>
          <source>Nat. Struct. Mol. Biol.</source>
          <volume>11</volume>
          <year>2004</year>
          <fpage>863</fpage>
          <lpage>867</lpage>
          <pub-id pub-id-type="pmid">15311268</pub-id>
        </element-citation>
      </ref>
      <ref id="bib185">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olson</surname>
              <given-names>S.T.</given-names>
            </name>
            <name>
              <surname>Bj&#xF6;rk</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Sheffer</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Craig</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Shore</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Choay</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement</article-title>
          <source>J. Biol. Chem.</source>
          <volume>267</volume>
          <year>1992</year>
          <fpage>12528</fpage>
          <lpage>12538</lpage>
          <pub-id pub-id-type="pmid">1618758</pub-id>
        </element-citation>
      </ref>
      <ref id="bib186">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bedsted</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Swanson</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Chuang</surname>
              <given-names>Y.-J.</given-names>
            </name>
            <name>
              <surname>Bock</surname>
              <given-names>P.E.</given-names>
            </name>
            <name>
              <surname>Bjork</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>S.T.</given-names>
            </name>
          </person-group>
          <article-title>Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites</article-title>
          <source>Biochemistry</source>
          <volume>42</volume>
          <year>2003</year>
          <fpage>8143</fpage>
          <lpage>8152</lpage>
          <pub-id pub-id-type="pmid">12846563</pub-id>
        </element-citation>
      </ref>
      <ref id="bib187">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Lundwall</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gadaleanu</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bjartell</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2</article-title>
          <source>Am. J. Pathol.</source>
          <volume>161</volume>
          <year>2002</year>
          <fpage>2053</fpage>
          <lpage>2063</lpage>
          <pub-id pub-id-type="pmid">12466122</pub-id>
        </element-citation>
      </ref>
      <ref id="bib188">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Castellino</surname>
              <given-names>F.J.</given-names>
            </name>
          </person-group>
          <source>Plasmin</source>
          <volume>vol. 2</volume>
          <year>2004</year>
          <publisher-name>Elsevier</publisher-name>
          <publisher-loc>London</publisher-loc>
          <comment>1692&#x2013;1699 pp.</comment>
        </element-citation>
      </ref>
      <ref id="bib189">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aoki</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>The past, present and future of plasmin inhibitor</article-title>
          <source>Thromb. Res.</source>
          <volume>116</volume>
          <year>2005</year>
          <fpage>455</fpage>
          <lpage>464</lpage>
          <pub-id pub-id-type="pmid">16181980</pub-id>
        </element-citation>
      </ref>
      <ref id="bib190">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Geiger</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Protein C inhibitor, a serpin with functions in- and outside vascular biology</article-title>
          <source>Thromb. Haemost.</source>
          <volume>97</volume>
          <year>2007</year>
          <fpage>343</fpage>
          <lpage>347</lpage>
          <pub-id pub-id-type="pmid">17334499</pub-id>
        </element-citation>
      </ref>
      <ref id="bib191">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huntington</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Structural insights into the multiple functions of protein C inhibitor</article-title>
          <source>Cell. Mol. Life Sci.</source>
          <volume>66</volume>
          <year>2009</year>
          <fpage>113</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="pmid">18818878</pub-id>
        </element-citation>
      </ref>
      <ref id="bib192">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lundwall</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Christensson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gadaleanu</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bjartell</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues</article-title>
          <source>Prostate</source>
          <volume>57</volume>
          <year>2003</year>
          <fpage>196</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">14518028</pub-id>
        </element-citation>
      </ref>
      <ref id="bib193">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Espa&#xF1;a</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Fink</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Sanchez-Cuenca</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gilabert</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Estell&#xE9;s</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Witzgall</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Complexes of tissue kallikrein with protein C inhibitor in human semen and urine</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>234</volume>
          <year>1995</year>
          <fpage>641</fpage>
          <lpage>649</lpage>
          <pub-id pub-id-type="pmid">8536714</pub-id>
        </element-citation>
      </ref>
      <ref id="bib194">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Espa&#xF1;a</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Gilabert</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Estell&#xE9;s</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Romeu</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Aznar</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Cabo</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen</article-title>
          <source>Thromb. Res.</source>
          <volume>64</volume>
          <year>1991</year>
          <fpage>309</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="pmid">1725227</pub-id>
        </element-citation>
      </ref>
      <ref id="bib195">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Espa&#xF1;a</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Navarro</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Medina</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Zorio</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Estell&#xE9;s</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The role of protein C inhibitor in human reproduction</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <volume>33</volume>
          <year>2007</year>
          <fpage>041</fpage>
          <lpage>045</lpage>
        </element-citation>
      </ref>
      <ref id="bib196">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>G.X.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence</article-title>
          <source>J. Biol. Chem.</source>
          <volume>267</volume>
          <year>1992</year>
          <fpage>25873</fpage>
          <lpage>25880</lpage>
          <pub-id pub-id-type="pmid">1334488</pub-id>
        </element-citation>
      </ref>
      <ref id="bib197">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chao</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Biochemistry, regulation and potential function of kallistatin</article-title>
          <source>Biol. Chem. Hoppe-Seyler</source>
          <volume>376</volume>
          <year>1995</year>
          <fpage>705</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="pmid">9072045</pub-id>
        </element-citation>
      </ref>
      <ref id="bib198">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>V.C.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1479</volume>
          <year>2000</year>
          <fpage>237</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="pmid">10862973</pub-id>
        </element-citation>
      </ref>
      <ref id="bib199">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>V.C.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein</article-title>
          <source>J. Biol. Chem.</source>
          <volume>275</volume>
          <year>2000</year>
          <fpage>38457</fpage>
          <lpage>38466</lpage>
          <pub-id pub-id-type="pmid">10993887</pub-id>
        </element-citation>
      </ref>
      <ref id="bib200">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>V.C.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Pimenta</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Bledsoe</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Juliano</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Identification of a Major heparin-binding site in kallistatin</article-title>
          <source>J. Biol. Chem.</source>
          <volume>276</volume>
          <year>2001</year>
          <fpage>1276</fpage>
          <lpage>1284</lpage>
          <pub-id pub-id-type="pmid">11016932</pub-id>
        </element-citation>
      </ref>
      <ref id="bib201">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chao</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>R.Q.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling</article-title>
          <source>Biol. Chem.</source>
          <volume>382</volume>
          <year>2001</year>
          <fpage>15</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">11258665</pub-id>
        </element-citation>
      </ref>
      <ref id="bib202">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miao</surname>
              <given-names>R.Q.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Structural elements of kallistatin required for inhibition of angiogenesis</article-title>
          <source>Am. J. Physiol. Cell Physiol.</source>
          <volume>284</volume>
          <year>2003</year>
          <fpage>C1604</fpage>
          <lpage>C1613</lpage>
          <pub-id pub-id-type="pmid">12734113</pub-id>
        </element-citation>
      </ref>
      <ref id="bib203">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cooley</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Takayama</surname>
              <given-names>T.K.</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Schechter</surname>
              <given-names>N.M.</given-names>
            </name>
            <name>
              <surname>Remold-O&#x2019;Donnell</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites</article-title>
          <source>Biochemistry</source>
          <volume>40</volume>
          <year>2001</year>
          <fpage>15762</fpage>
          <lpage>15770</lpage>
          <pub-id pub-id-type="pmid">11747453</pub-id>
        </element-citation>
      </ref>
      <ref id="bib204">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saedi</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Marker</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>R.-S.</given-names>
            </name>
            <name>
              <surname>Carpenter</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Rittenhouse</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Mikolajczyk</surname>
              <given-names>S.D.</given-names>
            </name>
          </person-group>
          <article-title>Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells</article-title>
          <source>Int. J. Cancer</source>
          <volume>94</volume>
          <year>2001</year>
          <fpage>558</fpage>
          <lpage>563</lpage>
          <pub-id pub-id-type="pmid">11745444</pub-id>
        </element-citation>
      </ref>
      <ref id="bib205">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mikolajczyk</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Millar</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Saedi</surname>
              <given-names>M.S.</given-names>
            </name>
          </person-group>
          <article-title>Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1</article-title>
          <source>Int. J.&#xA0;Cancer</source>
          <volume>81</volume>
          <year>1999</year>
          <fpage>438</fpage>
          <lpage>442</lpage>
          <pub-id pub-id-type="pmid">10209959</pub-id>
        </element-citation>
      </ref>
      <ref id="bib206">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>F.L.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Whisstock</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Bird</surname>
              <given-names>P.I.</given-names>
            </name>
          </person-group>
          <article-title>SerpinB6 is an inhibitor of kallikrein-8 in keratinocytes</article-title>
          <source>J. Biochem.</source>
          <volume>142</volume>
          <year>2007</year>
          <fpage>435</fpage>
          <lpage>442</lpage>
          <pub-id pub-id-type="pmid">17761692</pub-id>
        </element-citation>
      </ref>
      <ref id="bib207">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kato</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kishi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kamachi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Akisada</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Oka</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Midorikawa</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Takio</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Dohmae</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Bird</surname>
              <given-names>P.I.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Miyake</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Machida</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Shibata</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Serine proteinase inhibitor 3 and murinoglobulin i are potent inhibitors of neuropsin in adult mouse brain</article-title>
          <source>J. Biol. Chem.</source>
          <volume>276</volume>
          <year>2001</year>
          <fpage>14562</fpage>
          <lpage>14571</lpage>
          <pub-id pub-id-type="pmid">11278732</pub-id>
        </element-citation>
      </ref>
      <ref id="bib208">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M&#xE4;gert</surname>
              <given-names>H.-J.</given-names>
            </name>
            <name>
              <surname>St&#xE4;ndker</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Kreutzmann</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Zucht</surname>
              <given-names>H.-D.</given-names>
            </name>
            <name>
              <surname>Reinecke</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sommerhoff</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Fritz</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Forssmann</surname>
              <given-names>W.-G.</given-names>
            </name>
          </person-group>
          <article-title>LEKTI, a novel 15-domain type of human serine proteinase inhibitor</article-title>
          <source>J. Biol. Chem.</source>
          <volume>274</volume>
          <year>1999</year>
          <fpage>21499</fpage>
          <lpage>21502</lpage>
          <pub-id pub-id-type="pmid">10419450</pub-id>
        </element-citation>
      </ref>
      <ref id="bib209">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chavanas</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bodemer</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rochat</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hamel-Teillac</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Ali</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Irvine</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Bonafe</surname>
              <given-names>J.-L.</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Taieb</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Barrandon</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Harper</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>de Prost</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hovnanian</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome</article-title>
          <source>Nat. Genet.</source>
          <volume>25</volume>
          <year>2000</year>
          <fpage>141</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="pmid">10835624</pub-id>
        </element-citation>
      </ref>
      <ref id="bib210">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Descargues</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Deraison</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Prost</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Fraitag</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mazereeuw-Hautier</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>D&#x2019;Alessio</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ishida-Yamamoto</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bodemer</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Zambruno</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hovnanian</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome</article-title>
          <source>J.&#xA0;Invest. Dermatol.</source>
          <volume>126</volume>
          <year>2006</year>
          <fpage>1622</fpage>
          <lpage>1632</lpage>
          <pub-id pub-id-type="pmid">16628198</pub-id>
        </element-citation>
      </ref>
      <ref id="bib211">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Komatsu</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Saijoh</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Jayakumar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Clayman</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>Tohyama</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Suga</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Mizuno</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Tsukamoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Taniuchi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Takehara</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients</article-title>
          <source>J. Invest. Dermatol.</source>
          <volume>128</volume>
          <year>2007</year>
          <fpage>1148</fpage>
          <lpage>1159</lpage>
          <pub-id pub-id-type="pmid">17989726</pub-id>
        </element-citation>
      </ref>
      <ref id="bib212">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walley</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Chavanas</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Moffatt</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Esnouf</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Ubhi</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Abecasis</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>E.Y.</given-names>
            </name>
            <name>
              <surname>Harper</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Hovnanian</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cookson</surname>
              <given-names>W.O.C.M.</given-names>
            </name>
          </person-group>
          <article-title>Gene polymorphism in Netherton and common atopic disease</article-title>
          <source>Nat. Genet.</source>
          <volume>29</volume>
          <year>2001</year>
          <fpage>175</fpage>
          <lpage>178</lpage>
          <pub-id pub-id-type="pmid">11544479</pub-id>
        </element-citation>
      </ref>
      <ref id="bib213">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kabesch</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Carr</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Weiland</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>von Mutius</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Association between polymorphisms in serine protease inhibitor, kazal type 5 and asthma phenotypes in a large German population sample</article-title>
          <source>Clin. Exp. Allergy</source>
          <volume>34</volume>
          <year>2004</year>
          <fpage>340</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="pmid">15005725</pub-id>
        </element-citation>
      </ref>
      <ref id="bib214">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyer-Hoffert</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases</article-title>
          <source>Arch. Immunol. Ther. Exp. (Warsz.)</source>
          <volume>57</volume>
          <year>2009</year>
          <fpage>345</fpage>
          <lpage>354</lpage>
          <pub-id pub-id-type="pmid">19688185</pub-id>
        </element-citation>
      </ref>
      <ref id="bib215">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Briot</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Deraison</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Lacroix</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bonnart</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Robin</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Besson</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Dubus</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Hovnanian</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome</article-title>
          <source>J. Exp. Med.</source>
          <volume>206</volume>
          <year>2009</year>
          <fpage>1135</fpage>
          <lpage>1147</lpage>
          <pub-id pub-id-type="pmid">19414552</pub-id>
        </element-citation>
      </ref>
      <ref id="bib216">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lauber</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schweimer</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Adermann</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Marx</surname>
              <given-names>U.C.</given-names>
            </name>
          </person-group>
          <article-title>Homologous proteins with different folds: the three-dimensional structures of domains 1 and 6 of the multiple kazal-type inhibitor LEKTI</article-title>
          <source>J. Mol. Biol.</source>
          <volume>328</volume>
          <year>2003</year>
          <fpage>205</fpage>
          <lpage>219</lpage>
          <pub-id pub-id-type="pmid">12684009</pub-id>
        </element-citation>
      </ref>
      <ref id="bib217">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ardelt</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Laskowski</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Effect of single amino acid replacements on the thermodynamics of the reactive site peptide bond hydrolysis in ovomucoid third domain</article-title>
          <source>J. Mol. Biol.</source>
          <volume>220</volume>
          <year>1991</year>
          <fpage>1041</fpage>
          <lpage>1053</lpage>
          <pub-id pub-id-type="pmid">1880798</pub-id>
        </element-citation>
      </ref>
      <ref id="bib218">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egelrud</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Brattsand</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kreutzmann</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Walden</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vitzithum</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Marx</surname>
              <given-names>U.C.</given-names>
            </name>
            <name>
              <surname>Forssmann</surname>
              <given-names>W.G.</given-names>
            </name>
            <name>
              <surname>Magert</surname>
              <given-names>H.J.</given-names>
            </name>
          </person-group>
          <article-title>hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6</article-title>
          <source>Br. J. Dermatol.</source>
          <volume>153</volume>
          <year>2005</year>
          <fpage>1200</fpage>
          <lpage>1203</lpage>
          <pub-id pub-id-type="pmid">16307658</pub-id>
        </element-citation>
      </ref>
      <ref id="bib219">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schechter</surname>
              <given-names>N.M.</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Z.M.</given-names>
            </name>
            <name>
              <surname>Hanakawa</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Clayman</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>Jayakumar</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI)</article-title>
          <source>Biol. Chem.</source>
          <volume>386</volume>
          <year>2005</year>
          <fpage>1173</fpage>
          <lpage>1184</lpage>
          <pub-id pub-id-type="pmid">16307483</pub-id>
        </element-citation>
      </ref>
      <ref id="bib220">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyer-Hoffert</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Schr&#xF6;der</surname>
              <given-names>J.-M.</given-names>
            </name>
          </person-group>
          <article-title>Identification of lympho-epithelial kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor</article-title>
          <source>PLoS ONE</source>
          <volume>4</volume>
          <year>2009</year>
          <fpage>e4372</fpage>
          <pub-id pub-id-type="pmid">19190773</pub-id>
        </element-citation>
      </ref>
      <ref id="bib221">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brattsand</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Stefansson</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hubiche</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Egelrud</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>SPINK9: a selective, skin-specific kazal-type serine protease inhibitor</article-title>
          <source>J. Invest. Dermatol.</source>
          <volume>129</volume>
          <year>2009</year>
          <fpage>1656</fpage>
          <lpage>1665</lpage>
          <pub-id pub-id-type="pmid">19194479</pub-id>
        </element-citation>
      </ref>
      <ref id="bib222">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barrett</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Starkey</surname>
              <given-names>P.M.</given-names>
            </name>
          </person-group>
          <article-title>The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism</article-title>
          <source>Biochem. J.</source>
          <volume>133</volume>
          <year>1973</year>
          <fpage>709</fpage>
          <lpage>724</lpage>
          <pub-id pub-id-type="pmid">4201304</pub-id>
        </element-citation>
      </ref>
      <ref id="bib223">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andersen</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Dolmer</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Sottrup-Jensen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Nyborg</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Low resolution X-ray structure of human methylamine-treated alpha(2)-macroglobulin</article-title>
          <source>J. Biol. Chem.</source>
          <volume>270</volume>
          <year>1995</year>
          <fpage>25133</fpage>
          <lpage>25141</lpage>
          <pub-id pub-id-type="pmid">7559647</pub-id>
        </element-citation>
      </ref>
      <ref id="bib224">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sottrup-Jensen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Sand</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Kristensen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Fey</surname>
              <given-names>G.H.</given-names>
            </name>
          </person-group>
          <article-title>The alpha-macroglobulin bait region. Sequence diversity and localization of cleavage sites for proteinases in five mammalian alpha-macroglobulins</article-title>
          <source>J. Biol. Chem.</source>
          <volume>264</volume>
          <year>1989</year>
          <fpage>15781</fpage>
          <lpage>15789</lpage>
          <pub-id pub-id-type="pmid">2476433</pub-id>
        </element-citation>
      </ref>
      <ref id="bib225">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kolodziej</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Wagenknecht</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Strickland</surname>
              <given-names>D.K.</given-names>
            </name>
            <name>
              <surname>Stoops</surname>
              <given-names>J.K.</given-names>
            </name>
          </person-group>
          <article-title>The three-dimensional structure of the human alpha 2-macroglobulin dimer reveals its structural organization in the tetrameric native and chymotrypsin alpha 2-macroglobulin complexes</article-title>
          <source>J. Biol. Chem.</source>
          <volume>277</volume>
          <year>2002</year>
          <fpage>28031</fpage>
          <lpage>28037</lpage>
          <pub-id pub-id-type="pmid">12015318</pub-id>
        </element-citation>
      </ref>
      <ref id="bib226">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borth</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics</article-title>
          <source>FASEB J.</source>
          <volume>6</volume>
          <year>1992</year>
          <fpage>3345</fpage>
          <lpage>3353</lpage>
          <pub-id pub-id-type="pmid">1281457</pub-id>
        </element-citation>
      </ref>
      <ref id="bib227">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Christensen</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Sottrup-Jensen</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Mechanism of alpha 2-macroglobulin-proteinase interactions. Studies with trypsin and plasmin</article-title>
          <source>Biochemistry</source>
          <volume>23</volume>
          <year>1984</year>
          <fpage>6619</fpage>
          <lpage>6626</lpage>
          <pub-id pub-id-type="pmid">6085009</pub-id>
        </element-citation>
      </ref>
      <ref id="bib228">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crews</surname>
              <given-names>B.C.</given-names>
            </name>
            <name>
              <surname>James</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Beth</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Gettins</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cunningham</surname>
              <given-names>L.W.</given-names>
            </name>
          </person-group>
          <article-title>In support of the trap hypothesis. Chymotrypsin is not rigidly held in its complex with human alpha 2-macroglobulin</article-title>
          <source>Biochemistry</source>
          <volume>26</volume>
          <year>1987</year>
          <fpage>5963</fpage>
          <lpage>5967</lpage>
          <pub-id pub-id-type="pmid">2446656</pub-id>
        </element-citation>
      </ref>
      <ref id="bib229">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abe</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Sinohara</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Proteinase inhibitory spectrum of mouse murinoglobulin and {alpha}-macroglobulin</article-title>
          <source>J. Biochem.</source>
          <volume>106</volume>
          <year>1989</year>
          <fpage>564</fpage>
          <lpage>568</lpage>
          <pub-id pub-id-type="pmid">2481676</pub-id>
        </element-citation>
      </ref>
      <ref id="bib230">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grauer</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Finlay</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Mikolajczyk</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Pusateri</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Wolfert</surname>
              <given-names>R.L.</given-names>
            </name>
          </person-group>
          <article-title>Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum</article-title>
          <source>J. Androl.</source>
          <volume>19</volume>
          <year>1998</year>
          <fpage>407</fpage>
          <lpage>411</lpage>
          <pub-id pub-id-type="pmid">9733142</pub-id>
        </element-citation>
      </ref>
      <ref id="bib231">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heeb</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Espa&#xF1;a</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>a<sub>2</sub>-Macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein</article-title>
          <source>Blood Cells Mol. Dis.</source>
          <volume>24</volume>
          <year>1998</year>
          <fpage>412</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="pmid">9851894</pub-id>
        </element-citation>
      </ref>
      <ref id="bib232">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Christensson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Laurell</surname>
              <given-names>C.-B.</given-names>
            </name>
            <name>
              <surname>Lilja</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>194</volume>
          <year>1990</year>
          <fpage>755</fpage>
          <lpage>763</lpage>
          <pub-id pub-id-type="pmid">1702714</pub-id>
        </element-citation>
      </ref>
      <ref id="bib233">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jensen</surname>
              <given-names>P.E.</given-names>
            </name>
            <name>
              <surname>Stigbrand</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Differences in the proteinase inhibition mechanism of human alpha 2-macroglobulin and pregnancy zone protein</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>210</volume>
          <year>1992</year>
          <fpage>1071</fpage>
          <lpage>1077</lpage>
          <pub-id pub-id-type="pmid">1282886</pub-id>
        </element-citation>
      </ref>
      <ref id="bib234">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hengst</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Albrecht</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Monard</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>The phosphatidylethanolamine-binding protein is the prototype of a novel family of serine protease inhibitors</article-title>
          <source>J. Biol. Chem.</source>
          <volume>276</volume>
          <year>2001</year>
          <fpage>535</fpage>
          <lpage>540</lpage>
          <pub-id pub-id-type="pmid">11034991</pub-id>
        </element-citation>
      </ref>
      <ref id="bib235">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandstetter</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J.-S.</given-names>
            </name>
            <name>
              <surname>Groll</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of the tricorn protease reveals a protein disassembly line</article-title>
          <source>Nature</source>
          <volume>414</volume>
          <year>2001</year>
          <fpage>466</fpage>
          <lpage>470</lpage>
          <pub-id pub-id-type="pmid">11719810</pub-id>
        </element-citation>
      </ref>
      <ref id="bib236">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Groll</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ditzel</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>L&#xF6;we</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stock</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bochtler</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bartunik</surname>
              <given-names>H.D.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Structure of 20S proteasome from yeast at 2.4 A resolution</article-title>
          <source>Nature</source>
          <volume>386</volume>
          <year>1997</year>
          <fpage>463</fpage>
          <lpage>471</lpage>
          <pub-id pub-id-type="pmid">9087403</pub-id>
        </element-citation>
      </ref>
      <ref id="bib237">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Farrell</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Joshua-Tor</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of human bleomycin hydrolase, a self-compartmentalizing cysteine protease</article-title>
          <source>Structure</source>
          <volume>7</volume>
          <year>1999</year>
          <fpage>619</fpage>
          <lpage>627</lpage>
          <pub-id pub-id-type="pmid">10404591</pub-id>
        </element-citation>
      </ref>
      <ref id="bib238">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marquardt</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Zettl</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Sommerhoff</surname>
              <given-names>C.P.</given-names>
            </name>
          </person-group>
          <article-title>The crystal structure of human a1-tryptase reveals a blocked substrate-binding region</article-title>
          <source>J.&#xA0;Mol. Biol.</source>
          <volume>321</volume>
          <year>2002</year>
          <fpage>491</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="pmid">12162961</pub-id>
        </element-citation>
      </ref>
      <ref id="bib239">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pereira</surname>
              <given-names>P.J.B.</given-names>
            </name>
            <name>
              <surname>Bergner</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Macedo-Ribeiro</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Matschiner</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Fritz</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sommerhoff</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Human b-tryptase is a ring-like tetramer with active sites facing a central pore</article-title>
          <source>Nature</source>
          <volume>392</volume>
          <year>1998</year>
          <fpage>306</fpage>
          <lpage>311</lpage>
          <pub-id pub-id-type="pmid">9521329</pub-id>
        </element-citation>
      </ref>
      <ref id="bib240">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandstetter</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Groll</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>G&#xF6;ttig</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Structural basis for the processive protein degradation by tricorn protease</article-title>
          <source>Biol. Chem.</source>
          <volume>383</volume>
          <year>2002</year>
          <fpage>1157</fpage>
          <lpage>1165</lpage>
          <pub-id pub-id-type="pmid">12437101</pub-id>
        </element-citation>
      </ref>
      <ref id="bib241">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Voges</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Zwickl</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Baumeister</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>The 26S proteasome: a molecular machine designed for controlled proteolysis</article-title>
          <source>Annu. Rev. Biochem.</source>
          <volume>68</volume>
          <year>1999</year>
          <fpage>1015</fpage>
          <lpage>1068</lpage>
          <pub-id pub-id-type="pmid">10872471</pub-id>
        </element-citation>
      </ref>
      <ref id="bib242">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsui</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Moriyama</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Cloning and characterization of mouse Klk27, a novel tissue kallikrein expressed in testicular Leydig cells and exhibiting chymotrypsin-like specificity</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>267</volume>
          <year>2000</year>
          <fpage>6858</fpage>
          <lpage>6865</lpage>
          <pub-id pub-id-type="pmid">11082197</pub-id>
        </element-citation>
      </ref>
      <ref id="bib243">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oikonomopoulou</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>K.K.</given-names>
            </name>
            <name>
              <surname>Baruch</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hollenberg</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids</article-title>
          <source>Biol. Chem.</source>
          <volume>389</volume>
          <year>2008</year>
          <fpage>747</fpage>
          <lpage>756</lpage>
          <pub-id pub-id-type="pmid">18627291</pub-id>
        </element-citation>
      </ref>
      <ref id="bib244">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dentan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Tselepis</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Chapman</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Ninio</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1299</volume>
          <year>1996</year>
          <fpage>353</fpage>
          <lpage>357</lpage>
          <pub-id pub-id-type="pmid">8597590</pub-id>
        </element-citation>
      </ref>
      <ref id="bib245">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujimoto</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Watanabe</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Akihama</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Purification and characterization of a kallikrein from human submaxillary glands</article-title>
          <source>Biochem. Med. Metab. Biol.</source>
          <volume>44</volume>
          <year>1990</year>
          <fpage>218</fpage>
          <lpage>227</lpage>
          <pub-id pub-id-type="pmid">2288765</pub-id>
        </element-citation>
      </ref>
      <ref id="bib246">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernett</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Dhanarajan</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system</article-title>
          <source>J. Biol. Chem.</source>
          <volume>277</volume>
          <year>2002</year>
          <fpage>24562</fpage>
          <lpage>24570</lpage>
          <pub-id pub-id-type="pmid">11983703</pub-id>
        </element-citation>
      </ref>
      <ref id="bib247">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Bartels</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kutzbach</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Schmidt-Kastner</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bartunik</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Refined 2 A X-ray crystal structure of porcine pancreatic kallikrein A, a specific trypsin-like serine proteinase. Crystallization, structure determination, crystallographic refinement, structure and its comparison with bovine trypsin</article-title>
          <source>J. Mol. Biol.</source>
          <volume>164</volume>
          <year>1983</year>
          <fpage>237</fpage>
          <lpage>282</lpage>
          <pub-id pub-id-type="pmid">6551452</pub-id>
        </element-citation>
      </ref>
      <ref id="bib248">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fritz</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>F&#xF6;rg-Brey</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Umezawa</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Leupeptin and antipain. Strong competitive inhibitors of sperm acrosomal proteinase (boar acrosin) and kallikreins from porcine organs (pancreas, submand. glands, urine)</article-title>
          <source>Hoppe Seylers Z. Physiol. Chem.</source>
          <volume>354</volume>
          <year>1973</year>
          <fpage>1304</fpage>
          <lpage>1306</lpage>
          <pub-id pub-id-type="pmid">4807834</pub-id>
        </element-citation>
      </ref>
      <ref id="bib249">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fielder</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Rosenfeld</surname>
              <given-names>R.G.</given-names>
            </name>
            <name>
              <surname>Graves</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Grandbois</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Maack</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Sawamura</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Sommer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3</article-title>
          <source>Growth Regul.</source>
          <volume>4</volume>
          <year>1994</year>
          <fpage>164</fpage>
          <lpage>172</lpage>
          <pub-id pub-id-type="pmid">7538844</pub-id>
        </element-citation>
      </ref>
      <ref id="bib250">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sealock</surname>
              <given-names>R.W.</given-names>
            </name>
            <name>
              <surname>Laskowski</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Enzymic replacement of the arginyl by a lysyl residue in the reactive site of soybean trypsin inhibitor</article-title>
          <source>Biochemistry</source>
          <volume>8</volume>
          <year>1969</year>
          <fpage>3703</fpage>
          <lpage>3710</lpage>
          <pub-id pub-id-type="pmid">5387527</pub-id>
        </element-citation>
      </ref>
      <ref id="bib251">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>H.K.</given-names>
            </name>
            <name>
              <surname>Suh</surname>
              <given-names>S.W.</given-names>
            </name>
          </person-group>
          <article-title>Kunitz-type soybean trypsin inhibitor revisited: refined structure of its complex with porcine trypsin reveals an insight into the interaction between a homologous inhibitor from Erythrina caffra and tissue-type plasminogen activator</article-title>
          <source>J. Mol. Biol.</source>
          <volume>275</volume>
          <year>1998</year>
          <fpage>347</fpage>
          <lpage>363</lpage>
          <pub-id pub-id-type="pmid">9466914</pub-id>
        </element-citation>
      </ref>
      <ref id="bib252">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koepke</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ermler</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Warkentin</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Wenzl</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Flecker</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of cancer chemopreventive Bowman-Birk inhibitor in ternary complex with bovine trypsin at 2.3 &#xC5; resolution. Structural basis of Janus-faced serine protease inhibitor specificity</article-title>
          <source>J. Mol. Biol.</source>
          <volume>298</volume>
          <year>2000</year>
          <fpage>477</fpage>
          <lpage>491</lpage>
          <pub-id pub-id-type="pmid">10772864</pub-id>
        </element-citation>
      </ref>
      <ref id="bib253">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Chi</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Engh</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <article-title>The 0.25-nm X-ray structure of the Bowman-Birk-type inhibitor from mung bean in ternary complex with porcine trypsin</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>212</volume>
          <year>1993</year>
          <fpage>549</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="pmid">8444191</pub-id>
        </element-citation>
      </ref>
      <ref id="bib254">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kennedy</surname>
              <given-names>A.R.</given-names>
            </name>
          </person-group>
          <article-title>Prevention of carcinogenesis by protease inhibitors</article-title>
          <source>Cancer Res.</source>
          <volume>54</volume>
          <year>1994</year>
          <fpage>1999s</fpage>
          <lpage>2005s</lpage>
          <pub-id pub-id-type="pmid">8137328</pub-id>
        </element-citation>
      </ref>
      <ref id="bib255">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kukla</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Schwager</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bartels</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Deisenhofer</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Steigemann</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor: II. Crystallographic refinement at 1.9 &#xC5; resolution</article-title>
          <source>J. Mol. Biol.</source>
          <volume>89</volume>
          <year>1974</year>
          <fpage>73</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="pmid">4475115</pub-id>
        </element-citation>
      </ref>
      <ref id="bib256">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>R&#xFC;hlmann</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kukla</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Schwager</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bartels</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor: crystal structure determination and stereochemistry of the contact region</article-title>
          <source>J.&#xA0;Mol. Biol.</source>
          <volume>77</volume>
          <year>1973</year>
          <fpage>417</fpage>
          <lpage>436</lpage>
          <pub-id pub-id-type="pmid">4737866</pub-id>
        </element-citation>
      </ref>
      <ref id="bib257">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tschesche</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kupfer</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Hydrolysis-resynthesis equilibrium of the lysine-15-alanine-16 peptide bond in bovine trypsin inhibitor (Kunitz)</article-title>
          <source>Hoppe Seylers Z. Physiol. Chem.</source>
          <volume>357</volume>
          <year>1976</year>
          <fpage>769</fpage>
          <lpage>776</lpage>
          <pub-id pub-id-type="pmid">8370</pub-id>
        </element-citation>
      </ref>
      <ref id="bib258">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krowarsch</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Zakrzewska</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Smalas</surname>
              <given-names>A.O.</given-names>
            </name>
            <name>
              <surname>Otlewski</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Structure-function relationships in serine protease-bovine pancreatic trypsin inhibitor interaction</article-title>
          <source>Protein Pept. Lett.</source>
          <volume>12</volume>
          <year>2005</year>
          <fpage>403</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="pmid">16029151</pub-id>
        </element-citation>
      </ref>
      <ref id="bib259">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ascenzi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bocedi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bolognesi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Spallarossa</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Coletta</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>De Cristofaro</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Menegatti</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein</article-title>
          <source>Curr. Protein Pept. Sci.</source>
          <volume>4</volume>
          <year>2003</year>
          <fpage>231</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="pmid">12769721</pub-id>
        </element-citation>
      </ref>
      <ref id="bib260">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kraut</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>E.K.</given-names>
            </name>
            <name>
              <surname>Werle</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>&#xDC;ber die Inaktivierung des Kallikreins. (VI.&#xA0;Mitteilung &#xDC;ber dieses Kreislaufhormon.)</article-title>
          <source>Hoppe Seylers Z. Physiol. Chem.</source>
          <volume>192</volume>
          <year>1930</year>
          <fpage>1</fpage>
          <lpage>21</lpage>
        </element-citation>
      </ref>
      <ref id="bib261">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>S&#xF6;llner</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mentele</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Eckerskorn</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Fritz</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Sommerhoff</surname>
              <given-names>C.P.</given-names>
            </name>
          </person-group>
          <article-title>Isolation and characterization of hirustasin, an antistasin-type serine-proteinase inhibitor from the medical leech <italic>Hirudo medicinalis</italic></article-title>
          <source>Eur. J. Biochem.</source>
          <volume>219</volume>
          <year>1994</year>
          <fpage>937</fpage>
          <lpage>943</lpage>
          <pub-id pub-id-type="pmid">8112345</pub-id>
        </element-citation>
      </ref>
      <ref id="bib262">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ascenzi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Amiconi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Bolognesi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Coletta</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Menegatti</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects</article-title>
          <source>Mol. Aspects Med.</source>
          <volume>16</volume>
          <year>1995</year>
          <fpage>215</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="pmid">8569452</pub-id>
        </element-citation>
      </ref>
      <ref id="bib263">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mittl</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Di Marco</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fendrich</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pohlig</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Heim</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sommerhoff</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Fritz</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Priestle</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Grutter</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>A new structural class of serine protease inhibitors revealed by the structure of the hirustasin-kallikrein complex</article-title>
          <source>Structure</source>
          <volume>5</volume>
          <year>1997</year>
          <fpage>253</fpage>
          <lpage>264</lpage>
          <pub-id pub-id-type="pmid">9032072</pub-id>
        </element-citation>
      </ref>
      <ref id="bib264">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swedberg</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>de Veer</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>357</fpage>
          <lpage>374</lpage>
          <pub-id pub-id-type="pmid">20180638</pub-id>
        </element-citation>
      </ref>
      <ref id="bib265">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lipinski</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Lombardo</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Dominy</surname>
              <given-names>B.W.</given-names>
            </name>
            <name>
              <surname>Feeney</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title>
          <source>Adv. Drug Deliv. Rev.</source>
          <volume>46</volume>
          <year>2001</year>
          <fpage>3</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="pmid">11259830</pub-id>
        </element-citation>
      </ref>
      <ref id="bib266">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhal</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Kassam</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Peirson</surname>
              <given-names>I.G.</given-names>
            </name>
            <name>
              <surname>Pearl</surname>
              <given-names>G.M.</given-names>
            </name>
          </person-group>
          <article-title>The rule of five revisited: applying log D in place of log P in drug-likeness filters</article-title>
          <source>Mol. Pharm.</source>
          <volume>4</volume>
          <year>2007</year>
          <fpage>556</fpage>
          <lpage>560</lpage>
          <pub-id pub-id-type="pmid">17530776</pub-id>
        </element-citation>
      </ref>
      <ref id="bib267">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghose</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Viswanadhan</surname>
              <given-names>V.N.</given-names>
            </name>
            <name>
              <surname>Wendoloski</surname>
              <given-names>J.J.</given-names>
            </name>
          </person-group>
          <article-title>A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases</article-title>
          <source>J. Comb. Chem.</source>
          <volume>1</volume>
          <year>1998</year>
          <fpage>55</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">10746014</pub-id>
        </element-citation>
      </ref>
      <ref id="bib268">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>M.-Q.</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Drug discovery beyond the &#x2019;rule-of-five&#x2019;</article-title>
          <source>Curr. Opin. Biotechnol.</source>
          <volume>18</volume>
          <year>2007</year>
          <fpage>478</fpage>
          <lpage>488</lpage>
          <pub-id pub-id-type="pmid">18035532</pub-id>
        </element-citation>
      </ref>
      <ref id="bib269">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fear</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Komarnytsky</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Raskin</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Protease inhibitors and their peptidomimetic derivatives as potential drugs</article-title>
          <source>Pharmacol. Ther.</source>
          <volume>113</volume>
          <year>2007</year>
          <fpage>354</fpage>
          <lpage>368</lpage>
          <pub-id pub-id-type="pmid">17098288</pub-id>
        </element-citation>
      </ref>
      <ref id="bib270">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riester</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Wirsching</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Salinas</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gebinoga</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kamphausen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Merkwirth</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Goetz</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wiesenfeldt</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>St&#xFC;rzebecher</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Th&#xFC;rk</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schwienhorst</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Thrombin inhibitors identified by computer-assisted multiparameter design</article-title>
          <source>Proc. Natl. Acad. Sci. U S A</source>
          <volume>102</volume>
          <year>2005</year>
          <fpage>8597</fpage>
          <lpage>8602</lpage>
          <pub-id pub-id-type="pmid">15937115</pub-id>
        </element-citation>
      </ref>
      <ref id="bib271">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fattori</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Squarcia</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bartoli</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Fragment-based approach to drug lead discovery: overview and advances in various techniques</article-title>
          <source>Drugs R D</source>
          <volume>9</volume>
          <year>2008</year>
          <fpage>217</fpage>
          <lpage>227</lpage>
          <pub-id pub-id-type="pmid">18588353</pub-id>
        </element-citation>
      </ref>
      <ref id="bib272">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tobin</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Gustafsson</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Huisman</surname>
              <given-names>G.W.</given-names>
            </name>
          </person-group>
          <article-title>Directed evolution: the &#x2019;rational&#x2019; basis for &#x2019;irrational&#x2019; design</article-title>
          <source>Curr. Opin. Struct. Biol.</source>
          <volume>10</volume>
          <year>2000</year>
          <fpage>421</fpage>
          <lpage>427</lpage>
          <pub-id pub-id-type="pmid">10981629</pub-id>
        </element-citation>
      </ref>
      <ref id="bib273">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klebe</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Recent developments in structure-based drug design</article-title>
          <source>J. Mol. Med.</source>
          <volume>78</volume>
          <year>2000</year>
          <fpage>269</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="pmid">10954199</pub-id>
        </element-citation>
      </ref>
      <ref id="bib274">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walker</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Lynas</surname>
              <given-names>J.F.</given-names>
            </name>
          </person-group>
          <article-title>Strategies for the inhibition of serine proteases</article-title>
          <source>Cell. Mol. Life Sci.</source>
          <volume>58</volume>
          <year>2001</year>
          <fpage>596</fpage>
          <lpage>624</lpage>
          <pub-id pub-id-type="pmid">11361094</pub-id>
        </element-citation>
      </ref>
      <ref id="bib275">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adlington</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Baldwin</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>G.W.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Hermann</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Howe</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>McCoull</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>McNulty</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Neubauer</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Pritchard</surname>
              <given-names>G.J.</given-names>
            </name>
          </person-group>
          <article-title>Design, synthesis, and proposed active site binding analysis of monocyclic 2-azetidinone inhibitors of prostate specific antigen</article-title>
          <source>J. Med. Chem.</source>
          <volume>44</volume>
          <year>2001</year>
          <fpage>1491</fpage>
          <lpage>1508</lpage>
          <pub-id pub-id-type="pmid">11334560</pub-id>
        </element-citation>
      </ref>
      <ref id="bib276">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koistinen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wohlfahrt</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Mattsson</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lahdenper&#xE4;</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stenman</surname>
              <given-names>U.-H.</given-names>
            </name>
          </person-group>
          <article-title>Novel small molecule inhibitors for prostate-specific antigen</article-title>
          <source>Prostate</source>
          <volume>68</volume>
          <year>2008</year>
          <fpage>1143</fpage>
          <lpage>1151</lpage>
          <pub-id pub-id-type="pmid">18500692</pub-id>
        </element-citation>
      </ref>
      <ref id="bib277">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Krastel</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Liechty</surname>
              <given-names>B.-M.</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Schreiner</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Novartis</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <source>Use of Cyclic Depsipeptides to Inhibit Kallikrein 7</source>
          <year>2009</year>
        </element-citation>
      </ref>
      <ref id="bib278">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Bodendorf</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Meingassner</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Hassiepen</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Ostermann</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Gerhartz</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Berst</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Randl</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Ehrhardt</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Marzinzik</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Flohr</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Novartis</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <source>Kallikrein 7 Modulators</source>
          <year>2008</year>
          <comment>Australia</comment>
        </element-citation>
      </ref>
      <ref id="bib279">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fareed</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Messmore</surname>
              <given-names>H.L.</given-names>
            </name>
            <name>
              <surname>Kindel</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Balis</surname>
              <given-names>J.U.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of serine proteases by low molecular weight peptides and their derivatives</article-title>
          <source>Ann. N.Y. Acad. Sci.</source>
          <volume>370</volume>
          <year>1981</year>
          <fpage>765</fpage>
          <lpage>784</lpage>
          <pub-id pub-id-type="pmid">6455957</pub-id>
        </element-citation>
      </ref>
      <ref id="bib280">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pimenta</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Melo</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Caliendo</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Santagada</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Fiorino</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Severino</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>de Nucci</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Juliano</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Juliano</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>Design of inhibitors for human tissue kallikrein using non-natural aromatic and basic amino acids</article-title>
          <source>Biol. Chem.</source>
          <volume>383</volume>
          <year>2002</year>
          <fpage>853</fpage>
          <lpage>857</lpage>
          <pub-id pub-id-type="pmid">12108552</pub-id>
        </element-citation>
      </ref>
      <ref id="bib281">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolf</surname>
              <given-names>W.C.</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness</article-title>
          <source>Am. J. Pathol.</source>
          <volume>159</volume>
          <year>2001</year>
          <fpage>1797</fpage>
          <lpage>1805</lpage>
          <pub-id pub-id-type="pmid">11696440</pub-id>
        </element-citation>
      </ref>
      <ref id="bib282">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hekim</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Leinonen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Narvanen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Koistinen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Koivunen</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Vaisanen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Stenman</surname>
              <given-names>U.-H.</given-names>
            </name>
          </person-group>
          <article-title>Novel peptide inhibitors of human kallikrein 2</article-title>
          <source>J.&#xA0;Biol. Chem.</source>
          <volume>281</volume>
          <year>2006</year>
          <fpage>12555</fpage>
          <lpage>12560</lpage>
          <pub-id pub-id-type="pmid">16527822</pub-id>
        </element-citation>
      </ref>
      <ref id="bib283">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pakkala</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hekim</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Soininen</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Leinonen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Koistinen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Weisell</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Stenman</surname>
              <given-names>U.-H.</given-names>
            </name>
            <name>
              <surname>Veps&#xE4;l&#xE4;inen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>N&#xE4;rv&#xE4;nen</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors</article-title>
          <source>J. Pept. Sci.</source>
          <volume>13</volume>
          <year>2007</year>
          <fpage>348</fpage>
          <lpage>353</lpage>
          <pub-id pub-id-type="pmid">17436344</pub-id>
        </element-citation>
      </ref>
      <ref id="bib284">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hekim</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Riipi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Weisell</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>N&#xE4;rv&#xE4;nen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Koistinen</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Stenman</surname>
              <given-names>U.-H.</given-names>
            </name>
            <name>
              <surname>Koistinen</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Identification of IGFBP-3 fragments generated by KLK2 and prevention of fragmentation by KLK2-inhibiting peptides</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>475</fpage>
          <lpage>479</lpage>
          <pub-id pub-id-type="pmid">20180640</pub-id>
        </element-citation>
      </ref>
      <ref id="bib285">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Knoell</surname>
              <given-names>C.T.</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hazegh-Azam</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tashjian</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Hedstrom</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Abeles</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>Timasheff</surname>
              <given-names>S.N.</given-names>
            </name>
          </person-group>
          <article-title>Modulation of recombinant human prostate-specific antigen: activation by Hofmeister salts and inhibition by azapeptides. Appendix: thermodynamic interpretation of the activation by concentrated salts</article-title>
          <source>Biochemistry</source>
          <volume>40</volume>
          <year>2001</year>
          <fpage>11734</fpage>
          <lpage>11741</lpage>
          <pub-id pub-id-type="pmid">11570874</pub-id>
        </element-citation>
      </ref>
      <ref id="bib286">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>LeBeau</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>J.T.</given-names>
            </name>
            <name>
              <surname>Denmeade</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen</article-title>
          <source>Chem. Biol.</source>
          <volume>15</volume>
          <year>2008</year>
          <fpage>665</fpage>
          <lpage>674</lpage>
          <pub-id pub-id-type="pmid">18635003</pub-id>
        </element-citation>
      </ref>
      <ref id="bib287">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>LeBeau</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Banerjee</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Pomper</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Mease</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Denmeade</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer</article-title>
          <source>Bioorg. Med. Chem.</source>
          <volume>17</volume>
          <year>2009</year>
          <fpage>4888</fpage>
          <lpage>4893</lpage>
          <pub-id pub-id-type="pmid">19541487</pub-id>
        </element-citation>
      </ref>
      <ref id="bib288">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>LeBeau</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Kostova</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Craik</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Denmeade</surname>
              <given-names>S.R.</given-names>
            </name>
          </person-group>
          <article-title>Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer</article-title>
          <source>Biol. Chem.</source>
          <volume>391</volume>
          <year>2010</year>
          <fpage>333</fpage>
          <lpage>343</lpage>
          <pub-id pub-id-type="pmid">20180648</pub-id>
        </element-citation>
      </ref>
      <ref id="bib289">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swedberg</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Nigon</surname>
              <given-names>L.V.</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>de Veer</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Walpole</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Stephens</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>T.P.</given-names>
            </name>
            <name>
              <surname>Takayama</surname>
              <given-names>T.K.</given-names>
            </name>
            <name>
              <surname>Hooper</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Buckle</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4</article-title>
          <source>Chem. Biol.</source>
          <volume>16</volume>
          <year>2009</year>
          <fpage>633</fpage>
          <lpage>643</lpage>
          <pub-id pub-id-type="pmid">19549601</pub-id>
        </element-citation>
      </ref>
      <ref id="bib290">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vasileiou</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Barlos</surname>
              <given-names>K.K.</given-names>
            </name>
            <name>
              <surname>Gatos</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Adermann</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Deraison</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Barlos</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis of the proteinase inhibitor LEKTI domain 6 by the fragment condensation method and regioselective disulfide bond formation</article-title>
          <source>Biopolymers</source>
          <volume>94</volume>
          <year>2010</year>
          <fpage>339</fpage>
          <lpage>349</lpage>
          <pub-id pub-id-type="pmid">20069636</pub-id>
        </element-citation>
      </ref>
      <ref id="bib291">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cloutier</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Kundig</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Felber</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Fattah</surname>
              <given-names>O.M.</given-names>
            </name>
            <name>
              <surname>Chagas</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Gygi</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Jichlinski</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Leisinger</surname>
              <given-names>H.-J.</given-names>
            </name>
            <name>
              <surname>Deperthes</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>271</volume>
          <year>2004</year>
          <fpage>607</fpage>
          <lpage>613</lpage>
          <pub-id pub-id-type="pmid">14728688</pub-id>
        </element-citation>
      </ref>
      <ref id="bib292">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Felber</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>K&#xFC;ndig</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Borgo&#xF1;o</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Chagas</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Tasinato</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Jichlinski</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gygi</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Leisinger</surname>
              <given-names>H.-J.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Deperthes</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Cloutier</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14</article-title>
          <source>FEBS J.</source>
          <volume>273</volume>
          <year>2006</year>
          <fpage>2505</fpage>
          <lpage>2514</lpage>
          <pub-id pub-id-type="pmid">16704423</pub-id>
        </element-citation>
      </ref>
      <ref id="bib293">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farady</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Egea</surname>
              <given-names>P.F.</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>E.L.</given-names>
            </name>
            <name>
              <surname>Darragh</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Craik</surname>
              <given-names>C.S.</given-names>
            </name>
          </person-group>
          <article-title>Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition</article-title>
          <source>J. Mol. Biol.</source>
          <volume>380</volume>
          <year>2008</year>
          <fpage>351</fpage>
          <lpage>360</lpage>
          <pub-id pub-id-type="pmid">18514224</pub-id>
        </element-citation>
      </ref>
      <ref id="bib294">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sexton</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Martik</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kuzmic</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kuang</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Nixon</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Zuraw</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Forteza</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>W.M.</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>C.R.</given-names>
            </name>
          </person-group>
          <article-title>Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases</article-title>
          <source>Biochem. J.</source>
          <volume>422</volume>
          <year>2009</year>
          <fpage>383</fpage>
          <lpage>392</lpage>
          <pub-id pub-id-type="pmid">19527222</pub-id>
        </element-citation>
      </ref>
      <ref id="bib295">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bax</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Blundell</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Murray-Rust</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>N.Q.</given-names>
            </name>
          </person-group>
          <article-title>Structure of mouse 7S NGF: a complex of nerve growth factor with four binding proteins</article-title>
          <source>Structure</source>
          <volume>5</volume>
          <year>1997</year>
          <fpage>1275</fpage>
          <lpage>1285</lpage>
          <pub-id pub-id-type="pmid">9351801</pub-id>
        </element-citation>
      </ref>
      <ref id="bib296">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shooter</surname>
              <given-names>E.M.</given-names>
            </name>
          </person-group>
          <article-title>Early days of the nerve growth factor proteins</article-title>
          <source>Annu. Rev. Neurosci.</source>
          <volume>24</volume>
          <year>2003</year>
          <fpage>601</fpage>
          <lpage>629</lpage>
          <pub-id pub-id-type="pmid">11283322</pub-id>
        </element-citation>
      </ref>
      <ref id="bib297">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pattison</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Dunn</surname>
              <given-names>M.F.</given-names>
            </name>
          </person-group>
          <article-title>On the relationship of zinc ion to the structure and function of the 7S nerve growth factor protein</article-title>
          <source>Biochemistry</source>
          <volume>14</volume>
          <year>1975</year>
          <fpage>2733</fpage>
          <lpage>2739</lpage>
          <pub-id pub-id-type="pmid">1148178</pub-id>
        </element-citation>
      </ref>
      <ref id="bib298">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dong</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Bui</surname>
              <given-names>L.T.</given-names>
            </name>
            <name>
              <surname>Odorico</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>O.L.</given-names>
            </name>
            <name>
              <surname>Myers</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Samaratunga</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Gardiner</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms</article-title>
          <source>Endocr. Relat. Cancer</source>
          <volume>12</volume>
          <year>2005</year>
          <fpage>875</fpage>
          <lpage>889</lpage>
          <pub-id pub-id-type="pmid">16322328</pub-id>
        </element-citation>
      </ref>
      <ref id="bib299">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xi</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Klokk</surname>
              <given-names>T.I.</given-names>
            </name>
            <name>
              <surname>Korkmaz</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kurys</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Elbi</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Risberg</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Danielsen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Loda</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Saatcioglu</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer</article-title>
          <source>Cancer Res.</source>
          <volume>64</volume>
          <year>2004</year>
          <fpage>2365</fpage>
          <lpage>2370</lpage>
          <pub-id pub-id-type="pmid">15059887</pub-id>
        </element-citation>
      </ref>
      <ref id="bib300">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Clements</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Hooper</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Odorico</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>The tissue kallikrein gene cluster</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Barrett</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Rawlings</surname>
              <given-names>N.D.</given-names>
            </name>
            <name>
              <surname>Woessner</surname>
              <given-names>J.F.</given-names>
            </name>
          </person-group>
          <source>Handbook of Proteolytic Enzymes</source>
          <year>2004</year>
          <publisher-name>Elsevier Academic Press</publisher-name>
          <publisher-loc>London</publisher-loc>
          <fpage>1569</fpage>
          <lpage>1577</lpage>
        </element-citation>
      </ref>
      <ref id="bib301">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Schwager</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. The refined crystal structures of the bovine trypsinogen-pancreatic trypsin inhibitor complex and of its ternary complex with Ile-Val at 1.9 A resolution</article-title>
          <source>J. Mol. Biol.</source>
          <volume>118</volume>
          <year>1978</year>
          <fpage>99</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="pmid">625059</pub-id>
        </element-citation>
      </ref>
      <ref id="bib302">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Pei</surname>
              <given-names>X.Y.</given-names>
            </name>
            <name>
              <surname>Dafforn</surname>
              <given-names>T.R.</given-names>
            </name>
            <name>
              <surname>Lomas</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>Topography of a 2.0 &#xC5; structure of alpha-1-antitrypsin reveals targets for rational drug design to prevent conformational disease</article-title>
          <source>Protein Sci.</source>
          <volume>9</volume>
          <year>2000</year>
          <fpage>1274</fpage>
          <lpage>1281</lpage>
          <pub-id pub-id-type="pmid">10933492</pub-id>
        </element-citation>
      </ref>
      <ref id="bib303">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ota</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Stroupe</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ferreira-da-Silva</surname>
              <given-names>J.M.S.</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Mares-Guia</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Brunger</surname>
              <given-names>A.T.</given-names>
            </name>
          </person-group>
          <article-title>Non-Boltzmann thermodynamic integration (NBTI) for macromolecular systems: relative free energy of binding of trypsin to benzamidine and benzylamine</article-title>
          <source>Proteins</source>
          <volume>37</volume>
          <year>1999</year>
          <fpage>641</fpage>
          <lpage>653</lpage>
          <pub-id pub-id-type="pmid">10651279</pub-id>
        </element-citation>
      </ref>
      <ref id="bib304">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Helland</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Otlewski</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sundheim</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Dadlez</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Smal&#xE5;s</surname>
              <given-names>A.O.</given-names>
            </name>
          </person-group>
          <article-title>The crystal structures of the complexes between bovine b-trypsin and ten P1 variants of BPTI.J</article-title>
          <source>Mol. Biol.</source>
          <volume>287</volume>
          <year>1999</year>
          <fpage>923</fpage>
          <lpage>942</lpage>
        </element-citation>
      </ref>
      <ref id="bib305">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sichler</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hopfner</surname>
              <given-names>K.-P.</given-names>
            </name>
            <name>
              <surname>Kopetzki</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Brandstetter</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The influence of residue 190 in the S1 site of trypsin-like serine proteases on substrate selectivity is universally conserved</article-title>
          <source>FEBS Lett.</source>
          <volume>530</volume>
          <year>2002</year>
          <fpage>220</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="pmid">12387896</pub-id>
        </element-citation>
      </ref>
      <ref id="bib306">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schechter</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>On the size of the active site in proteases. I. Papain</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>27</volume>
          <year>1967</year>
          <fpage>157</fpage>
          <lpage>162</lpage>
          <pub-id pub-id-type="pmid">6035483</pub-id>
        </element-citation>
      </ref>
      <ref id="bib307">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>L.Y.</given-names>
            </name>
            <name>
              <surname>Shan</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Soosaipillai</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma</article-title>
          <source>Clin. Cancer Res.</source>
          <volume>12</volume>
          <year>2006</year>
          <fpage>742</fpage>
          <lpage>750</lpage>
          <pub-id pub-id-type="pmid">16467084</pub-id>
        </element-citation>
      </ref>
      <ref id="bib308">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ecke</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Geiger</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Resch</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Jerabek</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Sting</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Maier</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Binder</surname>
              <given-names>B.R.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of tissue kallikrein by protein C inhibitor. Evidence for identity of protein C inhibitor with the kallikrein binding protein</article-title>
          <source>J. Biol. Chem.</source>
          <volume>267</volume>
          <year>1992</year>
          <fpage>7048</fpage>
          <lpage>7052</lpage>
          <pub-id pub-id-type="pmid">1313031</pub-id>
        </element-citation>
      </ref>
      <ref id="bib309">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frenette</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Deperthes</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tremblay</surname>
              <given-names>R.R.</given-names>
            </name>
            <name>
              <surname>Lazure</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Dub&#xE9;</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>Purification of enzymatically active kallikrein hK2 from human seminal plasma</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1334</volume>
          <year>1997</year>
          <fpage>109</fpage>
          <lpage>115</lpage>
          <pub-id pub-id-type="pmid">9042371</pub-id>
        </element-citation>
      </ref>
      <ref id="bib310">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>B.A.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Springman</surname>
              <given-names>E.B.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution</article-title>
          <source>Protein Sci.</source>
          <volume>7</volume>
          <year>1998</year>
          <fpage>875</fpage>
          <lpage>885</lpage>
          <pub-id pub-id-type="pmid">9568894</pub-id>
        </element-citation>
      </ref>
      <ref id="bib311">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laxmikanthan</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>S.I.</given-names>
            </name>
            <name>
              <surname>Bernett</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Scarisbrick</surname>
              <given-names>I.A.</given-names>
            </name>
            <name>
              <surname>Juliano</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Blaber</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding</article-title>
          <source>Proteins</source>
          <volume>58</volume>
          <year>2005</year>
          <fpage>802</fpage>
          <lpage>814</lpage>
          <pub-id pub-id-type="pmid">15651049</pub-id>
        </element-citation>
      </ref>
      <ref id="bib312">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Refined 2.5 A X-ray crystal structure of the complex formed by porcine kallikrein A and the bovine pancreatic trypsin inhibitor. Crystallization, Patterson search, structure determination, refinement, structure and comparison with its components and with the bovine trypsin-pancreatic trypsin inhibitor complex</article-title>
          <source>J. Mol. Biol.</source>
          <volume>164</volume>
          <year>1983</year>
          <fpage>283</fpage>
          <lpage>311</lpage>
          <pub-id pub-id-type="pmid">6188842</pub-id>
        </element-citation>
      </ref>
      <ref id="bib313">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gomis-Ruth</surname>
              <given-names>F.X.</given-names>
            </name>
            <name>
              <surname>Bayes</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sotiropoulou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pampalakis</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Tsetsenis</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Villegas</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Aviles</surname>
              <given-names>F.X.</given-names>
            </name>
            <name>
              <surname>Coll</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family</article-title>
          <source>J. Biol. Chem.</source>
          <volume>277</volume>
          <year>2002</year>
          <fpage>27273</fpage>
          <lpage>27281</lpage>
          <pub-id pub-id-type="pmid">12016211</pub-id>
        </element-citation>
      </ref>
      <ref id="bib314">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fern&#xE1;ndez</surname>
              <given-names>I.S.</given-names>
            </name>
            <name>
              <surname>St&#xE4;ndker</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>M&#xE4;gert</surname>
              <given-names>H.-J.</given-names>
            </name>
            <name>
              <surname>Forssmann</surname>
              <given-names>W.-G.</given-names>
            </name>
            <name>
              <surname>Gim&#xE9;nez-Gallego</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of human epidermal kallikrein 7 (hK7) synthesized directly in its native state in E. coli: insights into the atomic basis of its inhibition by LEKTI domain 6 (LD6)</article-title>
          <source>J. Mol. Biol.</source>
          <volume>377</volume>
          <year>2008</year>
          <fpage>1488</fpage>
          <lpage>1497</lpage>
          <pub-id pub-id-type="pmid">18329042</pub-id>
        </element-citation>
      </ref>
      <ref id="bib315">
        <mixed-citation publication-type="other">M. Debela, C.S. Craik, E. Schneider, W. Bode, V. Magdolen and P. Goettig, Crystal structure, substrate specificity and zinc/calcium binding of human kallikrein-related peptidase 8 (KLK8). (unpublished) (2010).</mixed-citation>
      </ref>
      <ref id="bib316">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kishi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shiosaka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hakoshima</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of neuropsin, a hippocampal protease involved in kindling epileptogenesis</article-title>
          <source>J. Biol. Chem.</source>
          <volume>274</volume>
          <year>1999</year>
          <fpage>4220</fpage>
          <lpage>4224</lpage>
          <pub-id pub-id-type="pmid">9933620</pub-id>
        </element-citation>
      </ref>
      <ref id="bib317">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Timm</surname>
              <given-names>D.E.</given-names>
            </name>
          </person-group>
          <article-title>The crystal structure of the mouse glandular kallikrein-13 (prorenin converting enzyme)</article-title>
          <source>Protein Sci.</source>
          <volume>6</volume>
          <year>1997</year>
          <fpage>1418</fpage>
          <lpage>1425</lpage>
          <pub-id pub-id-type="pmid">9232643</pub-id>
        </element-citation>
      </ref>
      <ref id="bib318">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Pitt</surname>
              <given-names>G.R.</given-names>
            </name>
            <name>
              <surname>Ashworth</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>De Clerck</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Verheyen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Szelke</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Synthetic inhibitors of human tissue kallikrein</article-title>
          <source>Immunopharmacology</source>
          <volume>32</volume>
          <year>1996</year>
          <fpage>117</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="pmid">8796285</pub-id>
        </element-citation>
      </ref>
      <ref id="bib319">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawrence</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Veveris-Lowe</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Whitbread</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Nicol</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases</article-title>
          <source>Cells Tissues Organs</source>
          <volume>185</volume>
          <year>2007</year>
          <fpage>111</fpage>
          <lpage>115</lpage>
          <pub-id pub-id-type="pmid">17587816</pub-id>
        </element-citation>
      </ref>
      <ref id="bib320">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yousef</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Kishi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Diamandis</surname>
              <given-names>E.P.</given-names>
            </name>
          </person-group>
          <article-title>Role of kallikrein enzymes in the central nervous system</article-title>
          <source>Clin. Chim. Acta</source>
          <volume>329</volume>
          <year>2003</year>
          <fpage>1</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">12589961</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgments</title>
      <p content-type="ackknowledgement">We would like to thank Wolfram Bode and Mekdes Debela for valuable discussions and continuous support of our study, and Sabah Mirza for critical reading of the manuscript, as well as the Austrian Science Fund FWF (project P20582) for financial support.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Fig.&#xA0;1</label>
      <caption>
        <p>Primary and tertiary structure of KLKs A: Sequence alignment of kallikrein 1 (KLK1) and the human kallikrein-related peptidases KLKs 2&#x2013;15 with bovine chymotrypsin (bCTRA). Secondary structure is shown for KLK3/KLK5 for &#x3B2;-strands (arrows) and &#x3B1;-helices (cylinders). Propeptides are included and the numbering is derived from chymotrypsinogen <xref rid="bib247" ref-type="bibr">[247]</xref>. The &#x201C;classical&#x201D; KLKs 1, 2, and 3 share 61&#x2013;79% identical residues, while the conservation of the &#x201C;new&#x201D; KLKs 4&#x2013;15 ranges from 38% to 57% <xref rid="bib130 bib300" ref-type="bibr">[130,300]</xref>. Highly conserved residues are displayed with a grey background, while residue 16 that is located in the P1, position when the propeptide is cleaved off is shown with blue background. B: Overlay of KLK3 (beige) and KLK5 (green) as ribbon representation in stereo. The catalytic triad residues (His57, Asp102, Ser195), and Ser189 of KLK3 and Asp189 of KLK5, which determine chymotryptic or tryptic specificity, respectively, are depicted as stick models, as well as the N-terminal residue 16 with Asp194 that form a salt bridge, thereby stabilizing the active site <xref rid="bib301" ref-type="bibr">[301]</xref>. The long 99 loop of the classical KLK3 is depicted in red.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Fig.&#xA0;2</label>
      <caption>
        <p>Inhibitory metal binding sites in KLK crystal structures as ribbon representation with relevant residues as stick models. Dotted lines indicate hydrogen and coordination bonds, relevant residues are labelled with numbers. A: The Zn<sup>2+</sup> ion (grey sphere) bound to horse KLK3 involves ligands Asp91, His101, and His234. The equivalent residues in human KLK3 are His91, His101, and His233. Probably, the Zn<sup>2+</sup> binding to His101 causes a backbone shift of Asp102, concomitantly distorting the catalytic triad (Ser195, His57, and Asp102) and resulting in a reduced proteolytic activity. B: In KLK4, the inhibitory Zn<sup>2+</sup> site is located far away from the active site, which was confirmed by the single mutations His25Ala and Glu77Ala. Zn<sup>2+</sup> binding to KLK4 effects a disruption of the salt bridge Ile16-Asp194 via His25, thereby destabilizing the active site conformation and abolishing its functionality. C: Zn<sup>2+</sup> binding to the active site of KLK5 and rKLK2 in standard orientation. On the left, the free active site of KLK5 is shown with both His96 and His99 rotated away from the S2 pocket. The catalytic triad, consisting of Ser195, His57, and Asp102 is connected by hydrogen bonds. In the middle, a Zn<sup>2+</sup> ion (grey sphere) has bound to the ligands His96 and His99 with coordination bonds. On the right, the catalytic His57 of rKLK2 has relocated from the catalytic triad to become the third Zn<sup>2+</sup> ligand, together with His99 and His97. Most likely, a similar conformation in KLK5 represents the reversible Zn<sup>2+</sup> inhibited state. Since the S2 subsite is still accessible for most P2 side chains, the inhibited state allows binding, but not turnover of substrates, as long as the catalytic triad is disrupted. This mechanistic model is in agreement with the observed non-competitive Zn<sup>2+</sup> inhibition of KLK5. D: Cu<sup>2+</sup> binding to the active sites of KLK7 and the rat trypsin mutant Arg96His in standard orientation. On the left, the free active site of KLK7 is depicted with the catalytic triad connected by hydrogen bonds (dotted lines). In the middle, a Cu<sup>2+</sup> ion (orange sphere) has bound to the ligands His99 and Thr96-C=O via a water molecule (red sphere) with&#xA0;coordination bonds (dotted lines). On the right, the catalytic His57 of rat trypsin mutant Arg96His has rotated out from the catalytic triad to become the second Cu<sup>2+</sup> ligand,&#xA0;together with the mutated His96. A similar conformation in KLK7 with His99 instead of His96 may represent the reversible Zn<sup>2+</sup>/Cu<sup>2+</sup> inhibited state. As in KLK5 the S2 subsite is still accessible for P2 side chains, allowing binding, but not cleavage of substrates, as long as the catalytic triad is inactive, which agrees with the non-competitive Zn<sup>2+</sup>&#xA0;inhibition of KLK7.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="fig3">
      <label>Fig.&#xA0;3</label>
      <caption>
        <p>Reaction of a serine protease shown with the molecular surface with a serpin as ribbon representation. Left: Protease and unreacted &#x201C;virgin&#x201D; serpin with central four-stranded &#x3B2;-sheet (PDB codes of trypsin from 1OPH and &#x3B1;<sub>1</sub>-AT from 1QLP) <xref rid="bib166 bib302" ref-type="bibr">[166,302]</xref>. The reactive loop is depicted as black spheres, the P1 and P1&#x2032; side chain are labelled. Middle: Michaelis&#x2013;Menten complex of the protease with serpin corresponding to substrate-like canonical protease inhibitor interaction (PDB code 1OPH). Right: Covalent serpin&#x2013;protease complex that exhibits now a cleaved reactive center loop with an N-terminal P1&#x2032; residue and an inserted fifth strand (black) in the central &#x3B2;-sheet that is covalently linked with the P1 residues to the catalytic Ser195. The activation domain of the protease (black spheres) including a large region of the active site is disordered as seen in several protease zymogen structures (trypsin and &#x3B1;<sub>1</sub>-AT, PDB code 1EZX) <xref rid="bib165" ref-type="bibr">[165]</xref>.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="fig4">
      <label>Fig.&#xA0;4</label>
      <caption>
        <p>Serpin reactive center loop (RCL) inserted into the active site of a serine protease represented as molecular surface (trypsin and &#x3B1;<sub>1</sub>-AT, PDB code 1OPH). Canonical (substrate-like) binding before cleavage of the scissile bond between P1&#x2013;P1&#x2032; is mediated by residues P4 to P1&#x2032;, shown as black stick models. Various serpins exhibit canonical binding extended to P3&#x2032; and may overall interact with residues from P6 to P5&#x2032; <xref rid="bib184" ref-type="bibr">[184]</xref>.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="fig5">
      <label>Fig.&#xA0;5</label>
      <caption>
        <p>Kazal-type inhibitor with reactive center loop (RCL) bound to the active site of a serine protease represented as molecular surface (trypsinogen with pancreatic secretory inhibitor, PDB code 1TGS). The 15 LEKTI-1 domains are homologous to the classical Kazal-type inhibitors, but 12 domains may be classified as subtypes. Canonical binding is achieved by residues P4 to P2&#x2032;, shown as grey stick models with spheres. The&#xA0;bond between P1&#x2013;P1&#x2032; is scissile, but cleavage is extremely slow, since the hydrolysis constant is close to unity and the cleaved bond may reconstituted again <xref rid="bib89" ref-type="bibr">[89]</xref>. Specificity of LEKTI-1 domains for chymotryptic or tryptic KLK targets depends on the P1 residue, which is in most cases an Arg, but a Gln in the first domain.</p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
    <fig id="fig6">
      <label>Fig.&#xA0;6</label>
      <caption>
        <p>Potential autoinhibitory homocomplex of KLK4 with monomers depicted as alternating purple and orange surface representations. In solution and in crystals KLK4 forms oligomers, consisting of cyclic tetramers that assemble to octamers, or even higher oligomers, such as dimers and tetramers of octamers. Due to intermolecular contacts, the active site clefts of KLK4 become very narrow at the catalytic centers (labelled AS) with Ser195 shown as green balls. In particular the S1 and S2 subsites are hardly accessible for small chromogenic and fluorogenic substrates, not to mention large protein substrates <xref rid="bib137" ref-type="bibr">[137]</xref>.</p>
      </caption>
      <graphic xlink:href="gr6"/>
    </fig>
    <fig id="fig7">
      <label>Fig.&#xA0;7</label>
      <caption>
        <p>Inhibitory small molecules bound to KLK active sites with important residues depicted as stick models. Hydrogen bonds with a distance shorter than 3.5&#xA0;&#xC5; are shown as grey dotted lines and relevant residues are labelled with numbers. A: Porcine pKLK1 with benzamidine (BEN) occupying the S1 site. The BEN amidino group binds Asp189 only with one amino group, but involves the Ser226 O&#x3B3; and the backbone carbonyl O of His217. B: KLK6 binds the two amidino N atoms of benzamidine in the S1-pocket with both O&#x3B4; atoms and one with the O&#x3B3; of Ser190, as well as with the backbone carbonyl O of Asn217, similar to trypsin <xref rid="bib303" ref-type="bibr">[303]</xref>. C: The binding mode of para-aminobenzamidine (PABA) to KLK4 is similar to KLK6, but the Ser190 does not participate in stabilizing the amidino groups of the inhibitor, which is additionally bound at the amino group by Ser195. In addition to Asp189, the Ser190 O&#x3B3; is enhancing the specificity of the S1 subsite for P1-Lys residues <xref rid="bib304 bib305" ref-type="bibr">[304,305]</xref>. D: Leupeptin binds with the P1-Arg C covalently to the Ser195 O&#x3B3; of KLK5, while the former carbonyl O (now rather a &#x2013;O<sup>&#x2212;</sup>) is accommodated in the oxyanion hole, formed by the backbone NHs of Ser195 and Gly193. The P1 Arg side chain is stabilized by Asp189 and Ser190. For clarity, additional hydrogen bonds of the P2-Leu carbonyl O and P1 Arg N&#x25B; via a water to Gln192 have been omitted. The relatively small hydrophobic S2 subsite is filled with the P2-Leu side chain. While the P3-Leu side chain extends to the solvent, its carbonyl O and amide NH tightly bound to the corresponding atoms of Gly216. The acetyl group of leupeptin partially occupies the hydrophobic S4 pocket. E: Ala-Ala-Phe-chloromethyl ketone (AAF-CMK) is covalently linked with the P1 methylene group to His57 N&#x25B; and via the C atom to the Ser195 O&#x3B3; of KLK7, whereby the former carbonyl O occupies the oxyanion hole. The P1-Phe side chain is located in the large S1 pocket, but does not interact with the Asn189 at the bottom of the pocket, which is more suited to bind residues with polar tips, such as Tyr or Gln, while Ala190 contributes to the hydrophobic character of this subsite <xref rid="bib99" ref-type="bibr">[99]</xref>. Also, the S2 pocket is rather mixed hydrophobic polar and not completely filled by the P2 Ala, whereas the P3 Ala extends to the bulk solvent and forms hydrogen bonds from its backbone CO and NH to the backbone of Gly216. F: Covalent bonds of Suc-AAPF-CMK to His57 and Ser195 of KLK7, as well as the orientation of the oxyanion and the P1-Phe side chain are the same as for AAF-CMK (Fig.&#xA0;7E). The P2 Pro fits equally well as an Ala to the S2 subsite, bordered by His57 and His99 (Fig.&#xA0;7E). Again, the P3 Ala makes only backbone interactions with Gly216, but contrary to the AAF-CMK, the P4 Ala occupies to some extent the hydrophobic S4 pocket, with the Trp215 side chain as base and His99 and Leu175 as borders, while the succinyl group in P5 position has no interaction partner on the KLK7 surface.</p>
      </caption>
      <graphic xlink:href="gr7"/>
    </fig>
    <fig id="fig8">
      <label>Fig.&#xA0;8</label>
      <caption>
        <p>Two complexes of porcine and human KLK1 with the exogenous inhibitors BPTI (Kunitz-type) and hirustasin (antistasin-type), respectively. Proteins are shown as ribbon representation, relevant residues as sticks labelled with numbers, and hydrogen bonds as grey dotted lines. A: pKLK1-BPTI complex displayed with the protease in purple and the inhibitor in white. B: Closer view of the active pKLK1 site, where only the interacting reactive loop residues of BPTI are shown. The P1 Lys is bound with its carbonyl O to the oxyanion hole, while its N&#x3B6;-atom is hydrogen bonded to the Thr190 O&#x3B3; and carbonyl O, the Ser226 O&#x3B3; and virtually not to the O&#x3B4;1 of Asp189. The P2 Cys14I-Cys38I (I for inhibitor chain) disulfide bridge occupies the S2 pocket, while the P3 Pro only forms one hydrogen bond with its carbonyl O to the NH of Gly216. In contrast to many other canonical binding inhibitors, no interaction of the P4 residue Gly is observed. On the prime side, P1&#x2032; Ala fits to the S1, pocket, but the P2&#x2032; Arg exhibits a non-canonical binding around the S2, and S3, subsites. C: KLK1-hirustasin complex depicted with the protease in magenta and the inhibitor in white. D: Closer view of the active KLK1 site, where the inhibitor residues P4 to P3&#x2032; are displayed, although canonical binding ends with P1&#x2032;. The P1 Arg of hirustasin is bound the oxyanion hole and its side chain fills the S1 pocket largely, whereby the N&#x3B7;1 atom is hydrogen bonded to the Thr190 O&#x3B3; and carbonyl O, the N&#x3B7;1 binds the carbonyl O of His217, whereas the interaction distances with the O&#x3B4; atoms of Asp189 are relatively long. Similar to BPTI, the P2 Cys29-Cys48 disulfide bridge is located in the S2 pocket and rigidifies the reactive loop region together with the P3&#x2032; Cys33I-Cys50I disulfide, which adopts as the P2&#x2032; Arg a not-substrate-like position, in contrast to the P1&#x2032; Ile. Typical for canonical P3 and P4 residues, the side chain of His28I extends to the solvent and Val27I occupies the S4 subsite.</p>
      </caption>
      <graphic xlink:href="gr8"/>
    </fig>
    <table-wrap id="tbl1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Statistical specificity patterns of human KLK peptidases cleavage sites, according to MEROPS specificity matrices for peptide residue positions P4 to P4&#x2032; that bind to protease subsites S4 to S4&#x2032; with the scissile bond between P1&#x2013;P1&#x2032; (Schechter&#x2013;Berger nomenclature <xref rid="bib306" ref-type="bibr">[306]</xref>). In cases without established matrix, the information on natural and synthetic substrates was used to derive a score from the incidence of a residue, whereby the P1 value was always set to 100%. The font size corresponds to the frequency of a residue in published KLK substrates (an incidence cutoff was individually chosen, in order to limit the number of residues at a given position). Hydrophobic residues are depicted in black, polar ones in green, acidic ones in red, and basic ones in blue. For KLK9 only data of one substrate of the rat ortholog (rKLK9) were available <xref rid="bib112" ref-type="bibr">[112]</xref>, while for KLKs 10, 11, and 13, results from substrate profiling studies <xref rid="bib99 bib100 bib307" ref-type="bibr">[99,100,307]</xref> have been treated as one substrate per study, employing only the top ranked residues in positions P4 to P1. For KLK12 published substrates from two studies were analyzed <xref rid="bib17 bib96" ref-type="bibr">[17,96]</xref>. The primary tryptic specificity for Arg and Lys in P1 of many KLKs is conferred by an Asp189 at the bottom of the S1 pocket, which is replaced by a Glu189 in KLK15. The three chymotryptic KLKs with a preference for P1-Tyr, -Phe, or -Gln possess a Ser189 (KLK3), an Asn189 (KLK7), and a Gly189 (KLK9), but rat KLK that shares 40% identical residues with KLK9 (61% homology) exhibits an Asp189, although it has a tendency to cleave chymotryptic substrates. Apparently, KLK1 has a mixed tryptic/chymotryptic specificity, as was also observed for KLKs 10 and 11 <xref rid="bib99" ref-type="bibr">[99]</xref>.</p>
      </caption>
      <graphic xlink:href="fx1"/>
    </table-wrap>
    <table-wrap id="tbl2" position="float" orientation="landscape">
      <?landscape?>
      <?legal?>
      <label>Table 2</label>
      <caption>
        <p>KLK affinity matrix for the most relevant endogenous inhibitors. Data for KLKs 9, 10, and 15 were not available. The rating depended on given inhibition constants K<sub>i</sub> or IC<sub>50</sub> values that are roughly the doubled K<sub>i</sub> (&#x25CB; no inhibition, &#x25CF; &#x3BC;M, &#x25CF;&#x25CF; nM, &#x25CF;&#x25CF;&#x25CF; pM range), or association constants that were also represented (<italic>K</italic><sub>ass</sub>&#xA0;&#x2265;&#xA0;10<sup>5</sup>&#xA0;M<sup>&#x2212;1</sup>&#xA0;s<sup>&#x2212;1</sup> &#x25CF;&#x25CF;&#x25CF;, &#x2264; 10<sup>3</sup>&#xA0;M<sup>&#x2212;1</sup>&#xA0;s<sup>&#x2212;1</sup> &#x25CF;&#x25CF;), otherwise it was chosen according to the description of the respective publication (&#x201C;strong inhibition&#x201D; &#x25CF;&#x25CF;&#x25CF;, etc., &#x25CF; slow inhibition). * IC<sub>50</sub> ** the protease remains active against small molecule substrates, while protein substrates cannot be cleaved anymore.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th>KLK</th>
            <th>Zn<sup>2+</sup></th>
            <th>&#x3B1;<sub>1</sub>-AT</th>
            <th>&#x3B1;<sub>1</sub>-ACT</th>
            <th>ATIII</th>
            <th>&#x3B1;<sub>2</sub>-AP</th>
            <th>PCI</th>
            <th>Kallistatin</th>
            <th>Other serpins</th>
            <th>LEKTI-1</th>
            <th>a2M**</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>KLK1</td>
            <td>&#x25CB;</td>
            <td>&#x25CF;<xref rid="bib171" ref-type="bibr">[171]</xref></td>
            <td>&#x25CB;<xref rid="bib196" ref-type="bibr">[196]</xref></td>
            <td>&#x25CB;<xref rid="bib196" ref-type="bibr">[196]</xref></td>
            <td/>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib308" ref-type="bibr">[308]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib196" ref-type="bibr">[196]</xref></td>
            <td/>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib229" ref-type="bibr">[229]</xref></td>
          </tr>
          <tr>
            <td>KLK2</td>
            <td>&#x25CF;(3&#xA0;&#x3BC;M)*<xref rid="bib129" ref-type="bibr">[129]</xref></td>
            <td>&#x25CB;<xref rid="bib172 bib309" ref-type="bibr">[172, 309]</xref></td>
            <td>&#x25CF;<xref rid="bib205 bib172" ref-type="bibr">[205], [172]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;(+heparin)<xref rid="bib187 bib309" ref-type="bibr">[187, 309]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib172 bib309" ref-type="bibr">[172, 309]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;&lt; 25 pM <xref rid="bib129" ref-type="bibr">[129]</xref></td>
            <td/>
            <td>&#x25CF;&#x25CF;&#x25CF;PI-6 <xref rid="bib204" ref-type="bibr">[204]</xref>&#x25CF;&#x25CF;&#x25CF;PAI-1 <xref rid="bib205" ref-type="bibr">[205]</xref></td>
            <td/>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib230" ref-type="bibr">[230]</xref><xref rid="bib231" ref-type="bibr">[231]</xref></td>
          </tr>
          <tr>
            <td>KLK3</td>
            <td>&#x25CF;(24&#xA0;&#x3BC;M)<xref rid="bib134" ref-type="bibr">[134]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib175 bib176" ref-type="bibr">[175, 176]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib232 bib176" ref-type="bibr">[232], [176]</xref></td>
            <td>&#x25CF;<xref rid="bib187" ref-type="bibr">[187]</xref></td>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib192" ref-type="bibr">[192]</xref></td>
            <td/>
            <td>&#x25CF;&#x25CF;MNEI <xref rid="bib203" ref-type="bibr">[203]</xref></td>
            <td/>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib232" ref-type="bibr">[232]</xref></td>
          </tr>
          <tr>
            <td>KLK4</td>
            <td>&#x25CF;(15&#xA0;&#x3BC;M)*<xref rid="bib137" ref-type="bibr">[137]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib178" ref-type="bibr">[178]</xref></td>
            <td>&#x25CB;<xref rid="bib178" ref-type="bibr">[178]</xref></td>
            <td>&#x25CF;<xref rid="bib178" ref-type="bibr">[178]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib178" ref-type="bibr">[178]</xref></td>
            <td/>
            <td/>
            <td>&#x25CF;PAI-1<xref rid="bib155" ref-type="bibr">[155]</xref></td>
            <td/>
            <td>&#x25CF;<xref rid="bib178" ref-type="bibr">[178]</xref></td>
          </tr>
          <tr>
            <td>KLK5</td>
            <td>&#x25CF;(4&#xA0;&#x3BC;M)<xref rid="bib15 bib144" ref-type="bibr">[15, 144]</xref></td>
            <td>&#x25CB;/&#x25CF;<xref rid="bib173 bib170" ref-type="bibr">[173], [170]</xref></td>
            <td>&#x25CB;<xref rid="bib173" ref-type="bibr">[173]</xref></td>
            <td>&#x25CB;<xref rid="bib173 bib170" ref-type="bibr">[173], [170]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib173 bib170" ref-type="bibr">[173], [170]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CB;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;C1I<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib218 bib219" ref-type="bibr">[218, 219]</xref></td>
            <td>&#x25CF;<xref rid="bib173" ref-type="bibr">[173]</xref></td>
          </tr>
          <tr>
            <td>KLK6</td>
            <td>&#x25CB;</td>
            <td>&#x25CF;<xref rid="bib174" ref-type="bibr">[174]</xref></td>
            <td>&#x25CF;<xref rid="bib182" ref-type="bibr">[182]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib174" ref-type="bibr">[174]</xref></td>
            <td>&#x25CF;<xref rid="bib174" ref-type="bibr">[174]</xref></td>
            <td/>
            <td/>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib63" ref-type="bibr">[63]</xref></td>
            <td>&#x25CB;<xref rid="bib174" ref-type="bibr">[174]</xref></td>
          </tr>
          <tr>
            <td>KLK7</td>
            <td>&#x25CF;(10&#xA0;&#x3BC;M)<xref rid="bib147" ref-type="bibr">[147]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CB;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib218 bib219" ref-type="bibr">[218, 219]</xref></td>
            <td/>
          </tr>
          <tr>
            <td>KLK8</td>
            <td>&#x25CF;(3.3&#xA0;&#x3BC;M)<xref rid="bib123" ref-type="bibr">[123]</xref></td>
            <td>&#x25CB;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CB;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CB;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;PI-6 <xref rid="bib206" ref-type="bibr">[206]</xref></td>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK11</td>
            <td/>
            <td>&#x25CB;<xref rid="bib307" ref-type="bibr">[307]</xref></td>
            <td>&#x25CB;<xref rid="bib307" ref-type="bibr">[307]</xref></td>
            <td>&#x25CB;<xref rid="bib307" ref-type="bibr">[307]</xref></td>
            <td>&#x25CB;<xref rid="bib307" ref-type="bibr">[307]</xref></td>
            <td>&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CB;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK12</td>
            <td>&#x25CF;(10&#xA0;&#x3BC;M)*<xref rid="bib17" ref-type="bibr">[17]</xref></td>
            <td>&#x25CF;/&#x25CF;&#x25CF;<xref rid="bib17 bib170" ref-type="bibr">[17], [170]</xref></td>
            <td>&#x25CB;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;<xref rid="bib17 bib170" ref-type="bibr">[17], [170]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib17" ref-type="bibr">[17]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib17" ref-type="bibr">[17]</xref></td>
            <td>&#x25CB;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;C1I<xref rid="bib17" ref-type="bibr">[17]</xref></td>
            <td/>
            <td>&#x25CB;<xref rid="bib17" ref-type="bibr">[17]</xref></td>
          </tr>
          <tr>
            <td>KLK13</td>
            <td/>
            <td>&#x25CB;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CB;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;PAI-1<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib63" ref-type="bibr">[63]</xref></td>
            <td>&#x25CF;<xref rid="bib14" ref-type="bibr">[14]</xref></td>
          </tr>
          <tr>
            <td>KLK14</td>
            <td>&#x25CF;(2&#xA0;&#x3BC;M)<xref rid="bib15 bib31" ref-type="bibr">[15, 31]</xref></td>
            <td>&#x25CF;&#x25CF;(162&#xA0;nM)<xref rid="bib63 bib170" ref-type="bibr">[63], [170]</xref></td>
            <td>&#x25CF;(5.6&#xA0;&#x3BC;m)<xref rid="bib63" ref-type="bibr">[63]</xref></td>
            <td>&#x25CF;&#x25CF;(198&#xA0;nM)<xref rid="bib63" ref-type="bibr">[63]</xref></td>
            <td>&#x25CF;&#x25CF; (130&#xA0;nM)<xref rid="bib63 bib170" ref-type="bibr">[63], [170]</xref></td>
            <td>&#x25CF;&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib170" ref-type="bibr">[170]</xref></td>
            <td>&#x25CF;PAI-1<xref rid="bib63" ref-type="bibr">[63]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib63" ref-type="bibr">[63]</xref></td>
            <td/>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="tbl3" position="float">
      <label>Table 3</label>
      <caption>
        <p>Exogenous and non-natural inhibitor affinity matrix. The rating (&#x25CB; no inhibition, etc.) is applied as for Table 2. &#x2217;TPCK related compounds (see Table 4).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th>KLK</th>
            <th>PMSF/AEBSF/DIPF</th>
            <th>BEN/p-ABA</th>
            <th>Leupeptin/antipain</th>
            <th>Chymostatin</th>
            <th>TLCK/PPACK</th>
            <th>TPCK</th>
            <th>SBTI/LBTI</th>
            <th>BPTI</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>KLK1</td>
            <td>&#x25CF;<xref rid="bib245" ref-type="bibr">[245]</xref></td>
            <td>&#x25CF;<xref rid="bib310" ref-type="bibr">[310]</xref></td>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib245" ref-type="bibr">[245]</xref></td>
            <td/>
            <td>&#x25CB;<xref rid="bib245" ref-type="bibr">[245]</xref></td>
            <td>&#x25CF;<xref rid="bib245" ref-type="bibr">[245]</xref></td>
          </tr>
          <tr>
            <td>KLK2</td>
            <td/>
            <td>&#x25CF;<xref rid="bib129" ref-type="bibr">[129]</xref></td>
            <td>&#x25CF;<xref rid="bib129" ref-type="bibr">[129]</xref></td>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib129" ref-type="bibr">[129]</xref></td>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib129" ref-type="bibr">[129]</xref></td>
          </tr>
          <tr>
            <td>KLK3</td>
            <td>&#x25CF;<xref rid="bib42 bib175" ref-type="bibr">[42, 175]</xref></td>
            <td>&#x25CB;<xref rid="bib42" ref-type="bibr">[42]</xref></td>
            <td>&#x25CB;<xref rid="bib42" ref-type="bibr">[42]</xref></td>
            <td>&#x25CF;<xref rid="bib249" ref-type="bibr">[249]</xref></td>
            <td>&#x25CB;<xref rid="bib42" ref-type="bibr">[42]</xref></td>
            <td>&#x25CB;<xref rid="bib42" ref-type="bibr">[42]</xref></td>
            <td>&#x25CB;<xref rid="bib42" ref-type="bibr">[42]</xref></td>
            <td>&#x25CB;<xref rid="bib42" ref-type="bibr">[42]</xref></td>
          </tr>
          <tr>
            <td>KLK4</td>
            <td/>
            <td>&#x25CF;<xref rid="bib48 bib137" ref-type="bibr">[48, 137]</xref></td>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib48" ref-type="bibr">[48]</xref></td>
            <td/>
            <td>&#x25CF;<xref rid="bib48" ref-type="bibr">[48]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib48" ref-type="bibr">[48]</xref></td>
          </tr>
          <tr>
            <td>KLK5</td>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib15 bib144" ref-type="bibr">[15, 144]</xref></td>
            <td>&#x25CB;<xref rid="bib15" ref-type="bibr">[15]</xref></td>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib15" ref-type="bibr">[15]</xref></td>
            <td>&#x25CF;<xref rid="bib15" ref-type="bibr">[15]</xref></td>
          </tr>
          <tr>
            <td>KLK6</td>
            <td/>
            <td>&#x25CF;<xref rid="bib174" ref-type="bibr">[174]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib174" ref-type="bibr">[174]</xref></td>
            <td/>
          </tr>
          <tr>
            <td>KLK7</td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib147" ref-type="bibr">[147]</xref>*</td>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK8</td>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib123" ref-type="bibr">[123]</xref></td>
            <td>&#x25CF;<xref rid="bib123" ref-type="bibr">[123]</xref></td>
            <td>&#x25CF;<xref rid="bib123" ref-type="bibr">[123]</xref></td>
            <td>&#x25CB;<xref rid="bib123" ref-type="bibr">[123]</xref></td>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK12</td>
            <td/>
            <td>&#x25CF;<xref rid="bib17" ref-type="bibr">[17]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td>&#x25CB;<xref rid="bib17" ref-type="bibr">[17]</xref></td>
            <td>&#x25CF;<xref rid="bib17" ref-type="bibr">[17]</xref></td>
          </tr>
          <tr>
            <td>KLK14</td>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib15" ref-type="bibr">[15]</xref></td>
            <td>&#x25CF;<xref rid="bib15" ref-type="bibr">[15]</xref></td>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib15" ref-type="bibr">[15]</xref></td>
            <td>&#x25CF;<xref rid="bib15" ref-type="bibr">[15]</xref></td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="tbl4" position="float">
      <label>Table 4</label>
      <caption>
        <p>Structures of KLK peptidases with PDB accession codes: pKLK, mKLK, rKLK, eKLK: porcine, murine, rat, equine kallikrein-related peptidase. Leupeptin&#xA0;=&#xA0;N-acetyl-<sc>l</sc>-leucyl-<sc>l</sc>-leucyl-<sc>l</sc>-argininal, Suc&#xA0;=&#xA0;succinyl, CMK&#xA0;=&#xA0;chloromethyl ketone, BPTI&#xA0;=&#xA0;bovine pancreatic trypsin inhibitor. *Acyl-intermediate, derived from morpholino-carbonyl-KGISSQY-7-amino-4-(trifluoromethyl)-coumarin. ** Structure not deposited. *** Un-published data.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th>KLK</th>
            <th>pro</th>
            <th>apo</th>
            <th>Inhibitor</th>
            <th>Ion</th>
            <th>Small molecule</th>
            <th>Polypeptide</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>KLK1</td>
            <td/>
            <td>1SPJ <xref rid="bib311" ref-type="bibr">[311]</xref></td>
            <td>1HIA <xref rid="bib263" ref-type="bibr">[263]</xref></td>
            <td/>
            <td/>
            <td>hirustasin</td>
          </tr>
          <tr>
            <td>pKLK1</td>
            <td/>
            <td/>
            <td>2KAI <xref rid="bib312" ref-type="bibr">[312]</xref></td>
            <td/>
            <td/>
            <td>BPTI</td>
          </tr>
          <tr>
            <td/>
            <td/>
            <td/>
            <td>2PKA <xref rid="bib247" ref-type="bibr">[247]</xref></td>
            <td/>
            <td>benzamidine</td>
            <td/>
          </tr>
          <tr>
            <td>rKLK2 (tonin)</td>
            <td/>
            <td/>
            <td>1TON <xref rid="bib145" ref-type="bibr">[145]</xref></td>
            <td>Zn<sup>2+</sup></td>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK3</td>
            <td/>
            <td>2ZCH <xref rid="bib134" ref-type="bibr">[134]</xref></td>
            <td>2ZCK <xref rid="bib134" ref-type="bibr">[134]</xref></td>
            <td/>
            <td>Mu-KGISSQY- *</td>
            <td/>
          </tr>
          <tr>
            <td>eKLK</td>
            <td/>
            <td>1GVZ <xref rid="bib136" ref-type="bibr">[136]</xref></td>
            <td/>
            <td>Zn<sup>2+</sup><xref rid="bib136" ref-type="bibr">[136]</xref>**</td>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK4</td>
            <td/>
            <td/>
            <td>2BDH <xref rid="bib137" ref-type="bibr">[137]</xref></td>
            <td>Zn<sup>2+</sup></td>
            <td>p-aminobenzamidine</td>
            <td/>
          </tr>
          <tr>
            <td>KLK5</td>
            <td/>
            <td/>
            <td>2PSX <xref rid="bib144" ref-type="bibr">[144]</xref></td>
            <td/>
            <td>Ac-LLR- (leupeptin)</td>
            <td/>
          </tr>
          <tr>
            <td/>
            <td/>
            <td/>
            <td>2PSY <xref rid="bib144" ref-type="bibr">[144]</xref></td>
            <td>Zn<sup>2+</sup></td>
            <td>Ac-LLR- (leupeptin)</td>
            <td/>
          </tr>
          <tr>
            <td>KLK6</td>
            <td>1GVL <xref rid="bib313" ref-type="bibr">[313]</xref></td>
            <td/>
            <td>1L2E <xref rid="bib246" ref-type="bibr">[246]</xref></td>
            <td/>
            <td>benzamidine</td>
            <td/>
          </tr>
          <tr>
            <td>KLK7</td>
            <td/>
            <td>3BSQ <xref rid="bib314" ref-type="bibr">[314]</xref></td>
            <td>2QXG <xref rid="bib147" ref-type="bibr">[147]</xref></td>
            <td/>
            <td>AAF-CMK</td>
            <td/>
          </tr>
          <tr>
            <td/>
            <td/>
            <td/>
            <td>2QXH <xref rid="bib147" ref-type="bibr">[147]</xref></td>
            <td/>
            <td>Suc-AAPF-CMK</td>
            <td/>
          </tr>
          <tr>
            <td/>
            <td/>
            <td/>
            <td>2QXJ <xref rid="bib147" ref-type="bibr">[147]</xref></td>
            <td>Cu<sup>2+</sup></td>
            <td>Suc-AAPF-CMK</td>
            <td/>
          </tr>
          <tr>
            <td>KLK8</td>
            <td/>
            <td/>
            <td>*** <xref rid="bib315" ref-type="bibr">[315]</xref></td>
            <td>Zn<sup>2+</sup></td>
            <td>Ac-LLR- (leupeptin)</td>
            <td/>
          </tr>
          <tr>
            <td>mKLK8</td>
            <td/>
            <td>1NPM <xref rid="bib316" ref-type="bibr">[316]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>mKLK13</td>
            <td/>
            <td>1AO5 <xref rid="bib317" ref-type="bibr">[317]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK b3</td>
            <td/>
            <td/>
            <td>1SGF <xref rid="bib295" ref-type="bibr">[295]</xref></td>
            <td>Zn<sup>2+</sup></td>
            <td/>
            <td/>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="tbl5" position="float" orientation="landscape">
      <?landscape?>
      <?legal?>
      <label>Table 5</label>
      <caption>
        <p>Disease matrix for human kallikrein-related peptidases. The double dots indicate confirmed and the single dots putative roles in the respective disease, also in cases when the KLK is used as a disease marker or acts as a tumor suppressor.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="2">KLK</th>
            <th colspan="3">Cancer<hr/></th>
            <th colspan="2">Skin disease<hr/></th>
            <th>Teeth<hr/></th>
            <th>Lung<hr/></th>
            <th colspan="3">Brain<hr/></th>
          </tr>
          <tr>
            <th>Prostate</th>
            <th>Ovarian</th>
            <th>Breast</th>
            <th>Netherton syndrome</th>
            <th>Atopic dermatitis</th>
            <th>Amylo-genesis Imperfecta</th>
            <th>Asthma</th>
            <th>Multiple sclerosis</th>
            <th>Alzheimer</th>
            <th>Epilepsy</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>KLK1</td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib318" ref-type="bibr">[318]</xref></td>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK2</td>
            <td>&#x25CF;<xref rid="bib25" ref-type="bibr">[25]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK3</td>
            <td>&#x25CF;&#x25CF;<xref rid="bib25" ref-type="bibr">[25]</xref></td>
            <td/>
            <td>&#x25CF;<xref rid="bib25" ref-type="bibr">[25]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK4</td>
            <td>&#x25CF;&#x25CF;<xref rid="bib47 bib319" ref-type="bibr">[47,319]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib58 bib59" ref-type="bibr">[58,59]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK5</td>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib25 bib114" ref-type="bibr">[25,114]</xref></td>
            <td>&#x25CF;<xref rid="bib25" ref-type="bibr">[25]</xref></td>
            <td>&#x25CF;&#x25CF;<xref rid="bib211" ref-type="bibr">[211]</xref></td>
            <td>&#x25CF;<xref rid="bib60" ref-type="bibr">[60]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK6</td>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib25 bib114" ref-type="bibr">[25,114]</xref></td>
            <td>&#x25CF;<xref rid="bib26" ref-type="bibr">[26]</xref></td>
            <td>&#x25CF;<xref rid="bib211" ref-type="bibr">[211]</xref></td>
            <td/>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib70" ref-type="bibr">[70]</xref></td>
            <td>&#x25CF;<xref rid="bib320" ref-type="bibr">[320]</xref></td>
            <td/>
          </tr>
          <tr>
            <td>KLK7</td>
            <td/>
            <td/>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib211" ref-type="bibr">[211]</xref></td>
            <td>&#x25CF;<xref rid="bib60" ref-type="bibr">[60]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK8</td>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib25 bib114" ref-type="bibr">[25,114]</xref></td>
            <td>&#x25CF;<xref rid="bib26" ref-type="bibr">[26]</xref></td>
            <td>&#x25CF;<xref rid="bib211" ref-type="bibr">[211]</xref></td>
            <td>&#x25CF;<xref rid="bib60" ref-type="bibr">[60]</xref></td>
            <td/>
            <td/>
            <td/>
            <td>&#x25CF;<xref rid="bib76" ref-type="bibr">[76]</xref></td>
            <td>&#x25CF;<xref rid="bib77" ref-type="bibr">[77]</xref></td>
          </tr>
          <tr>
            <td>KLK10</td>
            <td/>
            <td>&#x25CF;&#x25CF;<xref rid="bib25 bib114" ref-type="bibr">[25,114]</xref></td>
            <td>&#x25CF;<xref rid="bib25" ref-type="bibr">[25]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK11</td>
            <td>&#x25CF;<xref rid="bib25" ref-type="bibr">[25]</xref></td>
            <td>&#x25CF;<xref rid="bib25" ref-type="bibr">[25]</xref></td>
            <td>&#x25CF;<xref rid="bib26" ref-type="bibr">[26]</xref></td>
            <td>&#x25CF;<xref rid="bib211" ref-type="bibr">[211]</xref></td>
            <td>&#x25CF;<xref rid="bib60" ref-type="bibr">[60]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK13</td>
            <td/>
            <td>&#x25CF;<xref rid="bib25" ref-type="bibr">[25]</xref></td>
            <td/>
            <td>&#x25CF;<xref rid="bib211" ref-type="bibr">[211]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td>KLK14</td>
            <td>&#x25CF;&#x25CF;<xref rid="bib31" ref-type="bibr">[31]</xref></td>
            <td/>
            <td>&#x25CF;<xref rid="bib25" ref-type="bibr">[25]</xref></td>
            <td>&#x25CF;<xref rid="bib211" ref-type="bibr">[211]</xref></td>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
